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Corannulene is a C5v symmetric polyaromatic hydrocarbon (PAH) and it can be considered the 
smallest fragment of buckminsterfullerene that displays a curvature of the carbon skeleton, which 
gives corannulene interesting physical properties differing from those of planar -conjugated 
analogs (i.e. bowl-shaped structure, rapid bowl-to-bowl inversion at room temperature and a dipole 
moment). With the advent of corannulene in kilogram scale, and a robust procedure for converting 
corannulene into sym-pentachlorocorannulene, came the motivation to create an array of 5-fold 
symmetric pentasubstituted corannulene derivatives suitable for incorporation into polymers, 
materials, bioconjugates and supramolecular architectures. The development of a robust synthetic 
pathway for the preparation of C5-symmetric pentasubstituted corannulenes functionalized with the 
main classes of biomolecules (carbohydrates, oligopeptide, lipids and nucleic acids) and their 
applications and properties are described in this dissertation. 
The first goal is having access to a library of sym-pentasubstituted corannulene derivatives 
bearing a broad window of functional groups and displaying high solubility in organic solvents. 
Iron-catalyzed alkyl-aryl cross-coupling and further elementary chemical reactions allow the 
synthesis in hundreds of milligrams scale of a wide range of penta-substituted corannulenes 
displaying the principal organic functional groups. 
Copper nanoparticles catalyzed and microwave assisted CuAAC “click” reaction provides 
optimal reaction conditions for the conjugation of sym-penta-(1-butyn-4-yl)-corannulene with 
azide-containing biomolecules; corannulene derivatives bearing nucleosides (thymidine and deoxy-
adenosine), sugars (ribose and galactose), short oligopeptide and lipids can be prepared in good 
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yield and purity. In the case of the synthesis of sym-penta-(DNA) corannulene, the CuAAC reaction 
conditions need to be optimized using CuBr-TBTA as catalytic species. The assembling behavior of 
these molecules and the computational studies for the formation of supramolecular architectures are 
described in this dissertation.  
Cholera toxin (CT) from Vibrio cholerae belongs to the AB5 bacterial toxins family. Following 
the “Finger-Linker-Core” approach, several five-fold symmetric pentasubstituted corannulene 
derivatives conjugated to PEG-like chains functionalized with CT binders galactose and GM1os are 
synthesized and their inhibition potency toward CT evaluated. The synthesized GM1os-based 
inhibitors show high binding to CT with IC50 values in the range of nanomolar concentrations. 
Several pentakis-lipido corannulene derivatives displaying different aliphatic chains are 
synthesized and their thermal and gelation behaviors investigated. While oleyl-functionalized 
corannulene derivative exists in a lamellar liquid-crystalline phase at room temperature and shows 
gelator properties, the saturated analog is partially crystallized at room temperature but forms gel in 
cyclohexane; heptyl-functionalized corannulene does not show neither gelator nor liquid-crystalline 
behavior. The results suggest that the length and geometry of the alkyl chains attached onto 
corannulene play an important role on the physical properties of pentakis-lipido corannulenes. 
In summary, this PhD dissertation describes the development of a powerful “toolbox” for the 
synthesis of C5-symmetryc pentasubstituted corannulene derivatives, which can find application in 
biology, pharmacology, material chemistry, polymers and supramolecular chemistry. 
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ZUSAMMENFASSUNG DER DISSERTATION 
 
von 
Martin Mattarella 
Universität of Zürich, 2013 
Prof. Dr. Jay S. Siegel, Vorsitz 
Corannulene, ein C5v symmetrischer polyaromatischer Hydrocarbon (PAH), ist das kleinstes 
Fragment der Buckminsterfullerene und weisst eine Wölbung des Kohlenstoffgerüstes auf. Dieses 
charakteristische Merkmal zeigt interessante physikalische Eigenschaften, welche im Vergleich zu 
den planaren π-Analogen komplett unterschiedlich sind (z.B. schalenförmige Struktur, rapide 
Inversion von Schale-zu-Schale bei Raumtemperatur, und der Dipolmoment). Mit dem Durchbruch 
Corannulene in Kilogramm-Massstab herzustellen und mit einer robusten Methode in sym-
Pentachlorocorannulene umzuformen, kam die Motivation eine Reihe von fünfach symmetrischen, 
pentasubsitutierten Corannulenederivaten herzustellen, welche eine Andwendung in vielerlei 
Bereichen aufweisen, wie z.B. in Polymeren, Materialen, biokonjugierte und supramolekularen 
Strukturen. In dieser Dissertation wird die Entwicklung eines robusten Syntheseweges zur 
Herstellung von C5-funktionalisieren, symmetrischen pentasubstituierten Corannulenen mit dem 
hauptsächlichem Anwendungsgebiet in Biomolekülen (Karbonhydrate, Oligopeptide, Lipide und 
Nukleinsäure) beschrieben. 
 
Das erstes Ziel bestand aus einer weitreichenden Sammlung von sym-pentasubstituierten 
Corannulenderivaten, welche ein breites Spektrum von funktionellen Gruppen und eine hohe 
Löslichkeit in organischen Lösungsmitteln aufweisen. Eisenkatalysierte Alkyl-Aryl-Kreuzkupplung 
und weitere darauf folgende elementare chemische Reaktionen erlauben eine vielfältige Synthese 
im Milligrammmassstab unter Herstellung von einer solchen Sammlung an verschiedensten penta-
substituierten Corannulenen mit grundlegenden organischen funktionellen Gruppen. 
Die durch Kupfernanopartikeln katalysierte und Mikrowellen-unterstütze CuAAC 
“Klick”reaktion bietet optimale Bedingungen zur Konjugation von sym-penta-(1-butyn-4-yl)-
Corannulen mit aziden Biomolekülen. Corannulenderivate, welche Nukleoside (Thymidin und 
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Deoxyadenosin), Zucker (Ribose und Galactose), kurze Oligopeptide und Lipide besitzen, können 
so in guten Ausbeuten und Reinheit gewonnen werden. Im Fall der Synthese von sym-penta-
(DNA)-Corannulen musste die CuAAC-Reaktion optimiert werden, indem CuBr-TBTA als 
Katalysator verwendet wurde. Das sich aggregierende Verhalten dieser Moleküle und 
computeranimierte Studien zur Bildung dieser supramolekularen Architekturen sind in dieser 
Dissertation besschrieben. 
Cholera Toxin (CT) der Vibrio cholerae gehört zur der AB5 der Familie der bakteriellen Toxine. 
Verschiedene fünffach-symmertrische, pentasubstituierte Corannulenderivate verknüpft mit PEG-
ähnlichen Ketten, welche mit CT-bindern Galactose und GM1os funkionalisiert sind, wurden 
gemäss dem “Finger-Linker-Core”-Prinzip synthetisiert und ihre inhibitorische Fähigkeit im 
Hinblick auf CT evaluiert. Die synthetisierten GM1os-Inhibitoren wiesen eine hohe Bindung zu CT 
mit einer IC50 –Werte in nanomolekularen Konzentrationen auf.  
Verschiendenste pentakis-lipido-Corannulenderivate mit unterschiedlichen aliphatischen Ketten 
wurden synthetisiert und deren thermisches Verhalten und Gelierungsverhalten studiert. Während 
oleyl-funktionalisierte Corannulenderivate in einer lamellelenarigen flüssigkristallinen Phase bei 
Raumtemperatur existiert und gelatierende Eigenschaften aufweist, zeigt das gesättigte Analogon 
nur einen teilweisen kristallinen Zustand bei Raumtemperatur und formt Gele in Cylcohexan. 
Hingegen weist das heptylfunktionalisierte Corannulen weder gelatierenden Eigenschaften, noch 
flüssigkristallines Verhalten auf. Diese Resultate lassen darauf schliessen, dass die Länge und 
Geometrie der Alkylketten, welche an Corannulen gebunden sind, eine entscheidende Rolle 
hinsichtlich der physikalischen Eigenschaften der pentakis-lipido Corannulene spielen. 
Zusammenfassend wird in dieser Doktorarbeit die Kreation eines vielversprechenden 
“Baukastens” zur Synthese von C5-symmetrischen pentasubstituierten Corannulenderivaten mit 
einer ebenso vielversprechenden Anwendung in der Biologie, Pharmakolgie, Materialchemie, 
Polymer- und supramolekulare Chemie, beschrieben. 
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1. CORANNULENE: AN INTRODUCTION 
1.1. STRUCTURE OF CORANNULENE 
Corannulene (1) is a non-planar polycyclic aromatic hydrocarbon (PAHs) and its carbon skeleton 
can be found in the structure of another member of the non-planar PAHs family: 
buckminsterfullerene (2).  
 
 
Figure 1.1. Corannulene 1 and buckminsterfullerene 2. 
The structure of 1 consists in five condensed benzene rings arranged around a central pentagon; 
this particular disposition imposes a bowl-shaped geometry to the molecule. This arrangement of 
the carbon atoms represents the optimal compromise between strain and electronic delocalization. A 
proposed polar resonance form of 1 consists in the presence of two concentric aromatic systems, the 
inner cyclopentadyenil anion and the peripheral cyclopentadecaheptaenyl cation. 1 
 
 
Figure 1.2. Resonance form of 1. 
Both of the aromatic systems in the resonance form satisfy the Hückel’s rule and MO 
calculations suggest the resonance has a significant contribution on the  electron distribution. 2 
2 
 
The first X-ray analysis reveals the bowl-shaped geometry of 1 and its C5v symmetry, which is 
confirmed by the magnetic isochrony of the ten hydrogen atoms showed in 1H-NMR experiment 
(= 7.81 ppm) and the presence of three signals in 13C-NMR experiment (= 135.81, 130.84 and 
127.18 ppm for hub, spoke and rim respectively). 3 These values suggest a dominant [5]-radialene 
structure of 1; however, synchrotron measurements of the electron density at 12 K reveal a slightly 
negative region in the center of 1, as expected from the resonance form 1b. 4 
The symmetry of 1 imposes three chemically different carbon atoms and four different C-C 
bonds with different lengths: flank (1.45 Å), rim (1.38 Å), spoke (1.38 Å) and hub (1.42 Å). 5 In 
comparison, compound 2 show a shorter bowl-depth (1.50 Å) and only two different C-C bonds 
length (1.38 Å and 1.45 Å). 6 The value of the bowl-depth, defined as the distance between the 
imaginary planes defined one by the five central carbons and the other by the ten peripherial carbon 
atoms, has been determined to be 0.875 Å. 7,8 
 
 
Figure 1.3. Structure of 1 and 2. 
While 2 shows a static spherical geometry, 1 has a dynamic structure: the bowl-to-bowl 
inversion process consist in the inversion of the bowl (ground state) through a high energetic flat 
form (transition state). 2 Given the symmetry of 1, the inversion barrier cannot be measured by 
variable temperature NMR (VT-NMR) experiments; however, the value of the inversion barrier of 1 
(11.5 kcal mol-1) was estimated from VT-NMR measurements of several derivatives of 1 containing 
stereo probes, which have little effects on the bowl-to-bowl process. 9,10 
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Figure 1.4. Energy diagram for the bowl-to-bowl inversion process of 1. 
1.2. SYNTHESIS OF CORANNULENE 
1.2.1. PIONEERING SYNTHESIS OF CORANNULENE 
The first synthesis of 1 was achieved in 1966 11 by Lawton through a laborious synthetic 
pathway. The strategy for the formation of the carbon framework of 1 consists in a gradually 
introduction of 4-carbons fragments and sequent annulation of the carbon rings starting from 
acenaphthene (3), which represents an optimal starting substrate. 
 
 
Scheme 1.1. Retrosynthetic disconnection for the carbon network of 1. 
The first part of the synthetic route is the formation of ring C: alkylation of 3 with maleic 
anhydride (4-carbon unit), intramolecular acylation and further chemical transformations lead to 
compound 4. The formation of another ring (D) was achieved following the same strategy: a 4-
carbon unit was attached to the methylene position of 4 and cyclized to 5. The author claims the 
selective hydrogenation of 5 to acid 6, whose apparent cup-like structure brings the carboxylic 
4 
 
groups in a position favorable for the ring closure. The last ring (E) was closed by intramolecular 
acyloin condensation and further reduction to alcohol 7. The further dehydrogenation leads to the 
fully aromatic system 1.  
 
 
Scheme 1.2. First synthesis of 1. 
The formation of the saturated carbon network was crucial for the success of this synthetic 
pathway since the formation of strained structures by ring closure has been bypassed. 
Unfortunately, this long synthetic route is not optimal for the preparation of 1 in amounts large 
enough for detailed studies on its physical and chemistry properties (17 steps, and yield <1%). 
1.2.2. SYNTHESIS OF CORANNULENE BY FLASH VACUUM PYROLYSIS 
After its first synthesis in 1966, the interest in non-planar PAHs decreased and only two new 
attempts for the synthesis of 1 were tried in the next 20 years and both of them failed. 12–14 The 
discovery of fullerene in 1985 15 gave new energy and motivations to the synthesis of various 
curved PAHs, which can be considered as subunits of fullerene. 
In 1991 Scott reported an improved synthesis of 1 using flash vacuum pyrolysis (FVP) starting 
from the diyne 8. 3 This synthesis was inspired by the work of Brown who demonstrated the 
reversible rearrangement of terminal acetylenes to viniylidenes 16 and the cyclization of 2-
ethynylbiphenyl to phenantrene 17 by apparent trapping of transient carbene via intramolecular C-H 
insertion, when FVP conditions are applied. 
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Scheme 1.3. First synthesis of 1 via FVP. 
The success of FVP in the synthesis of strained non-planar PAHs depends on the high 
temperature applied, which allows the bending of the planar precursors to curved geometries in 
which the reaction centers are close in space. Furthermore, since the reaction takes place in gas 
phase, the polymerization of the precursor is minimized.  
Due to the success of the FVP approach, several works report different syntheses of 1 starting 
from various precursors. After his first synthesis, Scott reports that tetrabromide 9 leads to better 
yield due to its small thermal polymerization during sublimation. It’s also reported that bis(1-
chlorovinyl)fluoranthene 12 allows access to 1 in gram scale with good yield; the authors speculate 
that 12 thermally eliminate HCl to form 8 in situ. 18 Rabideau showed that silyl vinyl ethers 13 can 
also be deployed, however with less efficacy. 19 In 1992 Siegel reported the syntheses of 1 from 
tetrakis(bromomethyl)-fluoranthene 10 and from bissulfone 11. 5 In 1999 Knölker devised an 
alternative route from bis(trimethylsilyl)fluoranthene 14, which produces 1 upon FVP condition. 20 
Although slightly different, all the above precursors have fluoranthene as common basic structure. 
Zimmermann in 1994 21 and Mehta in 1997 22 reported the synthesis of 1 starting from precursors 
with a different carbon skeleton: diyne 15 and helicenes 16 were converted to 1 under FVP 
conditions. 
Despite the success of FVP in the production of 1, this procedure suffers from some 
disadvantages: the FVP equipment restricts the synthesis to several hundred milligrams from which 
only modest amount of 1 can be obtained. Since high temperatures are applied, the FVP procedure 
does not tolerate functional groups, which limits the methods for the synthesis of unsubstituted 
corannulenes. 
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Scheme 1.4. Alternative syntheses of 1 via FVP. 
1.2.3. SOLUTION PHASE SYNTHESIS OF CORANNULENE 
Since the attempts to prepare 1 by formation of the flanking bonds under intramolecular Friedel-
Crafts conditions were unsuccessful, 12–14 new restrosynthetic approach based on the disconnection 
of the rim bonds was proposed. 
The first solution phase synthesis of a corannulene derivative 21 was reported by Siegel in 1996. 
23 The key step of this synthetic approach is the reductive coupling reaction of the brominated 
fluoranthene derivatives (20) with low-valent titanium followed by hydrogenation (Scheme 1.5). 
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Scheme 1.5. First solution phase synthesis of a corannulene derivative. 
A slightly modified pathway was applied for the synthesis of 1 reported by Siegel;24 the 11 steps 
synthesis gave an overall yield of 20% starting from the commercial available 2,7-dimethyl 
acenaphtalene 22. In the same year Rabideau reported new condition for the reductive coupling 
based on low-valent vanadium species. 25 
 
 
Scheme 1.6. Solution phase synthesis of 1. 
Recently Siegel reported the optimization and scale-up to kilogram production for the synthesis 
of 1 following an analogous synthetic route. 26 
A disadvantage of the use of low-valent titanium or vanadium in the reductive coupling step is 
the lack of functional group compatibility. Rabideau suggested a refinement for the reductive 
coupling based on the use of sodium hydroxide (Scheme 1.7). 27,28 
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Scheme 1.7. Base-catalyzed synthesis of 1. 
This new approach shows a solvent dependency: when the ring closure is run in water and 
acetone, a complicated mixture of dibrominated corannulenes is obtained which is then converted to 
1 by reaction with n-butyl lithium followed by quenching with water. On the other hand, the use of 
a mixture of dioxane and water as solvent leads to 1,2,7,8-tetrabromocorannulene, which undergoes 
to reductive debromination afforting 1 in better yield.  
1.3. CORANNULENE DERIVATIVES AND THEIR SYMMETRY 
In the following section, a general view on the synthesis of various substituted corannulene 
derivatives with different symmetry will be discussed. Benzo-fused, 29 indenoannelated 30–32 and 
other ring-extended system, 10,23,33 as well as metal complexes of 1 will not be covered. As an 
overview, three different symmetries are possible for substituted corannulenes: Cs, C5 and C1. 
1.3.1. CS-SYMMETRIC CORANNULENE DERIVATIVES 
The synthetic route to 1 through 1,6,7,10-tetrasubstituted fluoranthenes retains the bilateral 
symmetry of the initial disubstituted naphthalene. In general, the synthesis of fluoranthenes by this 
pathway is based on the retrosynthetic analysis shown in Scheme 1.8. 
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Scheme 1.8. 1,2- and 1,3,4,6-substituted corannulene derivatives. 
Following this synthetic route, the desired substituents of the final Cs-symmetric corannulene 
derivative must be chosen at the level of acenaphthenequionone V, dialkylketone VI and 
disubstituted dienophile VII. Depending on the particular location of the desired substituents and 
their position on corannulene, changes in the synthetic strategy are required. 
By following this strategy, a number Cs-symmetric of di- and tetrasubstituted corannulene have 
been synthesized (Figure 1.5). 
 
 
Figure 1.5. Cs-symmetric di- and tetrasubstituted corannulenes. 
1,2-Disubstituted corannulenes can be readily accessed as reported by Rabideau. 34 The Ni-
mediated ring closing method 28,35 was applied to brominated fluoranthene diester 26 and the 
dicarboxylated corannulene 27 was obtained in good yield. The authors suggest that the formation 
of intermediate tetrahydrocorannulene 28, which has not been observed probably due to the facile 
double elimination of HBr. 
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Although accompanied by hydrolysis of the esters, the base mediated ring closing method 
delivers the hydrolyzed 1,6-dibromo derivative 29 in low yield (Scheme 1.9). 
 
 
Scheme 1.9. General disconnection for the synthesis of Cs-symmetric corannulene derivatives. 
Siegel was the first to publish the preparation of alkyl substituted corannulenes starting from 
adequately presubstituted fluoranthene derivatives. 23,24 The synthesis of 2,5-disubstituted 
corannulene 21 from tetrabromide 20 was achieved by low-valent metal reductive coupling 
(Scheme 1.5). When the base-mediated ring closing condition in dioxane/water is applied to 
hexabromide 30, the dialkyl dibromo corannulene 31 is obtained directly in over 60% yield. 36,37 
Compound 31 can then be hydrodehalodenated 38 to disubstituted compound 21 (Scheme 1.10). The 
same procedure can be followed for the synthesis 1,6-disubstituted corannulene 24 32 and its 2,5-
dibrominated analog 33. 
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Scheme 1.10. 1,2 and 1,2,5,6-substituted corannulene derivatives. 
For the introduction of R5 substituents needed for the 2,5-disubstituted corannulenes (Figure 
1.5), the synthesis of the acenaphthenequinone moiety must be modified. Starting from 
acenaphthene 3, chlorination leads to peri-substituted 5,6-dichloroacenaphtene 34. 39 Further 
bromination delivers 5,6-dichloro-3,8-dibromoacenaphthene 35, which is then oxidized to 
acenaphthenequinone 36 (Scheme 1.11). The preparations of the corresponding fluoranthene 37 and 
corannulene derivative 38 are analog to the cases explained above.  
 
 
Scheme 1.11. Synthetic route to 2,3-dichlorocorannulene 38. 
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Cs-symmetric tetrasubstituted corannulene derivatives have almost all been obtained by a 
combination of the methods described above; depending on the functional groups present, one of 
the several ring closing methods was chosen. 
 
 
Scheme 1.12. General synthesis of Cs-symmetric tetrasubstituted corannulene derivatives. 
1.3.2. C5-SYMMETRIC CORANNULENE DERIVATIVES 
While the synthesis of Cs-symmetric corannulenes is generally accomplished by starting from the 
corresponding fluoranthene precursor that already possess the desired carbon skeleton for the final 
corannulene derivatives, the synthesis of C5-symmetric penta- and deca-substituted corannulene 
derivatives starts from corannulene (Scheme 1.13). 
 
 
Scheme 1.13. C5-symmetric penta- and decasubstituted corannulene derivatives. 
Five-fold symmetric pentasubstituted corannulene derivatives are synthesized from 1 by 
controlled pentachlorination 40,41 to sym-pentachlorocoranulene a  39 or by direct electrophilic 
aromatic substitution with bulky groups under Friedel-Crafts conditions. 8 Reaction with sterically 
less demanding alkyl- or acyl groups, as well as bromination, gives multiple isomers with different 
degrees of substitution. 
                                                 
a Sym- here means 1,3,5,7,9-pentasubstitution. 
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Recently Scott 42 reported the synthesis of sym-pentakis[(pinacolato)boryl]corannulene (40) by 
direct Ir-catalyzed borylation of 1.  
 
 
Scheme 1.14. C5-symmetric penta-substituted corannulene derivatives. 
Sym-pentachloro corannulene 39 is synthesized from 1 by reaction with iodine monochloride 
with surprising high selectivity. Furthermore, due to the polarization of the I-Cl bond towards the 
more electronegative chlorine atom, iodination instead of chlorination would be expected. The 
proposed mechanism for the chlorination suggests a first addition of iodine to the hub bond of 1, 
followed by the attack of chloride to the rim. The corannulene system is then restored by 
rearomatization by HI elimination. Repetition of these steps eventually leads to 39 in about 50% 
yield along with small amounts of under- and over-chlorinated corannulenes as side products 
(mainly tetra- and hexa-chlorinated). 40 The formation of under-substituted side products is also 
observed for the synthesis of compound 40. However, the higher solubility of these molecules 
allows an easy isolation of the desired sym-pentaborylated corannulene. 
14 
 
 
Scheme 1.15. Proposed chlorination mechanism of 1 with ICl. 
The proposed chlorination mechanism is strongly supported by the addition of the 
dichlorocarbenium ion CDCl2
+ to the one of the hub carbon atoms of 1. 43  
Sym-pentachloro corannulene 39 is the common starting point for the five-fold derivatization of 
the corannulene core, but it is far from to be an ideal synthetic intermediate. 39 is sparingly soluble 
in common organic solvents, even at high temperatures, making it difficult to manipulate at 
reasonable concentrations. However, as the coupling advances, the solubility of the respective 
intermediates usually gradually increase, accelerating further the coupling reaction. Furthermore, 
aryl chlorides are generally less reactive in transition-metal catalyzed cross-coupling reaction than 
aryl bromides or iodides and, since the pentasubstitution, the catalytic cycle has to be completed 
five times per molecule, demanding high reaction yield per site. Moreover, due to the difficulties of 
isolation of 39, the under- and over-chlorinated corannulenes present lead to a mixture of isomers of 
tetra- and hexasubstituted byproducts. 
Although all the issues described, several synthetic procedures for the preparation of C5-
symmetric pentasubstituted corannulene derivatives starting from 39 have been developed. Sym-
pentaalkylcorannulenes 41 have been synthesized by 1,3-bis(diphenylphosphino) nickel (II) 
chloride catalyzed alkylation of 39 with trialkylaluminiums (i.e. Al(CH3)3, Al(C2H5)3, Al(C8H17)3) 
in between 30 and 50% yield (Scheme 1.16). 24,44 In the synthesis of sym-pentaarylated 
corannulenes 42, Zn-based Negishi-type coupling conditions were employed using Ni(dppp)Cl2. 
45 
The catalyst system with Pd(OAc)2 or Pd2(dba)3 and Nolan’s N-heterocyclic carbene (NHC) ligand 
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1,3-bis(2,6-diisopropylphenyl)imidazoliumchloride) (IPr·HCl), 46 or alternatively (IPr)Pd(allyl)-
complex could be used as well. 47 The thermal more stable NHC ligands proved to be successful in 
the coupling of sterically hindered aryl zincates (i.e. manisyl), and yields could be improved from 7 
to 18–35%. The yields for unhindered coupling partners range from about 30–50%. Buchwald’s 
system for the coupling of amines to arylchloride, RuPhos palladium (II) phenethylamine chloride, 
48 was recently used by Scott and coworkers to give sym-pentakis(2,6-dichlorophenyl)corannulene 
in more than 50% yield. 49 Suzuki-type chemistry was also successful using Nolan’s NHC ligand. 31 
Improved conditions with Pd-catalyst, bearing Fu’s bulky phosphine ligand tri(tert-butyl)phosphine, 
50,51 which tolerates boronic acids with a variety of functional groups were claimed by Keinan and 
coworkers to deliver the sym-pentaarylated corannulene derivatives in 59-83% yield (Scheme 1.16). 
52 
The introduction of five sp carbons to form sym-pentaethynyl corannulene 43 has been solved in 
several different approaches. Scott and coworkers report a Kumada-type coupling with 
trimethylsilylethynyl magnesium bromide catalyzed by Ni(acac)2. 
40 Indipendently, the Siegel group 
also reported a protocol developed by Eberhard group, 53 in which the trimethylsilyl acetylene is 
used in large excess with the pincer catalyst and zinc dichloride to give sym-
pentakis(trimethylsilylacetylene)corannulene in 53% yield. 45 An important improvement in the 
introduction of five acetylenes onto corannulene core has been recently reported by Wu and 
coworkers utilizing a Stille-kind coupling. 37 Stannanes of the corresponding acetylenes were 
employed with Nolan’s NHC ligand, and yields between 70-95% could be reached for a variety of 
acetylenes. 37 
Finally the chlorine atoms allow nucleophilic aromatic substitution with strong nucleophiles. 
Aromatic and aliphatic thiolates have been introduced onto corannulene by the Scott 54 and Siegel 45 
groups giving the corresponding corannulene thioethers 44 in 35-55% yield. Displacement of 
chlorines by thiolates occurrs at ambient temperature or at 120 °C in the polar solvent 1,3-
dimethylimidazolin-2-one (DMEU), whereas the synthesis of aryl ethers (45) requires more 
elevated temperature of 180 °C. Alternatively, Keinan and coworkers described a copper-catalyzed 
Ullmann condensation whith a variety of phenols. 55 Yields for coupling of sterically unhindered 
and electron rich phenols range from 75-85%, whereas hindered and electron deficient substrates 
gave between 17-50% of the corannulene ethers 45. 
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Scheme 1.16. Synthesis of sym-pentasubstituted corannulene derivatives. 
The synthetic intermediate for the preparation of decasubstituted corannulene is 
decachlorocorannulene 46. 40,54,56 Corannulene undergoes to perchlorination under Ballester 
conditions, 57 which delivers an overhalogenated tetrahydro intermediate 47. Refluxing in high 
boiling ether extrudes four chlorines yielding 46 (Scheme 1.17). 
 
 
Scheme 1.17. Synthetic route to decachlorocorannulene. 
Conversion of 46 to other decasubstituted corannulene derivatives is achieved by Pd-catalyzed 
reation with stannylalkyne and the NHC ligand IPr·HCl; under these reaction conditions delivered 
decaethynylated corannulenes are prepared in about 10% yield (80% yield for each reaction site). 58 
Furthermore, the addition of a variety of thioethers has been reported. 40,45,54,56,59 
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Recently Keinan 60 reported the synthesis of a C5-symmetric deca-heterosubstituted corannulene 
derivative starting from sym-pentachlorocorannulene 39 by Ullmann condensation and further 
electrophilic aromatic substitution to produce 1,3,5,7,9-pentaX-2,4,5,8,10-pentaY-corannulene 
derivatives (Scheme 1.18). 
 
 
Scheme 1.18. Synthesis of C5-symmetric deca-heterosubstituted corannulene derivatives. 
1.3.3. C1-SYMMETRIC MONOSUBSTITUTED CORANNULENE DERIVATIVES 
As seen previously for the synthesis of decachlorocorannulene 46, 1 undergoes to electrophilic 
aromatic substitution with several electrophiles. Although formylation, bromination, acylation and 
nitration have been previously reported, 45 experimental details are only available for the 
bromination 61 and nitration. Nitrocorannulene 48 has been synthesized by reaction of 1 with 
nitronium terafluoroborate on excellent yield. 62 
 
 
Scheme 1.19. Synthesis of C1-symmetric monosubstituted corannulene derivatives. 
  
18 
 
  
19 
 
2. SYNTHESIS OF FIVE-FOLD SYMMETRIC 
PENTABIOCONJUGATED CORANNULENE DERIVATIVES 
Five-fold symmetry is quite abundant in flowers, fruits and molecules, although somewhat less 
frequent than other symmetry e.g. six-fold symmetry. 63 At the molecular scale, five-fold symmetry 
is common in metal complexes 64 and in biomolecules such as proteins 65 and DNA-based 
nanostructures. 66–68 However, C5-symmetrical organic molecules can be considered quite rare. 
Only a few pentameric examples allow substitution of the periphery, and most of them consist of 
conformally flexible macrocycles, such as pentapeptides 50, 69 crown ethers and aza-crown ethers 
51. 70,71 Structurally more rigid examples are calix[5]arene 52, 72 calix[5]furans and -pyrroles, 73 
cucurbit[5]urils 74 and pillar[5]arenes 53. 75 A recently reported pentaamidic structure 76 folds into 
an almost planar disk arrangement with nearly C5-symmetry due to an interior H-bonded network. 
 
 
Scheme 2.1. Selected pentameric structures. 
More generally, five-fold symmetrical molecules can serve as scaffolds for extended 
supramolecular structures that might found application in material science, biology and 
pharmacology.  
2.1. AIM OF THE CURRENT WORK 
C5-symmetric pentasubstituted corannulene derivatives represent a new class of five-fold 
symmetric scaffold. With the advent of the kilogram scale synthesis of corannulene 1, 26 and a 
robust procedure for converting it into 1,3,5,7,9-pentachloro corannulene 39, 40,41 came the 
motivation to improve the general knowledge on the reactivity of 39 and to develop a robust 
20 
 
synthetic procedure that would make accessible a broad spectrum of C5-symmetric pentasubstituted 
corannulene derivatives suitable for incorporation into polymers, 77 materials, 78 bioconjugated 79 
and supramolecular architectures. 80 
The purpose of this thesis is the development of a synthetic route for the preparation of five-fold 
symmetric bioconjugated corannulene derivatives functionalizated with the main classes of 
biomolecules i.e. carbohydrates, lipids, peptides and nucleic acids. This new family of compounds 
based on corannulene would open the door to the study of high-order multivalent ligands, 47,81–83, 
corannulene-based material, template for protein folding mimics 84 or aromatic/nucleic acid 
conjugate assemblies, respectively (Scheme 2.2). 68,85,86  
 
 
Scheme 2.2. Possible applications of C5-symmetric corannulene derivatives. 
The research focus will be addressed to: 
1. develop an efficient synthetic route to access to five-fold symmetric corannulene 
derivatives bearing a broad spectrum of functional groups; 
2. develop an efficient procedure for the introduction of biomolecules onto corannulene 
core. 
3. investigate the material, supramolecular and biological properties of C5-symmetric 
bioconjugated corannulene derivatives. 
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Scheme 2.3. Proposed schematics synthetic pathway for the preparation of sym-pentabioconjugated corannulene 
derivatives. 
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3. SYNTHESIS OF -FUNCTIONALIZED C5-SYMMETRIC 
PENTASUBSTITUTED CORANNUELENE DERIVATIVES 
3.1. INTRODUCTION 
The first hurdle for the synthesis of C5-symmetric pentabioconjugated corannulene derivative is 
to access to a wide class of synthetic corannulene derivatives with a broad spectrum of functional 
groups with orthogonal reactivity. The synthetic route for the preparation of this family of 
compounds needs to tolerate the presence or the introduction of functional groups or their synthetic 
equivalents. Having access to several terminal functionalized corannulenes, would makes these 
compounds especially suitable for developing tectons for supramolecular chemistry, building blocks 
for dendrimer chemistry, cores for multivalent bioconjugate chemistry or active elements for liquid 
crystal and optoelectronic materials. 
In 2009, Keinan reported the synthesis of a variety of sym-pentaaryl corannulene derivatives 
bearing different functional groups that might be a good starting point for the synthesis of 
bioconjugated pentapods (Scheme 3.1). 52 These compounds have been prepared starting from 39 
and the appropriate arylboronic acids using Fu's bulky phosphine ligand, tri(tert-butyl)phopshine 
50,51,87 and, if necessary, further deprotection. 
 
Scheme 3.1. Sym-pentaaryl corannulene derivatives bearing different functional groups. 
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Unfortunately, these compounds display low solubility in common organic solvents, 52 most 
probably due to the rigidity of the molecule. Solubility issue limitates the reactions conditions that 
can be tested for the synthesis of five-fold symmetric pentapods based on corannulene. In order to 
overcome the low solubility issue, it was planned to prepare an array of five-fold substituted 
corannulene derivatives in which the aromatic linker between corannulene and the functional group 
will be replaced with more flexible alkyl chains.  
At first, the introduction of functionalized alkyl chains was tested by Ni(II)-catalyzed cross-
coupling following the condition reported for the synthesis of 41. 45 Unfortunately, the cross-
coupling reaction between 39 and 2-(1,3-dioxolan-2-yl)ethyl magnesium bromide under Kumada's 
condition (Scheme 3.2) led to a complicated mixture of di-, tri-, tetra- and pentasubstituted coupled 
products, which were detected by HRMS analysis. Since the introduction of functionalized alkyl 
chains onto corannulene is the first step for the preparation of more complicated pentapods, better 
cross-coupling reaction conditions for 39 have to be developed in order to increase the reaction 
yields and purity of the product. 
 
 
Scheme 3.2. Ni(II)-catalyzed cross-coupling between 39 and 2-(1,3-dioxolan-2-yl)ethyl magnesium bromide. 
 
3.2. IRON-CATALYZED ALKYL-ARYL CROSS-COUPLING REACTION 
In 1971, Kochi et al. 88 proposed the use of iron salt as catalyst for coupling reaction of Grignard 
reagents with alkenyl halides. Although the promising results, the iron-catalyzed methodology 
remained limited for cross-coupling reaction of Grignard or organomanganese species with alkenyl 
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halides, 89–91 alkenyl sulfones, 92 acid chlorides or thiolesters 93 and allylic phosphate. 94 An 
important improvement in this field was given by Cahiez et al., 89,90 which demostrated and 
recognized the advantages associated with the use of N-methyl-2-pyrrolidone (NMP) as cosolvent. 
89,90 
Advancements in the field of "inorganic Grignard reagent" by Bogdanovic et al. 95 re-evaluated 
the iron-catalyzed cross-coupling reaction. It was established that iron(II) chloride reacts with four 
equivalents of ethyl or higher Grignard to give a new species of formal composition [Fe(MgX)2], an 
"inorganic Grignard reagent" (Scheme 3.3). 96  
 
 
Scheme 3.3. Synthesis of iron "inorganic Grignard reagent". 
The rigorously established stoichiometry of this reaction implies that the reduction process does 
not stop to zerovalent iron species, but leads to species bearing a formally negative charge at iron 
Fe(-II). Such highly nucleophilic entities lacking of any stabilizing ligands are able to oxidatively 
add to aryl halides. 96,97 The resulting organometallic iron compounds, formally Fe(0), are again 
alkylated by the excess of the Grignard reagent present in the medium; subsequent reductive 
coupling of the organic ligands should then form the desired product and regenerate the propagating 
Fe(-II) species (Scheme 3.4).  
 
 
Scheme 3.4. Proposed "low valent iron" catalytic cycle for Fe-catalyzed cross-coupling. 
26 
 
In the past decade, Fürstner research groups reported iron-based procedures for cross-coupling 
reaction of Grignard compounds with aryl chloride and aryl-pseudohalide (aryl bromides and 
iodides undergo to reductive dehalogenation). 98–100  
The "low valent iron" catalytic cycle requires the formation in situ of the catalytic specie 
[Fe(MgX)2] which can only be obtain if the alkyl Grignard compound can undergo to -elimination. 
However, reactions with methyl- phenyl- and vinyl donors lead to organoferrate complexes which 
react with activated electrophiles only (Scheme 3.5); in this cases, an "organoferrate manifold" is 
followed. 101 
 
Scheme 3.5. Iron-catalyzed cross-coupling reaction conditions. 
3.3. IRON-CATALYZED CROSS-COUPLING REACTION ON SYM-
PENTACHLORO CORANNULENE 
Iron-catalyzed cross-coupling shows several advantages for reactions with aryl chloride than Ni- 
or Pd-catalyzed coupling: lower temperature, short reaction time, high tolerance to functional 
groups, higher yield, absence of side reactions (i.e. reductive dehalogenation), cheap catalyst and 
high reactivity on aryl chloride. 98,99 Therefore, Fe-catalyzed procedure is an optimal candidate for 
further functionalization of 39. 
3.3.1. SYM-PENTAALKYL CORANNULENE DERIVATIVES 
The synthesis of sym-pentaalkyl corannulene derivatives was already achieved by Ni(II)-
catalyzed alkylation. Sym-pentamethyl- (60), 24,44 pentaethyl- (61) 45 and pentaoctyl corannulene 
(62) 45 derivatives were synthesized in 33%, 51% and 31% yield, respectively, by reaction of 39 
with the correct trialkyl aluminium species in refluxing DME for 24, 16 and 46 hours, respectively 
(Scheme 3.6). 
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Scheme 3.6. Ni-catalyzed synthesis of sym-pentaalkyl corannulene derivatives. 
In order to test the iron-catalyzed cross-coupling procedure, the synthesis of compounds 60 and 
61 was performed under Fürstner conditions (Scheme 3.7). 102 
 
 
Scheme 3.7. Synthesis of 60 and 61 by Fe-catalyzed reaction. 
Both the desired compounds were obtained in good yield and high purity. This new coupling 
conditions display several advantages compared to the Ni-catalyzed procedure: under Fe-catalyzed 
conditions the reaction requires shorter reaction times (from days to few hours), it leads to higher 
yield of the desired product (from 30-50% to 60-70%) and it needs a very cheap precatalyst (i.e. 
iron (III) acetylacetonate). Since both 60 and 61 were obtain, the Fe-catalyzed cross-coupling on 39 
works following both the "low valent iron" pathway, in the case of 61, and the "organoferrate 
manifold" pathway in the case of 60, which implying an higher reactivity of 39 compared to normal 
aryl chlorides. 
The promising results gave the motivation to further explore the application and versatility of Fe-
catalyzed cross-coupling for the preparation of more complicated five-fold symmetric pentaalkyl 
corannulene derivatives displaying bulky (1-methyl-adamantyl, 63) or homochiral (S-2-methyl-
butyl, 64) moieties (Scheme 3.8). 102 
28 
 
 
 
Scheme 3.8. Synthesis of 63 and 64 by Fe-catalyzed reaction. 
While the preparation of 64 gave similar results of the previous Fe-catalyzed reaction on 39, 
compound 63 was obtained in lower yield and the reaction requires longer reaction time to reach 
full conversion of 39. The presence of the tetra-substituted product in the reaction mixture gave an 
hint for the explanation of the low yield obtain for 63: the bulky nature of adamantane might 
increases the energy of the transition state of the cross-coupling reaction decreasing the rate of the 
reaction; this makes the reductive dehalogenation pathway a competitive reaction. This explains the 
long reaction time, the low yield and the presence of the tetrasubstituted corannulene as side 
product of the coupling. 
3.3.2. SYM-PENTAALKENYL AND PENTAALKYNE CORANNULENE DERIVATIVES 
The results obtained using the Fe-catalyzed procedure for the functionalization of 39 with alkyl 
chain gave motivation for the application of this promising reaction for the synthesis of corannulene 
derivatives bearing terminal alkene and terminal protected alkynes group. The preparation of sym-
penta-(1-buten-4-yl)-corannulene 65 and sym-penta-(1-(trimethylsilyl)-1-butyn-4-yl)-corannulene 
66 was achieved by Fe-catalyzed cross-coupling on 39 (Scheme 3.9). 102 
 
Scheme 3.9. Synthesis of 65 and 66 by Fe-catalyzed reaction. 
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The terminal acetylene corannulene derivative 67 was obtained in high yield and purity by 
deprotection of compound 66 under basic conditions (Scheme 3.10). 102 
 
Scheme 3.10. Synthesis of 67 by deprotection of 66. 
Both the desired compounds 65 and 66 were obtained in yield and reaction time comparable to 
sym-pentaalkyl corannulene derivatives; this suggests that the mild conditions of Fe-catalyzed 
coupling procedure tolerates the presence of double and triple bonds.  
Based on the promising results obtained, the synthesis of the first sym-pentabioconjugated 
corannulene derivatives, functionalized with the terpenoid S-(+)-citronellyl chain (68), was 
achieved by Fe-catalyzed procedure (Scheme 3.11). 
 
 
Scheme 3.11. Synthesis of sym-pentaterpenoid corannulene derivative 68 by Fe-catalyzed reaction. 
All the compounds described so far show high solubility in common organic solvents.  
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3.3.3. SYM-PENTA-(-CARBONYL)- AND PENTA-(-CARBOXYL) CORANNULENE 
DERIVATIVES 
The preparation of C5-symmetric pentasubstituted corannulene derivatives functionalized with 
alkyl chains bearing carbonyl and carboxyl groups was achieved in two-steps pathway because 
these functional groups are not stable under Fe-catalyzed condition. The first step of the synthetic 
route is the introduction of a protected precursor of both carbonyl and carboxyl group on 
corannulene core. Alkyl acetal has been chosen as protective group since this chemical specie is 
stable under cross-coupling conditions and it can lead both to carbonyl and carboxyl group by 
hydrolysis 103 and oxidative deprotection, 104 respectively. The synthesis of five-fold terminal alkyl 
acetal corannulene 69 was achieved by Fe-catalyzed cross coupling (Scheme 3.12). 102 The key 
intermediate 69 was obtained in high yield and purity.  
 
 
Scheme 3.12. Synthesis of 69 by Fe-catalyzed reaction. 
The deprotection of acetal 69 under acidic condition 103 leads to the pentacarbonyl derivative 70 
in high yield and purity (Scheme 3.13.) 102 
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Scheme 3.13. Acidic deprotection of compound 69. 
The treatment of compound 69 with the mild oxidizer Oxone® (potassium peroxymonosulfate, 
KHSO5) in THF/water resulted in both deprotection and oxidation of the acetal to directly furnish 
carboxylic acid 71 (Scheme 3.14). 102 
 
 
Scheme 3.14. Oxidative deprotection of compound 69. 
Compound 71 was obtained in high yield and purity. According to this procedure, the acetal 
group serves as a protective specie for the carboxylic group; since the base-tolerant protection of 
this group is not easy, the acetal protocol offers a useful method. 104 
The reduction of carbonyl compound 70 to the correspondent alcohol 72 was performed under 
different reaction conditions (temperature, reducing agent, addition rate of reducing agent, etc.). 
However, yields higher than 50% were never achieved due tothe formation of byproducts 73 by 
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dehydroxylation of semi-acetals formed during the course of the reaction. The best result in order of 
yield of 72 was obtained when a solution of NaBH4 in methanol was added over 24 hours to a ice-
cold solution of the carbonyl in methanol (Scheme 3.15).  
 
Scheme 3.15. Reduction of compound 70. 
All compounds 70, 71 and 72 display high solubility in common organic solvents; therefore, as 
expected, the introduction of alkylic linker between the corannulene core and the functional group 
increases the solubility of the functionalized corannulene derivatives. In comparison, the analog 
corannulene derivatives in which these functional groups are connected to corannulene through a 
benzene ring (Scheme 3.1) are poorly soluble in hot DMSO. 
 
3.3.4. SYM-PENTA-(-HYDROXY)-, PENTA-(-BROMO)- AND PENTA-(-THIOL) 
CORANNULENE DERIVATIVES 
The poor yield obtained for the reduction of carbonyl 70 gave the motivation to follow a 
different synthetic route for the preparation of alcohol 72. The new strategy is based on the direct 
introduction of a protected hydroxylic group onto corannulene core; the synthesis of compound 74 
was achieved by Fe-catalyzed cross-coupling on 39 in high yield and purity (Scheme 3.16). 102 
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Scheme 3.16. Synthesis of 74 by Fe-catalyzed reaction. 
The deprotection of compound 74 (Scheme 3.17) was performed using trifluoroacetic acid in 
mixture of acetone, water and THF; these conditions are necessary to provide an high nucleophilic 
medium 105 since common deprotection procedures did not afford product 72 but a mixture of tetra- 
and penta-desilylated product. 102,103  
 
 
Scheme 3.17. Synthesis of 72 by deprotection of 74. 
By treatment of compound 72 with NBS and triphenylphosphine, five-fold symmetric bromide 
75 was obtained in high yield and purity. C5-symmetric pentaalkylthiol corannulene was prepared in 
two-steps synthesis by further reaction of compound 75 with thiourea and sequent basic hydrolysis 
(Scheme 3.18). 102 
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Scheme 3.18. Synthesis of derivative 75 and 76. 
The synthesis of the C5-symmetric penta-alkylamino corannulene derivative 77 was tried under 
several conditions. The first strategy involves the reduction of the C5-symmetric penta-alkylazido 
corannulene derivative 78 prepared from nucleophilic substitution on bromide 75. Unfortunately, 
this synthetic pathway did not lead to the desired pentasubstituted product, but to a complicate 
mixture of compounds. Mass spectrometry analysis of the crude reveals a distribution of 
pentasubstituted corannulene derivatives functionalized both with azido and alkene groups; the 
nature of the byproduct suggests that under these condition, compound 75 undergoes both to 
nucleophilic substitution with sodium azide and elimination of HBr yielding the respective azido-
alkene corannulene derivative. The same strategy has been followed starting the synthesis from an 
activated form of alcohol 72 (i.e. tosylate, mesylate and triflate); however it was not possible to find 
reaction conditions in which all the five hydroxyl group of compound 72 react. 
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Scheme 3.19. Proposed synthetic strategy for the preparation of compound 77 from bromide 72 or alcohol 75. 
The second synthetic strategies involves the introduction of a protected amino group on 
corannulene core by Fe-catalyzed procedure. Two protected amino compounds have been selected: 
1-(3-bromopropyl)-,2,2,5,5-tetramethyl-1-aza-2,5-disilacyclopentane 79 and 1-(3-bromopropyl)-
2,5-dimethylpyrrole 80. 
 
 
Scheme 3.20. Proposed synthetic strategy for the preparation of compound 77 from 39. 
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While the reaction between compound 39 and 79 did not lead to the desired product due to low 
stability of this protective group, compound 81 was obtained in high yield and purity. 102 However, 
the deprotection of this corannulene derivative with hydroxylamine did not lead to the desired 
pentaamino compound 77 but to a complex mixture of product not easily characterizable by NMR 
and MS analysis. 
3.4. PROPERTIES OF -FUNCTIONALIZED C5-SYMMETRIC 
PENTASUBSTITUTED CORANNUELENE DERIVATIVES 
The most of the compounds synthesized by Fe-catalyzed cross-coupling are well soluble in 
common organic solvents (THF, DCM, MeOH, etc.); the only exception is compound 76, which 
shows good solubility only in strong polar organic solvents like DMF and DMSO.  
The five-fold symmetric corannulene derivatives 63–72, 74–76 and 81 show a small red shift of 
the -* absorption band in the UV-vis spectra compared to corannulene (1) (Table 3.1). 102 
 
Compound Absorption max Emission max Compound Absorption 
max 
Emission max 
124 251, 286 421 6024 260, 295 431 
6145 263, 297 431 63 263, 301 438 
64 261, 299 438 65 261, 298 436 
66 262, 299 438 67 262, 299 435 
68 264, 300 437 69 263, 298 433 
70 261, 298 438 71 263, 298 433 
72 261, 298 435 74 263, 298 439 
75 261, 299 438 76 263, 301 438 
81 262, 299 519    
Table 3.1. Absorption and emission measurements of corannulene derivatives in THF (in DMSO for 76), wavelengths 
in nm. 
The red shift follows what expected by Woodward-Fieser rules for UV absorption in substituted 
aromatic system. 106 Otherwise, the absorption profiles of these corannulene derivatives are 
relatively constant within the error of band shape and position. The data collected show that the 
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derivatives bearing functionalized alkyl chains have similar absorption behavior to those with 
unfunctionalized alkyl chains. Also the emission spectra show no serious differences in the 
properties of functionalized and unfunctionalized alkyl-chain derivatives; one exception is 
compound 81, which shows an higher Stokes’shift, probably due to the presence of the electron rich 
pyrrole ring. 
Sym-pentaalkyl functionalized corannulene derivatives undergo to a rapid a bowl-ﬂip mechanism 
that interconverts equal proportions of enantiomeric conformations. When the arms bear chiral 
substituents, as in the case of compound 64, the interconversion is between diasteromers and the 
symmetry required equality of proportions is then broken. One might expect to detect this in a 
deviation from van’t Hoff’s additivity rule for optical rotation; 107 i.e. the speciﬁc rotation for 64 
should deviate from 5 times the speciﬁc rotation for a reference “arm”. As such the speciﬁc rotation 
of compound 64 was measured: this compound has a [α]D value of +68.9° which is 6.5 times the 
speciﬁc rotation value of S-2-methyl-butylpheny ([α]D= +10.5°). 102 108 This result indicates that the 
contribution to the optical activity from the bias is small. This result could come about because the 
rotary power of an enantiomer of a sym-pentaalkyl corannulene derivative is small or because the 
energetic bias for one diasteromeric conformation of 64.  
3.5. CONCLUSION AND OUTLOOK 
In conclusion, a robust and efficient procedure for the synthesis of C5-symmetric 
pentasubstituted corannulene derivatives functionalized with alkyl chains bearing functional groups 
has been developed using Fe-catalyzed cross-coupling reaction. This procedure allows the 
functionalization of sym-pentachloro corannulene 39 under mild condition and using a cheap pre-
catalyst yielding the desired product up to hundreds of milligrams scale. As expected, the 
introduction of aliphatic chains between the corannulene core and the functional groups led to an 
increased solubility in organic solvent of the molecule respect to the one presenting a aromatic 
linker.  
Further studies should be performed in order to have access to the missing corannulene 
derivative functionalized with an amino group (compound 77). Moreover, the synthesis and 
reactivity of the side product 73 obtained from the reduction of the penta carbonyl derivative 70 
should be further investigated in order to study its potential as possible starting point for the 
desymmetrization of C5-symmetric pentasubstituted corannulene to C1-symmetric 1,3,5,7,9-
functionalized analog.  
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The possibility to synthesize hundreds of milligrams of a broad class of soluble corannulene 
derivatives with a broad spectrum of functionality facilitates the access to sym-pentapodal 
corannulenes conjugated to active molecular modules. This core-module approach should further 
stimulate to create molecular design and engineering of material based on these components.  
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4. SYNTHESIS OF C5-SYMMETRIC BIOCONJUGATED 
CORANNULENE DERIVATIVES 
4.1. INTRODUCTION 
Pentakis-bioconjugated corannulenes combine the properties of biomolecules (e.g. molecular 
recognition, biological activity, etc.) and the symmetric and structural features of corannulene 
derivatives leading to a new family of pentapods suitable as template for protein folding mimics, 
high-order multivalent ligands and aromatic/nucleic acid conjugate assemblies as explaned in 
Chapter 2. 
The availability of highly soluble corannulene derivatives bearing a broad window of functional 
groups 102 permit the screening of different synthetic routes for the preparation of five-fold 
symmetric corannulene derivatives functionalized with the main classes of biomolecules (i.e. 
carbohydrates, peptide, nucleosides, lipids and terpenes). The synthesis of a C5-symmetric terpenoid 
corannulene derivative (68) achieved by Fe-catalyzed cross-coupling has been already reported in 
the previous chapter. 
In this chapter, the various synthetic pathways and the preparation of basic bioconjugated 
pentapods using corannulene scaffold will be described.  
4.2. PROPOSED SYNTHETIC ROUTES 
The synthesis of the first bioconjugated corannulene derivative functionalized with a terpenoid 
chain (68) has been achieved by Fe-catalyzed cross-coupling (Chapter 2). However, the reaction 
conditions used for this synthesis do not allow the introduction of other classes of biomolecule onto 
corannulene core unless estensive use of protective groups. Therefore, different and more 
convenient synthetic routes have been proposed and tested (Scheme 4.1).  
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Scheme 4.1. Synthetic route proposed and tested for the synthesis of bioconjugated pentapods of corannulene. 
The conjugation of corannulene derivatives 72 and 71 with biomolecules was tried under 
different conditions. Upon reaction with 4-nitrophenyl chloroformiate, the activated form of alcohol 
72 did not yield to the desired pentaconjugated product after reaction with amino functionalized 
biomolecules (5'-amino thymidine and glycine methylester). The presence of tri- and 
tetrafunctionalized products and the formation of intramolecular carbonate linkage was detected by 
mass spectrometry analysis of the crude mixture.  
Condensation reaction of compound 71 with the same amino functionalized biomolecules using 
several condensing agents (HATU, DCC, BOPCl) yield to a mixture of under-substituted 
corannulene derivatives. Similar results were obtain when the carboxylic acid 71 was activated by 
reaction with thionyl chloride or 1,1'-carbonyldiimidazole: under these conditions, the presence of 
intramolecular anhydride derivatives was detected by MS analysis. 
Promising preliminary results were obtained for reductive amination reaction of pentacarbonyl 
corannulene derivative 70 with the methyl ester of glycine; the desired pentabioconjugated 
corannulene derivative 82 was obtained in high yield and purity and short reaction time (Scheme 
4.2). 
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Scheme 4.2. Synthesis of 82 by reductive amination reaction on corannulene derivative 70. 
However, the introduction of the tripeptide H2N-Ala-Ala-Ala-OMe onto corannulene core by 
reductive amination did not lead to complete conjugation: a mixture of tri- and tetraconjugated 
products were detected in the crude mixture by MS analysis. The reaction of 70 with 5'-amino 
thymidine under reductive amination conditions was not tried. Therefore, reductive amination was 
abandoned as protocol for the introduction of biomolecule onto corannulene. 
The formation of under-substituted corannulene derivatives or different byproducts under the 
reaction conditions described in this chapter might be caused by a intramolecular steric effect of tri- 
or tetrasubstituted corannulene derivatives. The bulky substituents hide the missing reacting site or, 
in the case of the trisubstituted product, give access to different reaction pathway leading to 
intramolecular bounded species. 
4.3. SYNTHESIS OF BIOCONJUGATED CORANNULENE BY COPPER 
CATALYZED AZIDE-ALKYNE CYCLIZATION 
Copper catalyzed azide-alkyne cycloaddition reaction (CuAAC) 109 is one of most representative 
member of the "click reaction" family. 110 High yield, high purity and functional groups 
orthogonality make this class of reactions widely used in different fields of science: bioconjugation, 
111 material science 112 and drug discovery. 113 Furthermore, due to the large number of azides 
known or commercial available, this procedure should be representative for the preparation of a 
wide window of corannulene architectures. 
Several CuAAC reaction conditions on corannulene derivative 67 were screened: copper source, 
temperature, solvent and heating system were varied. The best outputs in terms of purity and yield 
of the desired product wer obtained when CuAAC reaction was performed using copper 
42 
 
nanoparticles (CuNPS) 114 in DMF at 60 °C or 80 °C, depending from the azide, under microwave 
irradiation. 102 Under other CuAAC conditions the regioselectivity of triazole formation decreases 
and under-substituted corannulene derivatives were obtained. 
A library of pentakis-bioconjugated corannulene derivatives displaying the main classes of 
biomolecule was synthesized following the new CuNPs-catalyzed CuAAC procedure. 
4.3.1. SYNTHESIS OF DEOXYNUCLEOSIDE-CONJUGATED CORANNULENE 
DERIVATIVES 
A member for each of the two families of deoxynucleoside have been conjugated to corannulene: 
deoxyadenosine (83) for purine and thymidine (84) for pyrimidine. 
5'-azido-2'-deoxy-adenosine 85 was prepared in good yield and high purity by nucleophilic 
substitution reaction of 5'-tosylated-2'-deoxy adenosine 86 115 with lithium azide in DMF; the low 
yield obtained for the synthesis of compound 86 is due to the formation of 2'-tosylated and 5'-2'-
tosylated products. 5'-azido thymidine 87 was synthesized following the reported 116 one-step 
procedure by reaction of thymidine 64 with carbon tetrabromide, triphenylphopshine and sodium 
azide (Scheme 4.3). 
 
Scheme 4.3. Synthesis of 5'-azido deoxynucleosides 85 and 87. 
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Five-fold symmetric pentanucleoside corannulene derivatives 88 and 89 were then synthesized in 
good yield and high purity by CuAAC reaction of alkyne 67 with azides 85 and 87, respectively 
(Scheme 4.4). 
 
Scheme 4.4. Synthesis of deoxynucleosides pentapods 88 and 89. 
The poor solubility of corannulene derivatives 88 and 89 in non-polar organic solvents does not 
permit investigation on the formation of supramolecular assemblies by formation of H-bonding 
network. These bioconjugated compounds display high solubility in strong polar solvents such as 
DMF, DMSO and TFE. However, 1H-NMR and UV-vis investigation of solutions of 88 and 89 in 
these solvents did not substantiate the formation of any aggregates; most probably, the absence of 
supramolecular constructs is due to the saturation of the H-bonding sites by the solvent. The 
formation of supramolecular heteroaggregates between 88 and 89 in solid state have been studied 
by HRMS analysis: the high sensitivity of this technique allows the study of highly diluted solution 
of compounds 88 and 89 in methanol. The MS spectrum of a solution nearly equimolar of 88 and 89 
shows a peak corresponding to the heterodimer 88-89 (Figure 4.1). 
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Figure 4.1. HR-ESI-MS in MeOH + 0.05% formic acid of 88 (top), mixture of 88 and 89 (middle) and 89 (bottom). 
The higher intensity peak of the 88-89 heterodimer than the intensity of the homodimers is an 
evidence of the formation of dimeric aggregates between the two pentakis-nucleosides 
corannulenes. However, information about the geometry and symmetry of the dimer, and the 
intermolecular forces involved cannot be obtained from the MS data.  
4.3.2. SYNTHESIS OF OLIGOPEPETIDE-CONJUGATED CORANNULENE DERIVATIVE 
For this class of bioconjugated pentapods, the tripeptide H-Ala-Ala-Ala-OMe 90 was introduced 
onto corannulene core; this oligopeptide was selected due to its capability to form -strands in 
solution. 117 Five-fold substituted corannulene derivative functionalized with this oligopeptide 
might form supramolecular architectures in solution by formation of H-bonding network. 
Corannulene derivative 91 was prepared in good yield and high purity by CuAAC reaction of 67 
with azide 92, which was synthesized by reaction of amine 90 with triflic azide prepared in situ 
(Scheme 4.5). In the case of azide on secondary carbon, like 92, the CuAAC reaction requires 
higher temperature and longer reaction time to have full conversion of 67; this is most probably due 
to steric hindrance effects. 
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Scheme 4.5. Synthesis of oligopeptide pentapod 91. 
Compound 91 has been obtained in modest yield and high purity. This corannulene derivatives is 
well soluble only in polar H-bonding solvents like DMSO, DMF and trifluoroethanol which 
saturate the H-bonding sites of pentapod 91. Thus the formation of homodimers of 91 in solution 
has not been detected by UV-vis, emission and NMR studies. Like for compounds 88 and 89, a 
diluted solution of oligopeptide 91 in methanol was analyzed by HRMS; however, peaks relative to 
aggregates of this molecule were not detected suggesting the absence of any supramolecular 
structure. 
4.3.4. SYNTHESIS OF LIPID-CONJUGATED CORANNULENE DERIVATIVE 
Oleic acid 93 has been chosen as representative member of lipids for the synthesis of 
pentakislipido corannulene derivatives. This fatty acid has been chosen due to the important 
application of its glycerol ester in protein crystallization and soft material field. 118 
Five-fold symmetric pentalipido corannulene 94 was prepared in high yield and purity by 
CuAAC reaction of alkyne 67 with oleic acid derivative 95 119 (Scheme 4.6). 120 
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Scheme 4.6. Synthesis of pentakislipido corannulene 94. 
The physical properties of compound 94 will be discussed in details in Chapter 6. 
4.3.5. SYNTHESIS OF CARBOHYDRATED-CONJUGATED CORANNULENE DERIVATIVE 
Two different corannulene derivatives conjugated to carbohydrates were prepared; galactose and 
ribose have been selected as sugar units. 
Pentakis-glicosidic corannulene derivatives represent a leit-motif for potential multivalent binder 
to biological complex. 82,102,121  
The synthesis of the azidoalkyl galactoside 96 was a prerequisite to the coupling for the synthesis 
of galactoside 100. The preparation of 96 starts from 2,3,4,6-tetra-O-acetyl--D-galactopyranosyl 
bromide 97, which undergoes to a Koening-Knorr displacement with 2-bromoethanol affording 
compound 98. 122 Azide 99 can be prepared in excellent yield by treatment of 98 with sodium azide 
in DMF, followed by removal of acetyl groups with sodium methoxide to afford the sugar azide 96 
in high yield and purity. CuAAC reaction of alkyne 67 with azide 96 yields pentakis-galactoside 
corannulene 100 (Scheme 4.7). 102,123 
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Scheme 4.7. Synthesis of carbohydrate pentapod 100. 
The synthesis of pentakis-riboside 101 was achieved by CuAAC reaction of alkyne 67 with 
2,3,5-tri-O-acetyl-β-D-ribofuranosyl-1-azide 102 synthesized following a reported procedure. 124 
Deprotection of 101 with sodium methoxyde yields corannulene derivative 103 (Scheme 4.8). The 
protection of the hydroxyl groups of ribose was necessary for the isolation in high purity of 
compound 101 from the crude reaction mixture due to low solubility of riboside 103. 
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Scheme 4.8. Synthesis of corannulene pentapods 101 and 103. 
Due to the hydrophobic corannulene core of the amphiphilic sugar pentapods 100 and 103, 
combined with the strongly hydrophilic galactoside and riboside functionalization, these molecules 
may form stacked supramolecular aggregates in aqueous solution. Unfortunately, riboside 
corannulene 103 did not show any solubility in water, but was only soluble in strongly polar solvent 
such as DMF and DMSO. Therefore, the formation of aggregates in water was investigated only for 
galactoside 100 by 1H-NMR, absorption and emission spectroscopy. The assembling behavior of 
galactoside 100 will be described in details in Chapter 5. 
4.4. CONCLUSION AND OUTLOOK 
In conclusion, a powerful and robust procedure for the synthesis of five-fold symmetric 
pentabioconjugated corannulene derivatives has been developed. CuAAC “click” reaction catalyzed 
by Cu nanoparticles allowed the functionalization of terminal acetylene 67 with the main classes of 
biomolecules: sugars, oligopeptide and nucleoside. The studies characterizing the aggregation 
behavior of these new compounds support the formation of supramolecular architectures. Water-
soluble galactoside derivatives of corannulene were observed to form H-dimers in solution (details 
are reported in Chapter 5), while dimeric structures can be formed via H-bonding between pentakis-
nucleosides corannulene derivatives.  
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The facile synthesis of this new family of compounds, the results and observations on the 
assembling behavior of these molecules should motivate the design and synthesis of improved 
bioconjugated systems using corannulene scaffold. An example of such kind of system is described 
in Chapter 7. 
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5. SYNTHESIS OF CHOLERA TOXIN INHIBITORS BASED ON 
C5-SYMMETRIC CORANNULENE DERIVATIVES 
5.1. CHOLERA TOXIN: AN INTRODUCTION 
The World Health Organization (WHO) estimates that annually 3–5 million people worldwide 
are infected with cholera, resulting in over a hundred thousand fatalities. 125 The responsible 
pathogen, the Vibrio cholerae bacterium, produces the cholera toxin (CT) protein that is the cause 
for the severe clinical symptoms.  
CT belongs to the protein family of AB5 bacterial toxins. 
126 These proteins consist of two 
distinct domains (A and B) with different roles. 127 The A-subunit is an enzyme that - once inside 
the host cell - is toxic and responsible for the subsequent disease symptoms. A-subunit consists of 
two functional domains: wedge-shaped A1 moiety and elongated A2 moiety. The cholera toxin B-
subunit (CTB) is a lectin ans plays a crucial role in the recognition and interaction of the toxin with 
its natural ligand, ganglioside GM1, on the periphery of intestinal cells (Figure 5.1). 128 
 
Figure 5.1. Structure of CTB's natural ligand, ganglioside GM1. 
The crystal structure of CT 129 shows that the protein complex consists of five identical 
monomeric CTB subunits, arranged in a pentagonal symmetry, and each of those subunits can bind 
the ganglioside GM1 in a one-to-one stoichiometry. Detailed calorimetric studies revealed that CT 
exhibits allosteric cooperativity, 130 which contributes to increasingly higher binding affinities to CT 
when more ligands are bound. 131 
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Figure 5.2. Crystal structure of CT with the sites for molecular recognition. 
The mechanism of the Cholera Toxin’s reaction cascade has already been elucidated at the 
molecular level. 132,133 First of all, B-subunit binds to ganglioside GM1 on intestinal epithelial cell 
membranes, followed by cleavage of the A-subunit and disulfide bond reduction to yield the two 
separated fragments A1 and A2. Then after A1 is translocated across the cell membrane by 
endocytosis, it modifies the alpha subunit of the stimulatory G protein through a NAD-dependent 
ADP-ribosylation reation. This locks the G protein in its GTP-bound form, which continually 
stimulates adenylate cyclase to produce the second messenger cAMP whose intracellular 
concentration increases to more than 100-fold over normal and over-activates cytosolic protein 
kinase A (PKA). These active PKA then phosphorylate the cystic fibrosis transmembrane 
conductance regulator (CFTR) chloride channel proteins, which leads to ATP-mediated efflux of 
chloride ions and secretion of water, sodium and potassium cations and bicarbonate anions into the 
intestinal lumen. In addition, the entry of sodium and, consequently, of water into enterocytes are 
diminished. The combined effects result in rapid fluid loss from the intestine, up to two liter per 
hour, leading to severe dehydration and other factors associated with cholera. 133 
From the structural point of view, there are three potential target areas for drug design: blocking 
the enzyme-active site A1, the interruption of A2-B pentamer interaction or prevent the receptor-
recognition process. 134 The inhibition of receptor binding has received the most attention because 
of the relative ease of making antagonist that led to the structural studies of the receptor-binding 
sites on the CTB. Two major routes can be discerned in the literature to achieve this goal. The first 
strategy, monovalent receptor-binding approach, focuses on the design and synthesis of ligands that 
closely mimic the natural ligand on the cell surface 135 in order to obtain a strong interaction with 
the CTB receptor. To improve the affinity for the toxin pentamer, modified galactose derivatives 
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were explored: this led to the discovery of m-nitrophenyl-a-D-galactopyranoside (MNPG), which 
has a 100-fold increase in affinity relative to D-galactose. 136 Based on this result, the inhibitor 
design using MNPG was reported. 137 So far, many different kinds of galactose or MNPG 
derivatives have been investigated and utilized as monovalent inhibitor for CT. 138 
The second approach, multivalent receptor-binding, 81–83 exploiting chelate cooperativity, takes 
the advantages of the pentavalent character of the ligand-binding sites of CT. This approach is 
based on the synthesis of a functionalized branched system, in which each arm carries a single-site 
inhibitor, like galactose 47,139–141 or lactose, 70,71,142,143 leading to a compound that has an overall 
stronger interaction with the toxin than the sum of the independent inhibitors. The synthesis of 
dendritic multivalent inhibitors functionalized with GM1os has been reported: these inhibitors 
displayed unprecedented high inhibitor potencies for CTB, in the picomolar range. 144 
The most dramatic improvement in receptor-binding antagonist design using multivalent systems 
was achieved with a symmetrical pentavalent molecule by Fan and co-workers. 138 The basic 
concept to improve the affinity was a modular approach of "Finger-Linker-Core" (Figure 5.3). The 
pentavalent "Core" is connected by flexible "Linkers" to "Finger" that include the monovalent 
receptor-binding ligand. 
 
Figure 5.3. B-pentamer (left), pentavalent inhibitor (middle) and their complex (right). 
Pentavalent CT inhibitors were synthesized using various "cores": acylated pentacyclen, 70 large 
cyclic peptide 71 and calix[5]arene. 145  
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5.2. SYMMETRICAL PENTAVALENT  INHIBITORS BASED ON 
CORANNULENE SCAFFOLD 
5.2.1. SYNTHETIC ROUTE 
The five-fold symmetry of sym-pentachlorocorannulene 39 can be utilized for the synthesis of 
coranulene-based AB5 toxin antagonists using the "Finger-Linker-Core" approach (Scheme 5.1). 
 
Scheme 5.1. General corannulene-based AB5 toxins inhibitor. 
A first attempt of the synthesis of AB5 toxins inhibitors based on corannulene has been reported 
by Siegel group. 47 In this first approach, rigid linkers designed basing on the crystal data of AB5 
toxin have been used. Two ethylene glycol units were inserted in the linker structure in order to 
increase the water solubility of the inhibitor: a feature necessary for perform affinity assay with the 
toxin. In this approach, the rigid linkers should allow an optimal interaction of all the five galactose 
moieties of the inhibitor with the binding sites of the toxin, while corannulene adjusts the 
recognition circle by modulating the bowl depth.  
Galactose has been chosen as week binder of the toxin and conjugated to the "Core-Linker" 
moiety by CuAAC reaction (Scheme 5.2). The sugar pentapod 105 was prepared starting from 39 
by in a 4-steps pathway; in the first two reactions the linkers were introduced onto corannulene core 
as TIPS protected acetylene by Suzuki coupling and then deprotected by treatment with TBAF. In 
the last two steps, the conjugation of acetyl-protected galactose and its deprotection were achieved 
by CuAAC reaction followed by basic hydrolysis with sodium methoxide. 47 
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Scheme 5.2. Synthesis of first AB5 toxin inhibitor based on corannulene. 
Unfortunately. pentakisgalactoside 105 shows unexpected low solubility in water and 
DMSO/water mixtures; therefore affinity test with the toxin cannot be performed. Although the 
presence of five hydrophilic galactoside units, the high rigidity of the aromatic “Core-Linker” 
system of 105 might cause the low solubility of this molecule in water.  
The recent developments achieved on the functionalization of sym-pentachlorocorannulene 39 102 
make accessible new classes of five-fold symmetric pentasubstituted corannulene derivatives. In 
order to achieve the preparation of CT inhibitors based on corannulene the rigid linkers will be 
substituted with more flexible n-mers of -azidoethyl--propargyl diglyme (n = 1, 2, 4) (Scheme 
5.3) in order to increase the water solubility of the product. The design and synthesis of pentavalent 
GM1os-presenting inhibitors based on a five-fold symmetrical sym-pentasubstituted corannulene 
scaffold will combine the two strategies (multivalent system and strong monovalent binder) and 
obtain an optimal binding to CT. 
56 
 
 
Scheme 5.3. Synthesis of n-mers -azidoethyl--propargyl diglyme (108 n = 1; 111 n = 2 and 112 n = 4). A) TBAF, 
THF, 15 h, r.t. B) NaN3, DMF, 24 h, 70 °C. C) [CuIP(OEt)3], DIPEA, CHCl3, 4 h, 60 °C. 
The synthesis of the three linkers was achieved following a reported iterative strategy starting 
from compound 106, which was chosen as elementary building block. 146 This strategy allows the 
preparation of monodispersed PEG-based linker with exponential growing of the lengths in high 
yield and purity. Compounds 108, 111 and 112 were selected as linkers based on the crystal 
structure of CT: these linkers will cover a wide range of length permitting to reach an optimal 
binding of the inhibitor to CT. Moreover, they will improve the flexibility and the water solubility 
of the inhibitors. 
The synthetic pathway towards the corannulene-based inhibitors starts with the introduction of 
the linker systems onto corannulene core by conjugation of the terminal acetylene 67 with poly 
diglimes 108, 110 and 111 by copper nanoparticle-catalyzed CuAAC reaction (Scheme 5.4). 121 
This synthetic route gave satisfactory results for the synthesis of the "Core-Linker" systems in good 
yield and purity. The terminal TIPS-protected acetylenes 113, 114 and 115 were deprotected by 
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reaction with TBAF yielding the alkyne-terminated PEG-corannulene 116, 117 and 118 (Scheme 
5.4). 121 
 
Scheme 5.4. Synthesis of "Core-Linker" systems 116, 117 and 118. 
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Two different "Finger" systems has been selected: galactose, an easily obtainable but quite poor 
binder of CT, and the oligosaccharide moiety of ganglioside GM1 (GM1os), the natural binder of 
Cholera Toxin. 
The galactose-functionalized "Finger" 121 was synthesized by Koenigs-Knorr type glycosilation 
of azido-PEG hydroxide 119 147,148 with peracetylated -bromo-galactoside 97 followed by 
deprotection by treatment of glycoside 120 with sodium methoxide (Scheme 5.5). 121 
 
Scheme 5.5. Synthesis of galactose-functionalized linker 121. 
An array of pentavalent galactoside-functionalized sym-pentasubstituted corannulenes inhibitors 
was prepared employing the microwave-assisted CuAAC reaction of terminal acetylenes 67 and 
116 – 118 with azido galactose derivative 121 affording four galactose-based CT inhibitors 122 – 
125 (Scheme 5.6). 121 
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Scheme 5.6. Synthesis of galactose-functionalized corannulene-based CT inhibitors 122 – 125. 
Pentakis-galactose corannulene derivatives 122 – 125 were obtained in good yield and high 
purity. 121 
The second family of pentavalent inhibitors displays five GM1os moieties. The synthesis of 
GM1 mimic 130 has been previously achieved by a chemo-enzymatic pathway starting from 
lactoside 126, which is synthesized from lactose (Scheme 5.7). 149 
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Scheme 5.7. Chemoenzymatic synthesis of GM1os 130. 
The pentakis-GM1os corannulene derivatives 131 – 132 were synthesized by CuNPs-catalyzed 
microwave-assisted CuAAC reaction of azido pentasaccharide 130 with terminal acetylenes 116 – 
118. Due to the low solubility of 130 in DMF, the "click" reaction were performed in water in order 
to have complete dissolution of GM1os in the reaction media. (Scheme 5.8). 121 
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Scheme 5.8. Synthesis of GM1os-functionalized corannulene-based CT inhibitors 131 – 133. 
5.2.2. INHIBITION ASSAY 
The inhibition efficiencies of corannulene-based CT binders 122 – 125 and 131 – 133 towards 
the B-subunit of CT (CT-B) were evaluated by enzyme-linked immunosorbent assay (ELISA) on 
96-wells plate, in which each well was coated with native GM1. 150 Following a logarithmic serial 
dilution, solutions of each of the pentakis-saccharide corannulenes were mixed with CTB-HRP 
(HorseRadish Peroxidase) and incubated at room temperature for 2 hours and then transfered in the 
GM1-coated wells. The unbound CTB-HRP-corannulene complex were removed by washing. The 
amount of CTB-HRP on each well was determined by colorimetric analysis after addiction of ODP 
(o-phenylenediamine) and hydrogen peroxide (Scheme 5.9). 121 
 
Scheme 5.9. Oxidation of ODP catalyzed by CTB-HRP. 
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Solubility issues at concentrations higher than 1 mM limited the experiments intended to find the 
IC50 (half maximal inhibitory concentration) value for galactose-based compounds 122 – 125. 121 
When compared to previously reported IC50-values for multivalent CTB ligands functionalized with 
galactose, 47,139–141 these concentrations should not have been limiting. One hypothesis to account 
for this observation is that supramolecular aggregation of these amphiphilic molecules competes 
against binding to CTB. If the formation of the supramolecular assemblies is thermodinamically and 
kinetically favored over the interaction with CTB, the competition of these two processes might be 
a plausible explanation for the unexpected results obtained from the ELISA assays.121 The 
investigation on the aggregation of pentakisgalactose derivative 100 will be discussed in details in 
Session 5.3. 
ELISA-type assay on GM1os-functionalized inhibitors 131 – 133 showed high, nanomolar 
inhibitory potencies (Figure 5.4, Table 5.1). 
 
Figure 5.4. Fitted inhibition curves of GM1os-functionalized inhibitors 131, 132 and 133. 
Compound IC50 (nm) RIP Hill coefficient 
131 25 ± 4 770 14 ± 5 
132 5 ± 2 3700 9 ± 7 
133 7.3 ± 0.9 2600 3.2 ± 0.6 
Table 5.1. Inhibitory potency of pentakisGM1 corannulene-based ligands towards CTB. 
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The pentavalent GM1os-functionalized inhibitors 131 – 133 bind CTB at lower IC50 values than 
the monomeric GM1os. 143 The lowest IC50-value measured is for 132 with an inhibition potency 
that is nearly 4000 times stronger than that of the monomeric GM1os. 143 The lower binding affinity 
for CTB by compounds 131 and 133 is most probably due to the effects related to the linker length: 
if the linker is not long enough (compound 131), not all of the five ligands can simultaneously bind 
the five binding sites of CTB. In the opposite case (i. e. compound 133), binding would lead to a 
substantial ordering in the chain, making it entropically less favorable, while enthalpically the 
necessary folding of the longer linkers to enable binding of CTB by the GM1os fingers might create 
sufficient steric hindrance to cause an increased IC50-value. A further complicating factor is the 
possibility that also GM1os derivatives undergo to supramolecular aggregation that competes with 
binding to CTB and results in apparent higher inhibitory concentrations. 
In the assay, more information about the cooperativity of binding can be obtained from the Hill 
coefficients. 151 Hill plots have been used as a method to assess cooperativity in binding of a 
multivalent ligand to a multivalent receptor 152 (Hill coefficient >1 and <1 being diagnostic for 
positive and negative cooperativity, respectively).Interestingly, monovalent binders 130 shows 
negative cooperativity with a Hill coefficient of around 0.5: 143 after the first molecule of 130 binds 
to CTB, subsequent molecule of the ligand binds less strongly. For the pentavalent-GM1os 
inhibitors 130, 131 and 132 the Hill coefficients calculated are higher than 1, meaning that the 
binding event of these ligands is a cooperative phenomenon.  
However, other studies criticized this approach showing that attribution of a Hill coefficient 
higher than 1 to positive cooperativity is not always justified. 153 The cooperativity of CT binding 
has been previously claimed in calorimetric experiments. 154 However, it is not fully clear whether 
the effects observed for these compounds are in line with such claim. The observation depicted in 
Figure 5.4, low IC50-values and Hill coefficients >1, can indicate cooperative binding of the 
pentavalent inhibitors to CTB. On the other hand, they could also be result of increased local 
concentration of the ligands due to multivalency of the inhibitors, making binding of each following 
arm easier compared to the very first. Isothermal titration calorimetry (ITC) experiments are 
required to clarify this issue. 
Ceveats notwithstanding, 132 is as of yet one of the strongest multivalent CT inhibitors, 147,155 
and display the power of combining the pentavalency with the natural ganglioside to reach optimal 
blocking of multivalent lectins. Design efforts to create systems that optimize spacer geometry and 
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avoid self complexation will likely lead to new derivatives with inhibitory concentrations more 
favorably comparable to other previously reported GM1os-based inhibitor. 
5.3. SUPRAMOLECULAR ASSEMBLING STUDIES ON PENTAKIS-
GALACTOSIDE 100 
The formation of aggregates in water of 100 was investigated by 1H-NMR, absorption and 
emission spectroscopy. Compound 100 is an amphiphilic molecules since it display an hydrophobic 
part (corannulene core) and a strong hydrophilic rim (galactoses); this property might lead to the 
formation of supramolecular aggregates in aqueous solution. 
The thermodynamic behavior of the aggregation phenomenon was studied by 1H-NMR 
experiments. The chemical shift (obs) of the five homotopic hydrogens atoms on corannulene core 
was measured at different concentrations and temperatures. A downfield shift is observed upon 
increasing of the temperature of 100 (Figure 5.5). 
 
Figure 5.5. Aromatic region of 1H-NMR spectra of a solution 0.28 mM of 100 at 300 K (red), 310 K (black), 320 K 
(blu), 330 K (violet) and 340 K (green).  
The 1H-NMR spectra of several solutions of 100 with a broad range of concentration were 
measured at different temperatures. The association constant Ka of the aggregation of 100 in water 
was calculated at each temperature by non-linear least-square regression based on the equal K or 
isodesmic (KE) model of indefinite self-association described by Martin (Figure 5.6). 
156 This model 
assigns all equilibrium constants for self-association of all the n-mers as equal.  
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Figure 5.6. Fitted curves of obs values of corannulene hydrogens measured for several solutions of 100 at different 
temperatures. 
 
The Ka-values (Table 5.2) where obtained by fitting the experimental data with Equation 5.1, 
where obs is the observed chemical shift, mon is the chemical shift of monomer, Ka is the 
association constant, c is the molar concentration of the sample, and  is the different of the 
chemical shift of the monomer and the aggregate. 
 
𝛿𝑜𝑏𝑠 = 𝛿𝑚𝑜𝑛 − ∆ {1 +
[1 − √(4𝐾𝑎𝑐 + 1)]
2𝐾𝑎𝑐
} 
Equation 5.1 
 
T (K) Ka (x10
4) 
300 20 ± 10 
310 5 ± 2 
320 6 ± 2 
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330 3 ± 1 
340 1.4 ± 0.3 
Table 5.2. Association constant Ka for the aggregation of 100 at different temperature. 
The aggregation number N, i. e. the number of the monomers included in the aggregates, was 
determined using Equation 5.2, where obs is the observed chemical shift, mon is the chemical shift 
of monomer, Ka is the association constant, c is the molar concentration of 100 and N is the 
aggregation number. 
ln[𝑐(𝛿𝑚𝑜𝑛 − 𝛿𝑜𝑏𝑠)] = 𝑁 ln[𝑐(𝛿𝑜𝑏𝑠 − 𝛿𝑎𝑔𝑔)] + ln𝐾𝑎 + ln𝑁 − (N − 1)ln(𝛿𝑚𝑜𝑛 − 𝛿𝑎𝑔𝑔) 
Equation 5.2 
The aggregation number was estimated to 2, assuming that 100 is in equilibrium between the 
monomer and the aggregate. 157 
The thermodynamic parameter H (-13 ± 1 kcal mol-1) and S (-18 ± 4 cal mol-1) of the 
dimerization process were determined by van't Hoff plot from the Ka calculated at various 
temperatures (Figure 5.7). 
 
Figure 5.7. Van't Hoff plot for compound 100. 
Surprising, the driving force for the aggregation of 100 in solution is not the increasing of the 
entropy of the system (hydrophobic effect), like for the most amphiphilic molecules, but the 
exothermicity of the process. This suggest that other kind of intermolecular interaction are involved 
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like dipole-dipole interaction, - stacking, hydrogen bonds, nonspecific van der Waals 
interactions, electrostatic interactions and repulsive steric forces. 
Further information about the geometry and the organization of the corannulene cores in the 
dimeric system can be obtained by absorption and emission spectroscopy analysis. 
 
Figure 5.8. Absorption (left) and emission spectra (right) of compound 100 in water. 
The hypsochromic shift in the absorption spectra (Figure 5.8 left), upon increasing of the 
temperature, and the quenching of the fluorescence (Figure 5.8 right) due to the increasing of the 
concentration of 100 suggest the formation of H-dimers in solution. 158,159 CD analysis of this 
aggregation did not show any significant signal in the range of the studied concentration, because of 
the low signal-to-noise ratio obtained at these conditions. 
5.4. CONCLUSION AND OUTLOOK 
In conclusion, this chapter reports powerful method for the synthesis of a new class of Cholera 
Toxin inhibitors with a design based on a C5-symmetric pentasubstituted corannulene as core unit 
equipped with galactose and GM1os as CT binders. The Cu nanoparticles catalyzed and 
microwave-assisted CuAAC reaction described in Chapter 4 were employed for the conjugation of 
the monovalent CTB ligands (galactose and GM1os) onto corannulene core via azide-presenting 
PEG-linkers of various length. It was proven that the presence of such kind of linkers improves the 
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water solubility of the corannulene-based inhibitors when compared to the one that presents an 
aromatic linker (compound 105). The potent CTB inhibition in the nanomolar range observed for 
the penta-GM1os corannulenes, 131 – 133 proves that multivalent systems functionalized with 
strong CTB binders represent a solid strategic approach for the synthesis of CT inhibitors with high 
potency in comparison with previously reported mono- and multivalent inhibitors. 
The developed method allows the use of sym-substituted corannulenes as a possible core unit for 
the development of new multivalent binders of Cholera Toxin or other possible biological targets 
that rely on multivalent binding of their target ligand. Further investigation should be performed on 
the effect of the length of the linker to the inhibition potency: the PEG-like linker can be replaced 
by a polyproline moiety. This new system is highly hydrophilic, rigid and its length can be easily 
controlled changing the number of proline units. Crystal structure analysis of CT with GM1os-
based corannulene derivative should be performed in order to obtain better information regarding 
the stoichiometry of the binding phenomena of CTB with the pentavalent inhibitors. 
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6. C5-SYMMETRIC PENTA-SUBSTITUTED CORANNULENE 
WITH GELATION PROPERTIES AND LIQUID CRYSTALLINE 
PHASE 
6.1. INTRODUCTION 
Liquid crystals (LCs) 160,161 are a state of matter intermediate between that of a crystalline solid 
and an isotropic liquid. The liquid crystalline state has been discovered more than 100 years ago 
when in 1888 Reinitzer 162 and Lehmann 163 investigated some esters of cholesterol. LCs posses 
many of the mechanical properties of an isotropic liquid, like high fluidity, inability to support 
shear, formation and coalescence of droplets. At the same time LCs are similar to crystalline solid 
in that they exhibit anisotropy in their optical, electrical and magnetic properties. 160 The most 
important property of a liquid crystal is its anisotropy.  
LCs are found among a wide window of organic molecules and the role of molecular geometry 
on liquid crystals has been discussed by Gray. Certain structural features are often found in the 
molecule forming liquid crystal phases and they may be summarized as follow: 160 
(a) liquid crystallinity is more likely to occur if the molecule has flat segments;  
(b) a fairly rigid backbone containing double bonds defines the long axis of the molecule; 
(c) the existence of a strong dipole and easily polarizable groups in the molecule seems 
important; 
(d) the groups attached to the extremities of the molecule give disorder to the system. 
With its unique geometry, corannulene 1 is a good candidate as backbone for liquid crystalline 
molecule: it's a fairy rigid aromatic system and it has a dipole moment of roughly 5 D, 164 which is 
due to the different electron densities on the concave and convex -face of 1. Moreover, a material 
comprising derivatives of 1 ordered in a columnar manner might orient in an electric field and show 
ferroelectric properties. 165 Extended columnar order of corannulene core has been found in the 
solid state for few corannulene derivatives. 30,37,166 
In 2009 Aida 78 reported the synthesis of two decasubstituted corannulene derivatives 134 and 
135 starting from decachlorocorannulene 46 (Figure 6.1). These compounds are able to form liquid 
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crystalline assemblies; in particular, compound 135 forms columnar hexagonal LC phase which 
responds to an applied electric field, giving rise to a homeotropic alignment of the hexagonal 
columns with respect to the electrode surface. 78 
 
Figure 6.1. LC decasubstituted corannulene derivatives 134 and 135. 
6.2. SYM-PENTAKIS-LIPIDO CORANNULENE DERIVATIVES: SYNTHESIS 
AND PROPERTIES 
The development on the synthesis of sym-pentasubstituted corannulene derivatives described in 
the previous chapters gave access to new classes of C5-symmetric corannulenes. The easy 
preparation of the starting material 39 and the accessibility to a broad window of functionalized 
derivatives by high yielding procedures make sym-pentasubstituted corannulene derivatives 
possible new candidates for the preparation of LC materials instead of decasubstituted systems. 
The structure features of pentakis-lipido corannulene derivatives makes this family of molecules 
a good candidate for the preparation of material showing a liquid crystalline mesophase. Three fatty 
acids with different alkyl chain have been chosen: oleic acid 136, stearic acid 137 and heptanoic 
acid 138 (Figure 6.2). These three fatty acids were selected in order to study the effects of the nature 
of the alkyl chain (length and geometry) on the physical behavior of the corannulene derivatives of 
these compounds. 
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Figure 6.2. Selected lipids for the preparation of pentakis-lipido corannulene derivatives. 
In order to be introduced on corannulene core by CuAAC procedure, acids 136– 138 have to be 
functionalized in such a way that they bear an azido functional group. Moreover, Aida reported that 
the presence of amide bonds close to the aromatic core helps the formation of LC material. 78 
Therefore, the introduction of the azidic and amidic moieties was achieved by condensation reaction 
of the acyl chlorides of 139 – 141 with 2-azidoethanolamine to give amide azides 95, 119 142 and 
143 (Scheme 6.1).  
 
Scheme 6.1. Synthesis of lipid azides 95, 142 and 143. 
Pentakis-lipido corannulene derivatives 94, 144 and 145 were synthesized by CuAAC reaction of 
sym-pentabutynyl corannulene 67 with azide 95, 142 and 143, respectively (Scheme 6.2). 120 
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Scheme 6.2. Synthesis of C5-symmetric lipido corannulenes 94, 144 and 145. 
6.3. PHYSICAL PROPERTIES STUDY ON PENTAKIS-LIPIDO CORANNULENE 
DERIVATIVES 94, 144 AND 145 
6.3.1. DIFFERENTIAL SCANNING CALORIMETRY AND POLARIZED OPTICAL 
MICROSCOPY 
Differential scanning calorimetry or DSC is a thermoanalytical technique in which the difference 
in the amount of heat required to increase the temperature of a sample and reference is measured as 
a function of temperature. From DSC measurements, information regarding the number, type, 
transition temperature and enthalpy change of phase transition can be easily determined. 
Polarized optical microscopy (POM) is an optical microscopy technique that involves the 
irradiation of the sample with polarized light. POM technique is capable of providing information 
about the birefringence nature of the sample distinguishing between isotropic and anisotropic 
materials, thus POM finds application in the study of liquid crystalline compounds. 
In order to prove the formation of liquid crystalline phase, the thermal and optical behavior of 
corannulene derivatives 94, 144 and 145 were initially investigated by DSC and POM. While 
neither thermal signatures characteristic of phase transition in the DSC scan nor birefringence in 
73 
 
POM were not observed for pentakislipido 144, compounds 94 and 145 present different phase 
transitions in the DSC scan and birefringence in POM (Figure 6.3 and Figure 6.4). 120 
For corannulene derivative 94, thermal signatures characteristic for phase transition were 
observed at 132 °C and at 99 °C in the DSC cooling scan, and the birefringence texture in POM 
images is consistent with the presence of liquid crystalline phases below 132 °C (Figure 6.3). This 
study shows that 94 exists in three different phases: an anisotropic phase below 99 °C, a second 
anisotropic phase between 99 °C and 132 °C and an isotropic liquid phase above 132 °C (Figure 
6.3). 120 
 
Figure 6.3. (a) DSC of compound 94 at 2 K min-1 and (b) POM image of 94 at 20 °C. The birefringent phase proves the 
presence of a liquid-crystalline phase at room temperature. 
For compound 145, DSC cooling scan reveals phase transitions at 30 °C and at 80 °C; the 
birefringence of the liquid phase indicates the presence of liquid-crystalline phases at temperature 
higher than the melting at 30 °C. Therefore, 145 exists in three phases: an isotropic solid phase at 
temperature lower than 30 °C, an anisotropic phase between 30 °C and 80 °C and a second 
anisotropic phase above 80 °C (Figure 6.4). 120 
The results obtained by DSC and POM measurements suggest that the thermal behavior of the 
pentakis-lipido corannulenes is strongly influenced by the nature (length and geometry) of the 
aliphatic chain attached to corannulene core. 
74 
 
 
Figure 6.4. (a) DSC of compound 4 at 2 K min-1 and (b) POM image of 145 at 40 °C after melting, indicating a liquid-
crystalline phase. 
6.3.2. SMALL- AND WIDE-ANGLE X-RAY SCATTERING 
Small- and wide-angle X-ray scattering (SAXS and WAXS) are techniques where the scattering 
of X-rays by a sample, which shows inhomogeneities in the nm-range, is recorded at small and wide 
angles. The scattering gives information about the shape and size of molecules, characteristic 
distances of partially ordered materials, pore size, etc.  
SAXS and WAXS are one of the most powerful techniques for investigating the structure of 
liquid crystalline phases. Since such phases possess long-range structural order, interaction with 
electromagnetic radiation of a suitable wavelength results in the generation of diffraction patterns. 
These are characterized by constructive interference when Bragg's law is fulfilled. From the relation 
between the diffraction peaks, the nature of the liquid crystalline phase can be identified. When the 
composition of the sample is known together with the nature of liquid crystalline phase, X-ray 
diffraction data can be used to extract information about the characteristic dimension in the liquid 
crystalline structure. Also with system without long-range order, SAXS and WAXS may provide 
useful information, e.g., on the size of micelles, liposomes and other disperse system, as well as on 
gel structure. 
SAXS and WAXS were performed in order to obtain more information about the supramolecular 
organization on corannulene derivatives 94, 144 and 145 at room temperature. 120 In the wide-angle 
region of X-ray scattering pattern of compound 94, an isotropic halo indicates the liquid-like 
behavior of the component and the absence of a specific -interaction peak indicated the absence of 
-staked supramolecular organization of the molecules in this phase (Figure 6.5a). In the small-
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angle region, the appearance of a strong reflection followed by a weak second order reflection at 
q2:q1 of 2:1 suggests a lamellar organization of the molecules in this liquid crystalline phase (Figure 
6.5b). The azimuthally integrated X-ray scattered intensity shows the Bragg's reflections of lamella 
with a layer-to-layer distance of 4.4 nm after sample annealing (Figure 6.5c). 120 
SAXS and WAXS investigation of corannulene derivative 144, bearing a shorter alkyl tails than 
derivative 94 and 145, reveal only a diffuse peak, indicative of a correlation hole at 2.5 nm and 
corresponding to chemical heterogeneities on the scale of the molecule (Figure 6.5c). 167 These 
results further confirm that the length of the alkyl chains of fatty acid functionalized corannulene 
derivatives plays a central and important role on the phase behavior and the molecular organization 
for this class of five-fold symmetric corannulene derivatives. 120 
The SAXS and WAXS studies of compound 145, which is the direct saturated analog of 94, 
reveal the presence of a partially crystallized phase at room temperature (Figure 6.5c) suggesting 
that, not only the length, but also the geometry of the alkyl chain dictates the physical properties of 
C5-symmetric pentalipid corannulene derivatives. 
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Figure 6.5. (a) 2D Wide and (b) Small Angle X-ray Scattering (WAXS, SAXS) patterns of 94 and (c) the 1D scattering 
intensity distribution of 94 (red), 144 (black) and 145 (blu) after annealing. 
6.3.3. TRANSMISSION ELECTRON MICROSCOPY 
Transmission electron microscopy (TEM) is a microscopy technique whereby a beam of 
electrons is transmitted through an ultra-thin specimen, interacting with the specimen as it passes 
through. An image is then formed from the interaction of the electrons transmitted through the 
specimen; the image is then magnified and focused onto an imaging device. TEMs are capable of 
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imaging at a significantly higher resolution than light microscopes, owing to the small de Broglie 
wavelength of electrons; this enables to examine fine details of the specimen. 
After DSC, POM and SWAXS measurements, TEM images of compound 94 were performed in 
order to visualize and confirm the lamellar structure suggested from X-ray scattering pattern. TEM 
imagine (Figure 6.6a) show a very long-range ordered lamellar phase, with d-spacing of 4.1 – 4.3 
nm measured after Fourier transformation, in good agreement with the X-ray analysis. 120 
All the results obtained from investigation on 94, suggest a molecular model in which the 
microphase separation of the corannulene core and the symmetric substituents drives the molecule 
into a lamellar structure with partially interdigitated alkyl chains (Figure 6.6b) and reduced 
symmetry compared to the molecule itself. 
 
Figure 6.6. (a) Transmission Electron Microscopy (TEM) image of compound 94 with a lamellar structure. The insets 
show the Fourier transformation (FFT) and a zoom-up of a lamellar domain (edge size of 50 x 45 nm). (b) Possible 
molecular model of the molecular organization in the lamellar structure. 
6.4. GELATION PROPERTIES OF COMPOUNDS 94, 144 AND 145 
In 1999 Feringa and coworkers 168 reported the synthesis of 1,2-diaminobenzene derivatives 
functionalized with aliphatic or aromatic chains and their behavior as gelators for organic solvents 
was described. It has proven that the formation of intermolecular H-bonding network is the key 
phenomena for the gelating properties of this class of compounds. The similarity of the compounds 
described by Feringa et. al. with the the corannulene derivatives 94, 144 and 145 (i.e. aromatic core, 
amide groups and long aliphatic chains) gave the motivation to investigate the gelation properties. 
In order to study the propensity of these compounds for molecular aggregation, the gelator behavior 
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of 94, 144 and 145 was screened in organic solvents (Table 6.1), ethanol/water (Table 6.2) and 
isopropanol/water mixture (Table 6.3). 158,169 
 
Solvent 94 144 145 
Heptane I I I 
Hexane I I I 
Cyclohexane G (8) I G (10) 
Methylcyclohexane G (15) I S (> 40) 
Benzene VS I S (> 40) 
Toluene S (> 40) I S (> 40) 
CCl4 S (> 40) I S (> 40) 
CHCl3 S (> 40) S (> 40) S (> 40) 
CH2Cl2 S (> 40) S (> 40) S (> 40) 
THF S (> 40) S (> 40) S (> 40) 
Acetone S (> 40) S (> 40) I 
Ethyl Acetate S (> 40) I I 
Acetonitrile I I I 
Ethanol S (> 40) S (> 40) S (> 40) 
Isopropanol S (> 40) S (> 40) S (> 40) 
Water I I I 
Table 6.1. Gelation test for compounds 94, 144 and 145 in common organic solvents. The following abbreviations are 
used: gelation: G (minimum gelation concentration in mg compound per mL solvent); insoluble: I; soluble (solubility in 
mg mL-1): S; viscous solution: VS. 
Water : EtOH ratio 94 144 145 
90:10 S (< 40) S S (< 40) 
75:25 I S I 
60:40 I S (< 40) I 
50:50 I I I 
25:75 I I I 
Table 6.2. Gelation test for compounds 94, 144 and 145 in water/ethanol solutions. The following abbreviations are 
used: ); insoluble: I; soluble (solubility in mg mL-1): S. 
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Water : IPA ratio 94 144 145 
90:10 S (> 40) S S (< 40) 
75:25 S (< 40) S S (< 40) 
60:40 I S I 
50:50 I S (< 40) I 
25:75 I I I 
Table 6.3. Gelation test for compounds 94, 144 and 145 in water/isopropanol solutions. The following abbreviations are 
used: ); insoluble: I; soluble (solubility in mg mL-1): S. 
While corannulene derivative 144 does not show any gelation behavior, both compounds 94 and 
145 form organogel in cyclohexane (1 w/w%) and, only for 94, also in methylcyclohexane (2 
w/w%) (Figure 6.7). 120 Interestingly, compounds 94 and 145 don’t display gelator properties 
neither in benzene or toluene, which are isosteric to cyclohexane and methylcyclohexane, 
respectively. A possible explanation of this, is the formation of -stacked or -interactions in the 
gelation process which can be prevented by the presence of aromatic solvents, like benzene and 
toluene. 
 
Figure 6.7. Gel in of 94 (left) and 145 (right) in cyclohexane at 10 mg mL-1. 
The results obtained show that, like for the thermal behavior of the neat substances, the gelation 
properties are strongly influenced by the length of the alkyl chains and, in minor way, by the 
geometry of these. 
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In order to study the influence of hydrogen bonding on the formation of the gel, FTIR spectra 
were measured as a function of concentration of 94 and 145 in cyclohexane. It was observed that, 
upon increasing of the concentration of these compounds and gelation, neither of the two amide 
bands (C=O, N-H) were shifted (Table 6.4). 120 Thus, no evidence for the formation of hydrogen 
bonds in the gelation process was found, suggesting that other phenomena are involved in this 
process and responsible for the gelation. 
 
 94 145 
Concentration (mg mL-1)  NH (cm-1)  CO (cm-1)  NH (cm-1)  CO (cm-1) 
1.0 3298 1649 3316 1646 
5.0 3297 1650 3314 1647 
15.0 (gel) 3300 1652 3317 1646 
20.0 (gel) 3298 1647 3314 1645 
Table 6.4. FTIR  values of NH and CO bonds for solutions and gel of 94 and 145 in cyclohexane. 
In order to obtain further information about the orientation of corannulene cores with respect to 
each other, UV-vis and emission spectroscopy measurements were performed (Figure 6.8). 120 Upon 
increasing of the gelator material, a quenching of the fluorescence was observed. However, the 
absorption spectra do not show any hypsochromic or bathochromic shift, which augurs poorly for 
the existence of -stacked structures in the gel as well as H- and J-aggregate. 
 
Figure 6.8. Left: UV-vis spectra of 94 (solid lines) and 145 (dashed lines) in cyclohexane. Right: Emission spectra of 
94 (solid lines) and 145 (dashed lines) in cyclohexane. 
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Small and wide angle X-ray scattering measurements prove the absence of any ordered 
supramolecular organization in the gels; POM studies demonstrate the isotropic nature of the gels. 
6.5. CONCLUSION AND OUTLOOK 
The thermal behavior and gelation properties of pentakis-lipido-conjugated derivative of 
corannulene have been investigated. The results obtained and here described show that the nature of 
the hydrocarbon chains influence the phase behavior and the gelation properties of C5-symmetric 
pentakislipido-corannulene derivatives. Specifically, the derivative functionalized with oleyl chains 
(95) forms gels in cyclohexane and methylcyclohexane, and, as a neat substance, exhibits a room 
temperature liquid.crystalline phase with lamellar order and a 4.4 nm layer-to-layer spacing. In 
contrast, the presence of short saturated chains lead to the absence of appreciable LC or gelation 
properties, while the saturated analog of 95 appears in a partially crystallized phase at room 
temperature and forms gels only in cyclohexane. Further study should be performed in order to gain 
more information regarding the effect of the length, geometry and nature of the aliphatic chain on 
the thermal behavior of this class of corannulene derivatives. VT-FTIR measurements can lead to a 
better understanding of the role of the amidic groups in the phase behavior of lipido-conjugated 
corannulene derivatives. Further investigation should be planned in order to study the behavior of 
this family of corannulenes under effect of electric or magnetic field. 
The promising results obtained and the versatility of the synthetic strategy encourage the 
synthesis of a wide library of molecularly engineered sym-pentasubstituted corannulene derivatives 
suitable for numerous material application. Due to the structural features of these lipido derivatives 
of corannulene, the behavior of these compound at the air/water interface and the physical and 
electrochemical properties of their Langmuir-Blodgett films are being studied. 
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7. FIVE-FOLD SYMMETRIC PENTA-DNA CORANNULENE: 
SYNTHESIS AND INVESTIGATION OF ITS ASSEMBLING 
BEHAVIOR 
7.1. INTRODUCTION 
The controlled construction of three-dimensional (3D) architectures with a designed 
supramolecular structure is an important and long-standing goal in the field of supramolecular 
chemistry. 3D architectures have diverse potential as scaffolds for molecular organization, 170 gas 
storage materials, 171 drug delivery vehicles, 172 templates for the development of new materials 173 
and tools for encapsulating and controlling the reactivity of guest molecules. 174 In particular, 
noncovalent nanostructure are an interesting goal due to their thermal reversibility which is an 
important feature for guest releasing; promising results have been documented for amphiphilic 
systems functionalized with oligopeptide, 175 nucleosides 176 and carbohydrates. 177 
Over the past decades, a large number of methods for the formation of noncovalent nanostructure 
have been developed; 178 in particular, promising results were obtained using a DNA-functionalize 
approach. The pioneering work reported by Seeman 179 shows the potential of annealing 
complementary DNA strands as a high specificity approach to preparing nano-object with desired 
structure and symmetry. The linear ad rigid nature of double stranded DNA (dsDNA), the 
possibility to perform enzymatic amplification or modification of DNA strands and the accessibility 
to synthetic and chemically modified oligonucleotides all offers great advantages to a DNA-
functionalized approach.  
7.2. SYM-PENTASUBSTITUTED CORANNULENES AS BUILDING UNIT FOR 
THE CONSTRUCTION OF ICOSAHEDRAL SUPRAMOLECULAR 
ARICHITECTURES 
The five-fold symmetry and the bowl-shaped aromatic core of sym-pentasubstituted corannulene 
derivatives suggest the potential application of these compounds as building units for the formation 
of icosahedral supramolecular assemblies by interaction of twelve self-recognizable C5-symmetric 
building blocks (Figure 7.1). Each corannulene core will be positioned at each vertex of the 
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icosahedrons; the five-fold symmetry of sym-pentasubstituted corannulenes provide the correct 
geometry while the bowl-shaped aromatic core will provide the curvature needed for closure of the 
system in an icosahedral fashion. 
Although icosahedra are found in nature and in inorganic clusters, 180 the synthesis of such 
structures from organic building blocks has never been achieved which makes the formation of such 
kind of assembling a challenging and interesting goal. Icosahedral nano-object can find application 
as host in host-guest system and be used as nano-carrier for gases, drugs, small proteins or short 
genes. 
 
Figure 7.1. Formation of icosahedral polyhedra by assembling of twelve C5-symmetric units based on corannulene 
core. 
In 2007 Keinan and coworkes 181 conducted molecular dynamics simulation on corannulene-
based molecule to demonstrate the formation of icosahedral structures. They also suggested several 
corannulene derivatives that can assembly into supramolecular structures using different binding 
mechanisms: hydrogen bonding, metal binding and formation of disulfide bonds (Figure 7.2). 
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Figure 7.2. Proposed structures of corannulene-based building blocks 
The development on the synthesis of five-fold bioconjugated corannulene derivatives and the 
many reported work on the formation of supramolecular architecture using DNA gave the 
motivation to design and prepare a DNA-functionalized corannulene which can act as building unit 
for the assembling of supramolecular construct with icosahedral symmetry. 
7.3. DESIGN AND SYNTHESIS OF SYM-PENTA(OLIGONUCLEOTIDE) 
CORANNULENE DERIVATIVE 
Four general strategies for the construction of 3D DNA-based architectures have been 
developed. The first strategy, named “DNA origami”, involves the folding of long single stranded 
DNA (ssDNA) into the designed geometry by annealing with short “stable strands”. 68 This 
procedure enables high geometrical control, 182 but requires the use of hundreds of different stable 
strands, as well as a long assembly time. The second strategy involves the use of identical branched 
DNA building blocks that assembly into DNA cages which present only dsDNA and a defined 
symmetry; 67,183 following this strategy Mao and coworkers were able to form regular polyhedral 
(tetrahedron, dodecahedron and buckyball). 67 The third strategy, developed by Sleiman group, is 
based on the assembly of ssDNA polygons - displaying organic corner units - which are then 
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assembled into 3D DNA architectures by ligation; 85,184 by this strategy, several nanostructures with 
prism shape have been prepared. 185 This strategy has been improved and simplified by developing 
a procedure in which the DNA polygon is formed without the separate ligation step. 185 The fourth 
approach, developed by von Kiedrowski, involves forming a fully dsDNA 3D-architecture by 
annealing poly-DNA-functionalized organic molecules. 186,187 Following this procedure, von 
Kiedrowsky and coworkers were able to form a nanostructure with dodecahedral symmetry from 
trisoligonucleotides with C3h symmetric linkers. 
187 
The bowl-shaped geometry and the C5-symmetry make sym-pentasubstituted corannulene 
derivatives good candidates for the synthesis of icosahedral supramolecular aggregates following 
the last strategy. By this approach, twelve DNA-corannulene-based building units might form an 
isosahedral supramolecular architecture in which the corannulene cores will be positioned at each of 
the twelve vertexes of the icosahedron, while the dsDNA will form the thirty edges.  
The structure of the pentakis-DNA corannulene was designed such that the ssDNA is a self-
complementary 16-base palindromic sequence TATTACCGCGGTAATA. This sequence was 
designed with high concentration of T and A at the 5’- and 3’-end, to avoid the formation of loops, 
while the central C/G region increases the stability of the double stranded structure. Therefore, the 
ssDNA strands have the potential to fully anneal with the ssDNA strands of other molecules in 
solution into many polymeric structures, possibly including the expected supramolecular 
icosahedral capsid.  
In order to be conjugated on corannulene core by CuAAC reaction, the 16-mer selected was 
modified at the 5’-end with an alkyl chain bearing an azido group (Scheme 7.1). The length of the 
alkyl linker was chosen in order to allow the formation of five double stranded DNA units around 
corannulene core where it’s in an icosahedral fashion. 
 
Scheme 7.1. 5’-alkylazido modified oligonucleotide 146. 
The synthesis of the C5-symmetric penta(oligonicleotide) corannulene derivative 147 was 
achieved by a CuAAC “click” reaction of the alkyne 67 with the 5’-alkylazido-modified 
oligonucleotide 146. Since the oligonucleotide 146 is not stable under the conditions used for the 
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CuNPS-catalyzed CuAAC reaction (oxidation of 146 and reduction of CuNPs was observed), a new 
synthetic procedure was developed for the synthesis of corannulene derivative 147. 
Several CuAAC reaction conditions were screened changing copper source (CuNPs, CuSO4 and 
CuBr), solvent (water, DMSO, acetonitrile, THF and mixtures of these), temperature (room 
temperature or at reflux of the solvent) and heating system (oil bath and microwave). The best 
results in terms of yield and time were obtained by using  Cu(I) bromide as the copper source 
together with tris-(benzyltriazolymethyl)amine (TBTA) 188 as a ligand and stabilizer of Cu(I) 
species in a mixture of THF and water (Scheme 7.2) avoiding any radical side reaction of Cu(I) 
species with oligonucleotide 146. 
 
Scheme 7.2. Synthesis of oligonucleotide functionalized corannulene derivative 147. 
The desired compound 147 was obtained in high purity after D-PAGE purification, and the 
structure was verified by MALDI-TOF MS (Figure 7.3). 
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Figure 7.3. MALDI-TOF MS spectra of compound 147. 
7.4. ASSEMBLING STUDIES AND STRUCTURAL CALCULATIONS  
The ability of DNA corannulene derivative 147 to form ordered supramolecular assemblies was 
investigated by native PAGE and ssDNA-selective enzymatic digestion.  
Successful icosahedral supramolecular structure formation would require generating complete 
annealing of 12 units of compound 147, generating 30 dsDNA edges. Two annealing strategies 
were pursued utilizing either kinetic control or thermodynamic control. In the kinetic strategy, a 
solution of 147 is first melted of any dsDNA at 95 °C, then cooled to 4 °C by immersion in an ice-
bath. In the thermodynamic strategy, the melting step is followed by an annealing step at a 
temperature roughly 10 °C lower than the melting point of the double strand for at least an hour, 
and a final cooling step at 4 °C. Different outcomes were obtained from applying these two 
strategies to the same sample solution of 147 (1 M in TE buffer with Na+ 100 mM). The formation 
of small aggregates, mainly dimers and tetramers, was favored under thermodynamic control, 
whereas the kinetically-controlled strategy achieved aggregates up to 12-mers.  
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Based on this promising results, the annealing conditions were optimized, specifically the 
concentrations of 147, Na+ and Mg2+ and time of the annealing step, in order to mainly obtain the 
dimeric or 12-meric aggregate. The conditions maximizing formation of the 12-mer were found 
with the kinetically-controlled protocol with a solution 2 M of 147 in TE buffer with Na+ 100 mM 
and Mg2+ 5 mM (Figure 7.4). Applying the thermodynamically-controlled protocol, the optimal 
conditions for dimer formation were achieved with a solution 1 M of 147 in TE buffer with Mg2+ 
10 mM, and an annealing step of 50 hours (Figure 7.4). 
 
Figure 7.4. Native PAGE (4%) at 4 °C of assembling under kinetic (left) and thermodynamic control (right). Lanes M: 
50-bp DNA ladder; lanes 1 and 3: assembled samples; lane 2 and 4: results from enzymatic digestion with MBN. 
Enzymatic digestion reactions were performed in order to obtain more information regarding the 
structure of the aggregated formed during the annealing process. Mung bean nuclease (MBN) 189 is 
an enzyme that selectively digests ssDNA, while not disturbing dsDNA. Therefore, in order to 
investigate the formation of the fully double stranded dimer and 12-mer (icosahedral symmetric 
assembly), MBN digestion was performed on the two annealed solutions of the dimer and 12-mer of 
147 from the above protocols. The native PAGE of the samples shows that all supramolecular 
aggregates were digested by MBN, implying that neither the dsDNA strands associated with the 
dimer nor icosahedral supramolecular structures were formed. The stability of dsDNA toward 
treatment with MBN was tested on double-stranded oligonucleotide TATTACCGCGGTAATA 
under the same digestion conditions used for the aggregates of 147; the result proves that dsDNA is 
not hydrolyzed at these conditions (Figire 7.5). 
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Figure 7.5. PAGE (15%) Lane 1: sample; lane 2: sample after MBN digestion. 
Melting temperature (Tm) measurements were performed on compound 147 to study the stability 
of the annealed dimeric system; due to multivalent effect, 190 an higher Tm is expected compared to 
the one of the self-dimer of oligonucleotide TATTACCGCGGTAATA. Unfortunately, the 
temperature dependence of the absorption coefficient of corannulene at 260 nm did not permit 
accurate determination of Tm of the dsDNA formed under either kinetically- or thermodynamically-
controlled conditions. 
Due to the complexity of the interactions of compound 147, it has been selected to theoretically 
study of this molecule’s potential for interaction and aggregation into supramolecular arrangements. 
The RM1 methodology 191 was implemented in GAMESS 192 and validated on the MOPAC test 
sets. 193 RM1 calculations were performed on the neutral species of the ssDNA and 
complementarily paired dsDNA strands, optimizing each in gas phase.The final RM1-optimized 
structure is presented in Figure 7.6.  
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Figure 7.6. RM1-optimized ssDNA-conjugated corannulene structural model. 
This optimized structure is characterized by an arm-length of 75.1 Å, measuring from the center 
of corannulene to the oxygen of the final hydroxyl group of the ssDNA. The RM1-optimzied bowl 
depth of unsubstituted corannulene is 0.88 Å, comparing well to the experimentally observed 
crystalline bowl-depth of corannulene, 0.87 Å. 10 In contrast, the bowl depth in 147 is slightly 
flattened to 0.84 Å. While corannulene itself has an intrinsic curvature, the final structure of this 
compound was comparatively flattened, indicating that this linker does not rigidly adopt and extend 
the curvature of corannulene. The angle between neighboring arms measured from the center of 
corannulene is 71.91˚, and 143.6˚ between non-neighboring arms. In an idealized icosahedron, these 
angles stemming from one vertex of a regular icosahedron are 60˚ and 108˚, respectively, as in 
Figure 7.7, and therefore a substantially smaller than observed in the optimized structure of 147. 
This large discrepancy provides a further explanation for the lack of icosahedral 12-mer formation. 
Moreover, icosahedral aggregates are highly symmetric structures, and therefore strongly 
entropically disfavorable. 
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Given the conformational flexibility of the linker to the DNA strands, future theoretical studies 
could employ sampling techniques to search the potential energy surface of this molecule for other 
minima where this angle may be more conducive of icosahedral supramolecular aggregation. 
Nevertheless, this first ab initio minimum energy structure suggests the usage of a more rigid linker 
to the DNA to effectively restrict the angles of the bioconjugated arms nearer to 108˚, for increased 
probability of icosahedron formation.  
A.   B.  
Figure 7.7. Supramolecular structures of 147 resulting from (A) 12-mer aggregation into an icosahedron, or (B) dimer 
formation of a pentagonal prism. 
In contrast to the icosahedral structure, the dimer structure could easily accommodate a more 
flattened corannulene-linker structure as calculated for 147, but would then necessitate the bending 
of the linker-to-DNA junction to an angle, θ in Figure 7.7, of 98˚ to properly orient the ssDNA 
strands for annealing. This angle in the calculated structure of 147 is a much more linear 165˚, 
therefore, suggesting again a design modification for promoting dimer formation, by rigidifying the 
linkers to DNA to achieve this orientation. The structural calculations also suggest that the fully 
double stranded dimer cannot be formed due to steric stress and strain since this molecular 
geometry is unsupportive of the annealing of all five dsDNA 194 strands when two molecules of 147 
anneal in a dimeric fashion 
With future optimization of the structure, the formation of this dimer supramolecular aggregate 
would be more successful, given the greater probability of two molecules joining in concert, 
opposed to twelve molecules in the correct orientation in the icosahedral aggregation.  
7.5. CONCLUSION AND OUTLOOK 
Although the formation of the icosahedron aggregate was not observed in this work, this 
predicted approximately 2 nm diameter nanocapsule offers interesting potential for applications 
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given both the size and nature of its construction. This cavity size offers the capacity to enclose 
large cargo, such as small proteins or genes. The release of cargo could also be directed by the same 
parameters that affect the annealing of the DNA sequence, namely, temperature, ion and denaturant 
concentrations, and enzymatic activity. With ever-increasing applications for nano-scale delivery 
mechanisms in the fields of targeted medicine and materials science, DNA-based nanocapsules are 
an option of growing interest. Specifically, a bioconjugated-organic construct offers appealing 
advantages, including increased stability and rigidity of the organic framework, and potential for a 
longer lifetime in vivo due to lower degradation rates of organic compounds compared to purely 
biomolecular constructs. This work encourages the continuation of efforts towards the synthesis of 
bioconjugated-corannulene supramolecular structures, and through ab initio structural calculations 
offers suggestions to improve the design and success of organized dimer or 12-mer formation. 
The recent synthesis of C1-symmetric 1,3,5,7,9-pentasubstituted corannulene derivatives 
achieved in Siegel group 195 can be a possible alternative for the formation of supramolecular 
aggregates with icosahedral symmetry. Using fifteen different couples of complementary 
oligonucleotide sequences and conjugating them on twelve C1-symmetric 1,3,5,7,9-pentasubstituted 
corannulene in the correct order and in a way that they can only aggregate in an icosahedral fashion 
might lead to the formation of the desired 12-mer. This procedure was already used with success by 
von Kiedrowsk and coworkes 187 for the formation of a dodecahedral supramolecular aggregate 
starting from a designed series of trisoligonucleotides with C3h linker.  
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8. CONCLUSION AND OUTLOOK 
In conclusion, a robust and efficient synthetic procedure for the preparation of C5-symmetric 
pentabioconjugated corannulene derivatives has been developed. Iron-catalyzed alkyl-aryl cross-
coupling followed by copper nanoparticles catalyzed microwave-assisted CuAAC reaction give 
access to a new class of sym-pentasubstituted corannulene derivative bearing (oligo)saccharides, 
oligopeptide, lipids and (oligo)nucleotides.  
The properties and applications of some of these derivatives have been described in this 
dissertation. Pentakis-saccharide corannulene derivatives functionalized with GM1os strongly 
interact with Cholera Toxin at nanomolar concentrations acting as inhibitors of this protein; 
pentakis-lipido corannulenes display organogelator behavior and liquid-crystalline phases. 
Interesting and promising results on the formation of supramolecular aggregates have been obtained 
for pentakis-galactose and pentakis-DNA corannulene derivatives. 
The described “tool box” for the synthesis of C5-symmetric pentasubstituted corannulenes opens 
the way for the application of corannulene scaffold in biology, pharmacology, material science, 
polymers, optoelectronic devices, soft materials, etc. The application of the synthetic procedure 
might be also used for the functionalization of other corannulene-based systems with substitution 
grade and symmetry different form the C5-pentasubstitution. 
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9. EXPERIMENTAL SESSION  
9.1. GENERAL 
Reagents and Solvents: all reagents were used as purchased from commercial suppliers unless 
otherwise stated. For reactions, solvents of pro analysis grade were used. For reactions performed 
under dry atmosphere, solvents of puriss. grade were used. For work up and purification, distilled 
solvents of technical grade were used. 
 
Chromatography: thin layer chromatography (TLC): Merck TLC aluminum sheets, silica gel 
60 F254, 2 mm. Column chromatography (CC): Sigma-Aldrich Silica gel Merck Type 9385, 230-
400 mesh, 60 Å. 
 
Microwave Reaction: 
 
Infrared Spectroscopy (IR): Jasco 4100 FT-IR spectrometer; absorption values in cm–1. 
 
UV-vis Spectrometry: UV-Vis measurements were carried out on an Agilent 8453 UV/Vis 
spectrophotometer using a 1 mm path quartz cuvette. 
 
Emission Spectroscopy: emission spectra were recorded on an Edinburgh Instruments FLS920 
spectrometer with excitation at 300 nm using 1 cm path quartz cuvette. 
 
Optical Rotatory Power: []D values were recorded on JASCO P-2000 Polarimeter at 25 °C. 
 
Circular Dichroism (CD): circular dichroism spectra were recorded at room temperature on a 
Jasco J-810 spectropolarimeter using 1 mm path quartz cuvette. 
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Nuclear Magnetic Resonance (NMR): 1H- and 13C-NMR: Bruker AV-300, AV-400 or AV-500 
instruments. 13C-signal multiplicity was deduced from DEPT 90 and DEPT135 spectra. Peak 
assignment was performed by two-dimensional NMR experiment (NOESY, COSY). 
 
Mass Spectrometry (MS): Finnigan Trace GC ultra instrument equipped with a Zebron ZB-
5MS capillary GC column for CI and EI; Finnigan Surveyor MSQ quadrupole spectrometer for 
ESI; m/z (rel. %); Bruker Autoflex I spectrometer for MALDI-TOF (matrix assisted laser 
desorption/ionisation time of flight). 
 
Quantification of DNA: Nanodrop 2000C was used for quantification of 147 in solution. 
 
Differential Scanning Calorimetry (DSC): differential scanning calorimetry was performed on 
a DSC 2920 from TA Instruments equipped with a RCS cooling. The compounds were 
encapsulated in 40 µL crucibles and measured under nitrogen atmosphere in a temperature range 
from T=-10 to 150 °C with a heating and cooling rate of 2 Kmin-1. 
 
Polarized Optical Microscopy (POM): POM images were taken on a Leica DM LB optical 
microscope equipped with a Linkam CSS450 hot stage. 
 
Small and Wide Angle X-ray Scattering (SAXS and WAXS): SWAXS experiments were 
performed on a Rigaku MicroMax-002+ microfocused beam (4 kW, 45 kV, 0.88 mA) with the 
wavelength λCu-Kα= 0.15419 nm. The 2D scattering patterns were collected by a Fujifilm BAS-MS 
2025 imaging plate system (15.2 x 15.2 cm2, 50 μm resolution) with an effective scattering vector 
range of q= 1 nm-1 - 25 nm-1. 
 
Transmission electron microscopy (TEM): TEM experiments were carried out using aJeol 
JEM-3200FSC field emission cryo electron microscope operating at 300 kV voltage. The images 
were taken in bright field mode using zero loss energy filtering (omega type) with the slit width of 
20 eV. Micrographs were recorded using a GatanUltrascan 4000 CCD camera. The specimen 
temperature was maintained at -187 °C during imaging. Thin sections (~70 nm) were cut at -80 °C 
97 
 
by Leica Ultracut UTC ultramicrotome using a 25o Diatome diamond knife. The sections were 
collected on 300 mesh lacey carbon grids. The samples were imaged without any staining. 
 
Polyacrylamide Gel Electrophoresis (PAGE): preparative denaturating PAGE (D-PAGE) was 
peformed on 45x30 cm plates with 5 mm spacers at a constant power of 40 W. The DNA was 
visualized by UV irradiation (254 nm) of the gel placed on a fluorescent TLC plate. Analytical 
denaturating and native PAGE were performed on 10x10.8 cm plates with 1 mm spacers at constant 
current of 10 mA. Gels were stained with ethidium bormide and visualized with AlphaImager from 
AlphaInnotech. 
9.2. ABBREVIATIONS 
acac acetylacetonate 
AcOEt ethyl acetate 
APCI atmospheric pressure chemical ionization 
br  broad 
BSA bovine serum albumine 
d  duplet 
D-PAGE denaturing polyacrilamide gel electrophoresis 
dd  duplet of duplet 
DEPT Disortionless Enhancement by Polarization 
DCM dichloromethane 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
ESI  electrospray ionization,, 
HRMS high resolution mass spectrometry 
HRP horseradish peroxidase 
IR  Infrared spectroscopy 
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m  multiplet 
MALDI Matrix-assisted laser desorption/ionization 
MeOH methanol 
NBS N-bromosuccinimide 
NMP N-methyl-2-pyrrolidone 
NMR nuclear magnetic resonance 
OPD o-phenylenediamine 
PAGE polyacrilamide gel electrophoresis 
PBS Phosphate buffered saline 
q  quartet 
quint quintet 
s  singlet 
t  triplet 
TE  tris(hydroxymethyl)aminomethane, EDTA 
TEA triethylamine 
THF tetrahydrofuran 
TIPS triisopropylsilyl 
TMS trimethylsilyl 
UV  ultraviolet 
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9.3. SYNTHETIC PROCEDURES 
9.3.1. SYM-PENTAMETHYL-CORANNULENE (61) 
 
Methyl magnesium bromide (3.0 mL, 9.0 mmol, 3 M in THF) was added to a suspension of sym-
pentachlorocorannulene (347 mg, 0.82 mmol) and Fe(acac)3 (72 mg, 0.20 mmol) in THF (7 mL) 
and NMP (0.7 mL) at 0 °C. The reaction was stirred at room temperature for 2.5 hours. The solution 
was then cooled to 0 °C and quenched by slowly addition of diethyl ether followed by a 1 M 
solution of HCl in water. The organic layer was separated and the aqueous phase was extracted with 
diethyl ether. The collected organic phases were dried over Na2SO4 and evaporated to yield the 
crude product. The product was purified by column chromatography on silica gel eluted with 
hexane. The solvent was evaporated to yield a pale yellow solid (174 mg, 66%). The spectroscopic 
data were identical with those reported. 24,44 
9.3.2. SYM-PENTAETHYL-CORANNULENE (62) 
 
Ethyl magnesium bromide (4.6 mL, 9.2 mmol, 2 M in THF) was added to a suspension of sym-
pentachlorocorannulene (350 mg, 0.83 mmol) and Fe(acac)3 (73 mg, 0.21 mmol) in THF (7 mL) 
and NMP (0.7 mL) at 0 °C. The reaction was stirred at room temperature for 2.5 hours. The solution 
was then cooled to 0 °C and quenched by slowly addition of diethyl ether followed by a 1 M 
solution of HCl in water. The organic layer was separated and the aqueous phase was extracted with 
diethyl ether. The collected organic phases were dried over Na2SO4 and evaporated to yield the 
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crude product. The product was purified by column chromatography on silica gel eluted with 
hexane. The solvent was evaporated to yield a pale yellow solid (188 mg, 58%). The spectroscopic 
data were identical with those reported. 45 
9.3.3. SYM-PENTA-(1-METHYL-ADAMANTYL)-CORANNULENE (63) 
 
1-bromo-methyl-adamantane (2.2 g, 9.6 mmol) was added to a suspension of magnesium (1.0 g, 
42.8 mmol) and a crystal of iodine in diethyl ether (70 mL) at 0 °C; the mixture was stirred at room 
temperature for 5 hours. The Grignard solution was added to a suspension of sym-
pentachlorocorannulene (368 mg, 0.87 mmol) and Fe(acac)3 (77 mg, 0.22 mmol) in THF (5 mL) 
and NMP (0.5 mL) at 0 °C. The reaction was stirred at room temperature for 18 hours. The solution 
was then cooled to 0 °C and quenched by slowly addition of diethyl ether followed by a 1 M 
solution of HCl in water. The organic layer was separated and the aqueous phase was extracted with 
diethyl ether. The collected organic phases were dried over Na2SO4 and evaporated to yield the 
crude product. The product was purified by column chromatography on silica gel eluted with 
hexane. The solvent was evaporated to yield a pale yellow solid (302 mg, 35%). 
 
1H-NMR (500 MHz, CDCl3):  7.53 (s, 5H), 2.87 (s, 10H), 2.01 (s, 15H), 1.80 (s, 30H), 1.70 (dd, 
J= 12.5 Hz, J= 9.0 Hz, 30H).  
13C-NMR (125 MHz, CDCl3):  136.78, 134.05, 130.48, 126.57, 47.89, 43.28, 37.31, 34.84, 29.20.  
UV (THF) λmax, nm: 263, 301.  
HRMS (APCI) m/z: found 991.7109 (M + H); calc (C75H91) 991.7115. 
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9.3.4. SYM-PENTA-((S)-2-METHYL-BUTYL)-CORANNULENE (64) 
 
(S)-2-methyl-butylbromide (1.0 g, 6.6 mmol) was added to a suspension of magnesium (194 mg, 
8.0 mmol) and a crystal of iodine in THF (5 mL) at 0 °C; the mixture was stirred at room 
temperature for 2.5 hours. The Grignard solution was added to a suspension of sym-
pentachlorocorannulene (254 mg, 0.60 mmol) and Fe(acac)3 (53 mg, 0.15 mmol) in THF (5 mL) 
and NMP (0.5 mL) at 0 °C. The reaction was stirred at room temperature for 2.5 hours. The solution 
was then cooled to 0 °C and quenched by slowly addition of diethyl ether followed by a 1 M 
solution of HCl in water. The organic layer was separated and the aqueous phase was extracted with 
diethyl ether. The collected organic phases were dried over Na2SO4 and evaporated to yield the 
crude product. The product was purified by column chromatography on silica gel eluted with 
hexane. The solvent was evaporated to yield a yellow solid (222 mg, 61%).  
 
1H-NMR (500 MHz, CDCl3):  7.76 (s, 5H), 3.40 (dd, J= 13.5 Hz, J= 6.0 Hz, 5H), 3.02 (dd, J= 
13.5 Hz, J= 8.0 Hz, 5H), 2.24 (m, 5H), 1.85-1.80 (m, 5H), 1.62-1.56 (m, 5H), 1.26-1.23 (m, 30H).  
13C-NMR (125 MHz, CDCl3):  140.47, 135.02, 130.14, 123.87, 41.09, 37.75, 30.02, 19.73, 12.02. 
UV (THF) λmax, nm: 261, 299.  
[]25D = +68.9 (c=1.88 in CHCl3)  
HRMS (APCI) m/z: found 601.4765 (M + H); calc (C45H61) 601.4768. 
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9.3.5. SYM-PENTA-(1-BUTEN-4-YL)-CORANNULENE (65) 
 
4-bromo-1-butene (1.1 g, 8.1 mmol) was added to a suspension of magnesium (219 mg, 9.0 
mmol) and a crystal of iodine in THF (30 mL) at 0 °C; the mixture was stirred at room temperature 
for 2 hours. The Grignard solution was added to a suspension of sym-pentachlorocorannulene (311 
mg, 0.74 mmol) and Fe(acac)3 (65 mg, 0.18 mmol) in THF (5 mL) and NMP (0.5 mL) at 0 °C. The 
reaction was stirred at room temperature for 2.5 hours. The solution was then cooled to 0 °C and 
quenched by slowly addition of diethyl ether followed by a 1 M solution of HCl in water. The 
organic layer was separated and the aqueous phase was extracted with ethyl acetate. The collected 
organic phases were dried over Na2SO4 and evaporated to yield the crude product. The product was 
purified by column chromatography on silica gel eluted with a mixture hexane:ethyl acetate 98:2. 
The solvent was evaporated to yield a yellow solid (235 mg, 61%).  
 
1H-NMR (500 MHz, CDCl3):  7.69 (s, 5H), 6.11 (m, 5H), 5.27 (dd, J= 17.0 Hz, J= 1.5 Hz, 5H), 
5.17 (dd, J= 10.0 Hz, J= 1.5 Hz, 5H), 3.31 (t, J= 7,5 Hz, 10H), 2.76 (m, 10H).  
13C-NMR (125 MHz, CDCl3): 140.80, 138.38, 135.13, 129.91, 122.75, 115.38, 36.54, 33.12. 
UV (THF) λmax, nm: 261, 298.  
HRMS (ESI) m/z: found 521.3205 (M + H); calc (C40H41) 520.3203. 
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9.3.6. SYM-PENTA-(1-(TRIMETHYLSILYL)-1-BUTYN-4-YL)-CORANNULENE (66) 
 
1-bromo-4-trimethylsilyl-3-butyne (2.4 g, 11.7 mmol) was added to a suspension of magnesium 
(575 mg, 19.7 mmol) and a crystal of iodine in THF (40 mL) at 0 °C; the mixture was stirred at 
room temperature for 3.5 hours. The Grignard solution was added to a suspension of sym-
pentachlorocorannulene (465 mg, 1.1 mmol) and Fe(acac)3 (97 mg, 0.27 mmol) in THF (10 mL) 
and NMP (1.0 mL) at 0 °C. The reaction was stirred at room temperature for 2.5 hours. The solution 
was then cooled to 0 °C and quenched by slowly addition of diethyl ether followed by a 1 M 
solution of HCl in water. The organic layer was separated and the aqueous phase was extracted with 
ethyl acetate. The collected organic phases were dried over Na2SO4 and evaporated to yield the 
crude product. The product was purified by column chromatography on silica gel eluted with a 
mixture hexane:diethyl ether 98:2. The solvent was evaporated to yield a yellow solid (537 mg, 
61%).  
 
1H-NMR (500 MHz, CDCl3):  7.64 (s, 5H), 3.33 (t, J= 7.5 Hz, 10H), 2.75 (t, J= 7.5 Hz, 10H), 
1,53 (s, 45H).  
13C-NMR (125 MHz, CDCl3):  139.65, 135.22, 129.64, 123.26, 106.53, 86.02, 32.86, 23.10, 0.35.  
UV (THF) λmax, nm: 262, 299. 
HRMS (APCI) m/z: found 871.4396 (M + H); calc (C55H71Si5) 871.4397. 
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9.3.7. SYM-PENTA-(1-BUTYN-4-YL)-CORANNULENE (67) 
 
A solution of NaOH 10% in water was added to a solution of 66 (156 mg, 0.18 mmol) in MeOH 
(1.5 mL); THF was added until a clear solution was obtained. The reaction was stirred at room 
temperature for 24 hours. The solution was then cooled to 0 °C, acidified with a 1 M solution of 
HCl in water and extracted with diethyl ether. The collected organic phases were dried over Na2SO4 
and evaporated to yield the crude product. The product was purified by column chromatography on 
silica gel eluted with a mixture hexane:DCM 6:4. The solvent was evaporated to yield a pale yellow 
solid (77 mg, 84%). 
 
1H-NMR (500 MHz, CDCl3):  7.68 (s, 5H), 3.37 (t, J= 7.5 Hz, 10H), 2.73 (dt, J= 7.5 Hz, J= 2.5 
Hz, 10H), 2.05 (t, J= 2.5 Hz, 5H).  
13C-NMR (125 MHz, CDCl3):  139.35, 135.26, 129.66, 123.32, 83.88, 69.80, 32.54, 21.48.  
UV (THF) λmax, nm: 262, 299.  
HRMS (ESI) m/z: found 511.2420 (M + 23); calc (C40H31) 511.2420. 
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9.3.8. SYM-PENTA-((S)-(3,7-DIMETHYLOCT-6-ENE)-1-YL)-CORANNULENE (68) 
 
A flame-dried flask was charged with magnesium (176 mg, 7.24 mmol), THF (2 mL) and a 
crystal of I2; the solution was stirred until the solution turns from brownish to uncolor. S-(+)-
citronellyl bromide (332 mg, 1.51 mmol) was slowly added and the mixture was stirred at r.t. for 2 
h. A flame-dried flask was charged with sym-pentachlorocorannulene (49.5 mg, 0.12 mmol) and 
Fe(acac)3 (26.0 mg, 73.6 mol), THF (1 mL) and NMP (100 L) and put at 0 °C. The Grignard 
solution was added; the reaction mixture turned from red to black and the ice-water bath was 
removed. After 2.5 h ca. the reaction mixture was diluted with Et2O and quenched with a solution of 
HCl 1M; the organic layer was separated and the aqueous phase was extracted with DCM. The 
collected organic phases were anhydrified over Na2SO4, filtered and the solvent was removed by 
low-pressure evaporation. The crude was purified by flash chromatography (silica; hexane:DCM 
9:1). The product is a yellow oil (66.7 mg, 59%). 
 
1H-NMR (500 MHz, CDCl3): 7.60 (5H, s), 5.18 (t, J= 10.0 Hz, 5H), 3.24 – 3.06 (m, 10H), 2.13 – 
1.94 (m, 10H), 1.81 – 1.64 (m, 40H), 1.59 – 1.50 (m, 5H), 1.38 – 1.29 (m, 5H), 1.12 (d, J= 10.0 Hz, 
15H).  
13C-NMR (125 MHz, CDCl3): 141.92, 135.03, 131.30, 129.94, 125.06, 122.29, 39.97, 37.22, 32.83, 
31.24, 25.89, 25.78, 25.76, 19.87, 19.85, 17.84. IR (film):  cm-1 2960, 2921, 2856, 1734, 1674, 
1619, 1456, 1376, 1355, 1311, 1260, 1212, 1110, 1083, 984, 871, 827, 761, 739, 723, 466, 474.  
UV (DMSO) λmax, nm: 264, 299.  
[]25D = +3.4 (c= 0.007 in DMSO).  
HRMS (APCI) m/z: found 941.7894 (M + H); calc (C70H100) 941.7898. 
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9.3.9. SYM-PENTA-(1-[1,3]-DIOXOLANE-2-ETHYL)-CORANNULENE (69) 
 
2-(1,3-dioxa-2-cyclopentyl)-ethyl bromide (2.6 g, 14.4 mmol) was added to a suspension of 
magnesium (367 mg, 15.1 mmol) and a crystal of iodine in THF (60 ml) at 0 °C; the mixture was 
stirred at room temperature for 2.5 hours. The Grignard solution was added to a suspension of sym-
pentachlorocorannulene (553 mg, 1.3 mmol) and Fe(acac)3 (115 mg, 0.33 mmol) in THF (10 mL) 
and NMP (1.0 mL) at 0 °C. The reaction was stirred at room temperature for 2.5 hours. The solution 
was then cooled to 0 °C and quenched by slowly addition of diethyl ether followed by a 1 M 
solution of HCl in water. The organic layer was separated and the aqueous phase was extracted with 
ethyl acetate. The collected organic phases were dried over Na2SO4 and evaporated to yield the 
crude product. The product was purified by column chromatography on silica gel eluted with ethyl 
acetate. The solvent was evaporated to yield a yellow solid (674 mg, 69%).  
 
1H-NMR (500 MHz, CDCl3):  7.65 (s, 5H), 5.04 (t, J= 4.8 Hz, 10H), 4.09 (m, 10H), 3,92 (m, 
10H), 3.23 (t, J= 8.4 Hz, 10H), 2.24 (m, 10H).  
13C-NMR (125 MHz, CDCl3):  140.68, 135.15, 130.00, 122.83, 104.17, 65.28, 36.45, 27.80.  
UV (THF) λmax, nm: 263, 298.  
HRMS (ESI) m/z: found 773.3294 (M + Na); calc (C45H50NaO10) 773.3296. 
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9.3.10. SYM-PENTA-(1-AL-3-PROPYL)-CORANNULENE (70) 
 
Acetic acid (1.0 mL) and HCl 1 M (1.0 mL) were added to a solution of 69 (55 mg, 73.3 mol) 
in THF (1.0 ml) and was heated to reflux and stirred for 2 hours. The mixture was cooled to 0 °C, 
neutralized with NaHCO3 and extracted with ethyl acetate. The collected organic phases were dried 
over Na2SO4 and evaporated to yield an orange solid (41 mg, 99%). 
 
1H-NMR (500 MHz, CDCl3):  9.92 (s, 5H), 7.60 (s, 5H), 3.45 (dt, J= 7.5 Hz, J= 7.0 Hz, 10H), 
3.05 (t, J= 7.5 Hz, 10H).  
13C-NMR (125 MHz, CDCl3):  201.18, 139.89, 135.32, 129.70, 123.02, 46.03, 25.68.  
UV (THF) λmax, nm: 261, 298.  
HRMS (ESI) m/z: found 553.1983 (M + Na); calc (C35H30NaO5) 553.1986. 
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9.3.11. SYM-PENTA-(1-CARBOXY-2-ETHYL)-CORANNULENE (71) 
 
A suspension of Oxone® (1.8 g, 2.88 mmol) in water (2 mL) was added to a solution of 69 (54 
mg, 71.9 mol) in THF (400 L) at 0 °C. The reaction was stirred at room temperature for 2 days. 
The mixture was then diluted with water and ethyl acetate; the organic layer was separated and the 
aqueous phase was extracted with ethyl acetate. The collected organic phases were dried over 
Na2SO4 and evaporated. The crude was then dissolved in MeOH and a NaOH 1 M was slowly 
added until basic pH was reached; the aqueous phase was washed with ethyl acetate. The aqueous 
layer was then acidified with HCl 1 M to pH 1 and extractions with ethyl acetate were performed. 
The collected organic phases were dried over Na2SO4 and evaporated to yield a yellow solid (39 
mg, 89%). 
 
1H-NMR (500 MHz, d4-MeOD):  7.68 (s, 5H), 3.24 (t, J= 7.0 Hz, 10H), 2.87 (t, J= 7.0 Hz, 10H).  
13C-NMR (125 MHz, d4-MeOD):  176.90, 141.21, 136.14, 130.81, 123.93, 37.54, 29.64.  
UV (THF) λmax, nm: 263, 298.  
HRMS (ESI) m/z: found 609.1773 (M - H); calc (C35H29O10) 609.1766. 
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9.3.12. SYM-PENTA-(1-OL-3-PROPYL)-CORANNULENE (72) 
 
From compound 70. 
A solution of NaBH4 (284 mg, 7.5 mmol) in dry methanol (10 mL) was added over 24 hours by 
syringe pump to a solution of 70 (400 mg, 0.75 mmol) in dry methanol (10 mL) at 0 °C. The 
reaction mixture was stirred at room temperature for 1 day. The reaction mixture was then diluted 
with water and ethyl acetate; the organic layer was separated and the aqueous phase was extracted 
with ethyl acetate. The collected organic phases were dried over Na2SO4 and evaporated. The 
product was purified by column chromatography on silica gel eluted with a mixture 
dichloromethane:methanol 9:1. The solvent was evaporated to yield a pale yellow solid (203 mg, 
50%). 
From compound 74. 
Trifluoroacetic acid (2.0 mL, 26.1 mmol) was added to a well stirred solution of 74 (250 mg, 
0.19 mmol) in acetone (2.5 mL), THF (1.75 mL) and water (1.0 mL). The reaction was heated to 
reflux for 2 days. The mixture was cooled to room temperature and the organic solvents were 
evaporated. The solid was then filtrated and was washed with water and diethyl ether. The product 
was purified by column chromatography on silica gel eluted with a mixture 
dichloromethane:methanol 9:1. The solvent was evaporated to yield a pale yellow solid (93 mg, 
91%). 
 
1H-NMR (500 MHz, d4-MeOD):  7.59 (s, 5H), 4.47 (br, 5H), 3.64 (t, J= 6.0 Hz, 10H), 3.11 (t, J= 
7.5 Hz, 10H), 2.01 (m, 10H).  
13C-NMR (125 MHz, d4-MeOD):  142.50, 136.04, 131.09, 123.86, 62.58, 36.45, 30.73.  
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UV (THF) λmax, nm: 261, 298.  
HRMS (ESI) m/z: found 563.2766 (M + Na); calc (C35H40NaO5) 563.2768. 
 
9.3.13. SYM-PENTA-(1-(TRIISOPROPYLSILYLOXY)-3-PROPYL)-CORANNULENE (74) 
 
3-(triisopropylsilyloxy)-propylbromide (3.5 g, 11.9 mmol) was added to a suspension of 
magnesium (356 mg, 14.6 mmol) and a crystal of iodine in THF (25 mL) at 0 °C; the mixture was 
stirred at room temperature for 1 hours. The Grignard solution was added to a suspension of sym-
pentachlorocorannulene (457 mg, 1.1 mmol) and Fe(acac)3 (97 mg, 0.27 mmol) in THF (5 mL) and 
NMP (0.5 mL) at 0 °C. The reaction was stirred at room temperature for 2.5 hours. The solution 
was then cooled to 0 °C and quenched by slowly addition of diethyl ether followed by a 1 M 
solution of HCl in water. The organic layer was separated and the aqueous phase was extracted with 
diethyl ether. The collected organic phases were dried over Na2SO4 and evaporated to yield the 
crude product. The product was purified by column chromatography on silica gel eluted with ethyl 
acetate. The solvent was evaporated to yield a yellow oil (887 mg, 61%).  
 
1H-NMR (500 MHz, CDCl3):  7.62 (s, 5H), 3.87 (t, J= 6.0 Hz, 10H), 3.19 (t, J= 7.5 Hz, 10H), 
2.11 (m, 10H), 1.10 (m, 105H).  
13C-NMR (125 MHz, CDCl3):  141.38, 135.14, 130.06, 122.82, 63.17, 36.00, 30.06, 18.35, 12.33.  
UV (THF) λmax, nm: 263, 298.  
HRMS (ESI) m/z: found 1321.9610 (M + H); calc (C80H141O5Si5) 1321.9620. 
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9.3.14. SYM-PENTA-(1-BROMO-3-PROPYL)-CORANNULENE (75) 
 
NBS (106 mg, 0.60 mmol) was added to a solution of 73 (37 mg, 68.4 mol) and 
triphenylphosphine (149 mg, 0.57 mmol) in DMF (2.0 mL) at 0 °C. The reaction was stirred at 
room temperature for 1 hour. The DMF was evaporated at reduced pressure and the crude was 
diluted in dichloromethane. The organic phase was washed with water and brine, dried over Na2SO4 
and evaporated to yield the crude product. The product was purified by column chromatography on 
silica gel eluted with a mixture hexane:ethyl acetate 9:1; hexane:ethyl acetate 1:1 and then ethyl 
acetate:methanol 9:1. The solvent was evaporated to yield a pale yellow solid (45 mg, 77%). 
 
1H-NMR (400 MHz, CDCl3):  7.67 (s, 5H), 3.56 (t, J= 6.4 Hz, 10H), 3.30 (t, J= 7.2 Hz, 10H), 
2.45 (m, 10H).  
13C-NMR (100 MHz, CDCl3):  139.87, 135.24, 129.86, 123.36, 34.96, 33.61, 31.67.  
UV (THF) λmax, nm: 261, 299.  
HRMS (ESI) m/z: found 850.8714 (M + H); calc (C35H36Br5) 850.8728. 
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9.3.15. SYM-PENTA-(1-THIOL-3-PROPYL)-CORANNULENE (76) 
 
A solution of 75 (40 mg, 46.8 mol), thiourea (64 mg, 0.84 mmol) in ethanol (3.0 mL) and THF 
(1.0 mL) was heated to reflux and stirred for 2 hours. The mixture was cooled down and the solvent 
was evaporated. The crude was dissolved in NaOH 7.5 M (5.0 mL), heated to reflux and stirred for 
2 hours. The mixture was cooled down to 0 °C and acidified to pH 1 with HCl 1 M. The solid was 
filtrated and washed with water and diethyl ether to yield a pale yellow solid (28 mg, 96%). 
 
1H-NMR (400 MHz, d6-DMSO):  7.79 (s, 5H), 3.24 (t, J= 7.5 Hz, 10H), 2.66 (dt, J= 7.5 Hz, J= 
7.0 Hz, 10H), 2.11 (m, 10H).  
13C-NMR (100 MHz, d6-DMSO):  140.75, 133.96, 129.47, 122.86, 36.11, 31.20, 23.61.  
UV (DMSO) λmax, nm: 263, 301.  
HRMS (ESI) m/z: found 621.1812 (M + H); calc (C35H41S5) 621.1806. 
 
  
113 
 
9.3.16. SYM-PENTA-(3-(2,5-DIMETHYLPYRROLE)-1-PROPYL)-CORANNULENE (81) 
 
1-(3-bromopropyl)-2,5-dimethylpyrrole (4.1 g, 19.0 mmol) was added to a suspension of Mg 
(557 mg, 22.3 mmol) and a crystal of iodine in THF (15 mL) at 0 °C; the mixture was stirred at 
room temperature for 2 hours. The Grignard solution was added to a suspension of sym-
pentachlorocorannulene (730 mg, 1.7 mmol) and Fe(acac)3 (152 mg, 0.43 mmol) in THF (15 mL) 
and NMP (1.5 mL) at 0 °C. The reaction was stirred at room temperature for 2.5 hours. The solution 
was then cooled to 0 °C and quenched by slowly addition of diethyl ether followed by a 1 M 
solution of HCl in water. The organic layer was separated and the aqueous phase was extracted with 
ethyl acetate. The collected organic phases were dried over Na2SO4 and evaporated to yield the 
crude product. The product was purified by column chromatography on silica gel eluted with a 
mixture hexane:ethyl acetate 8:2. The solvent was evaporated to yield a pale yellow solid (976 mg, 
62%).  
 
1H-NMR (500 MHz, CDCl3):  7.39 (s, 5H), 5.83 (s, 10H), 3.97 (t, J= 7.0 Hz, 10H), 3.10 (t, J= 7.0 
Hz, 10H), 2.25 (m, 40H).  
13C-NMR (125 MHz, CDCl3):  140.64, 135.35, 129.53, 127.62, 122.33, 105.59, 43.44, 33.37, 
30.57, 12.87.  
UV (THF) λmax, nm: 262, 299.  
HRMS (ESI) m/z: found 948.5905 (M + Na); calc (C65H75N5Na) 948.5915. 
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9.3.17. SYM-PENTA-((N-METYL-ACETATE)3-AMINO-1-PROPYL)-CORANNULENE (82) 
 
To solution of 70 (41 mg, 77 mol) in methanol (2 mL) were added glycine methylester (146 
mg, 1.17 mmol) and NaBH3CN (30 mg, 0.48 mmol) at 0 °C and the solution was stirred for 2 hours 
at room temperature. The reaction was diluted with a saturated solution of NaHCO3 and extracted 
with AcOEt. The collected organic phases were anhydrified over Na2SO4 and filtrated. The solvent 
was evaporated to yield a yellow solid (64 mg, 93%).  
 
1H-NMR (500 MHz, CDCl3):  7.58 (s, 5H), 3.72 (s, 15H), 3.46 (s, 10H), 3.15 (t, J=7.5 Hz, 10H), 
2.81 (t, J= 6.5 Hz, 10H), 2.08 (m, 10H).  
13C-NMR (125 MHz, CDCl3): 173.26,141.09, 135.09, 129.91, 122.78, 52.03, 51.07, 49.55, 32.79, 
31.23.  
UV (THF) λmax, nm: 260, 300.  
HRMS (ESI) m/z: found 448.7438 (M + 2H); calc (C50H67N5O10) 448.7438.
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9.3.18. 5'-AZIDO-2',5’-DI-DEOXY-ADENOSINE (85)  
 
A solution of 5'-O-Toluenesulphonyl-2'-deoxy-adenosine 115 (270 mg, 6.67 mmol) in dry DMF 
(2.0 mL) was added dropwise to a mixture of LiN3 (525 mg, 10.7 mmol) in dry DMF (1.0 mL). The 
reaction mixture was stirred at room temperature for 2 days; the solvent was evaporated and the 
product was purified by column chromatography on silica gel eluted with a DCM:MeOH:TEA 
9:1:0.25. The solvent was evaporated to yield a colorless foam (140 mg, 76%). 
 
1H-NMR (500 MHz, d4-MeOD):  8.29 (s, 1H), 8.21 (s, 1H), 6.44 (t, J= 7.0 Hz, 1H), 4.57 (m, 1H), 
4.08 (m, 1H), 3.64 (dd, J= 13.5, 6.0 Hz, 1H), 3.56 (dd, J= 13.5, 4.0 Hz, 1H), 2.96 (m, 1H), 2.49 (m, 
1H).  
13C-NMR (125 MHz, d4-MeOD):  154.01, 141.29, 129.94, 127.12, 87.33, 85.90, 73.03, 53.46, 
47.51, 40.39, 40.39. 
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9.3.19. SYM-PENTA-2-(1,2,3-TRIAZOLE-1-(5’-YL-2’,5’-DI-DEOXY-ADENOSINE)-4-
ETHYL)-CORANNULENE (88)  
 
A mixture of sym-penta-(1-butyn-4-yl)-corannulene 67 (10 mg, 19.6 mol), 5'-azido-2',5'-
dideoxy-adenosine 85 (65.1 mg, 0.24 mmol) and copper nanoparticles (10.1 mg, 0.16 mmol) in 
DMF (1.0 mL) in a microwave vessel was heated at 60 °C in a microwave reactor for 2 hours. The 
mixture was then filtrated over celite and the solvent was evaporated and MeOH was added to the 
crude. The solid was then filtrated, washed with cold MeOH and recrystallized from water to yield a 
reddish solid (14.5 mg, 40%). 
 
1H-NMR (500 MHz, d6-DMSO, 373 K):  8.18 – 8.16 (m, 10H), 7.75 (s, 5H), 7.71 (s, 5H), 6.91 (br 
s, 10H), 6.35 (t, J= 6.5 Hz, 5H), 5.31 (d, J= 5.0 Hz, 5H), 4.70 (dd, J= 14.0, 4.5 Hz, 5H), 4.61 (dd, 
J= 14.5, 7.0 Hz, 5H), 4.53 (br s, 5H), 4.23 (br s, 5H), 3.42 (t, J= 7.0 Hz, 10H), 3.14 (t, J= 7.5 Hz, 
10H), 2.80 (m, 5H), 2.36 (m, 5H).  
13C-NMR (125 MHz, d6-DMSO):  156.09, 152.55, 149.22, 146.29, 140.41, 139.82, 133.93, 
129.35, 127.97, 125.46, 122.83, 84.90, 83.58, 71.14, 66.99, 64.88, 51.36, 38.06, 32.29, 27.72, 
25.10.  
IR (KBr):  cm-1 3329, 3186, 2928, 1653, 1647, 1640, 1599, 1577, 1474, 1420, 1366, 1331, 1299, 
1248, 1217, 1087, 1056, 939, 797, 726, 649.  
UV (DMSO) λmax, nm: 265, 299.  
[]D = +25.6 (c= 0.008 in DMSO).  
HRMS (ESI) m/z: found 946.3962 (M + 2H); calc (C90H92N40O10) 946.3955. 
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9.3.20. SYM-PENTA-2-(1,2,3-TRIAZOLE-1-(5’-YL-2’-DEOXY-RIBO-THYMIDINE)-4-
ETHYL)-CORANNULENE (89)  
 
A mixture of sym-penta-(1-butyn-4-yl)-corannulene 67 (9.9 mg, 19.4 mol), 5’-azido thymidine 
87 116 (43.0 mg, 0.16 mmol) and copper nanoparticles (10.9 mg, 0.17 mmol) in DMF (1.0 mL) in a 
microwave vessel was heated at 60 °C in a microwave reactor for 2 hours. The mixture was then 
filtrated over celite and the solvent was evaporated and MeOH was added to the crude. The solid 
was then filtrated and washed with cold MeOH to yield a pale yellow solid (24.6 mg, 69%).  
 
1H-NMR (500 MHz, d6-DMSO):  11.30 (s, 5H), 7.98 (s, 5H), 7.77 (s, 5H), 7.31 (s, 5H), 6.15 (t, J= 
6.5 Hz, 5H), 5.49 (d, J= 4.5 Hz, 5H), 4.69 – 4.58 (m, 10H), 4.27 (m, 5H), 4.06 (m, 5H), 3.45 (br, 
10H), 3.17 (d, J= 5.0 Hz, 10H), 2.15 – 2.07 (m, 10H), 1.75 (s, 15H).  
13C-NMR (125 MHz, d6-DMSO):  163.67, 150.41, 146.35, 140.43, 136.05, 134.06, 129.41, 
123.06, 109.83, 84.06, 83.96, 70.70, 51.06, 48.62, 37.93, 32.43, 27.85, 12.10.  
IR (KBr):  cm-1 3421, 2926, 1688, 1472, 1438, 1273, 1221, 1135, 1084, 1056, 958, 874, 766, 558.  
UV (DMSO) λmax, nm: 265, 298.  
[]D = +108.5 (c= 0.012 in DMSO).  
HRMS (ESI) m/z: found 923.8662 (M + 2H); calc (C90H97N25O20) 923.8665. 
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9.3.21. N-(2-AZIDE-PROPIONYL)-DI-L-ALANINE METHYL ESTER (92) 
 
Triflic anhydride (0.65 mL, 3.88 mmol) was added to a solution of NaN3 (1.2 g, 18.5 mmol) in 
DCM (3.0 mL) and water (2.0 mL) at 0 °C; the reaction was stirred at room temperature for 2 
hours. The organic phase was separated and the aqueous extracted with DCM. The reunited organic 
phases were washed with a saturated solution of NaHCO3.The organic phase was then added to a 
solution of H-Ala-Ala-Ala-OMe acetate salt (454 mg, 1.49 mmol), CuSO4*5H2O (5.6 mg, 0.02 
mmol) and K2CO3 (387 mg, 2.80 mmol) in methanol (6.6 mL) and water (3.2 mL) at room 
temperature; the mixture was stirred for 22 hours. The organic layer was then separated and the 
aqueous phase was extracted with DCM. The reunited organic phases were dried over Na2SO4 and 
evaporated to yield the crude product. The product was purified by column chromatography on 
silica gel eluted with a mixture DCM:MeOH 9:1. The solvent was evaporated to yield a white solid 
(211 mg, 52%). 
 
1H-NMR (500 MHz, CDCl3):  6.89 (d, J= 6.5 Hz, 1H), 6.43 (d, J= 6.5 Hz, 1H), 4.56 (quint, J= 
7.0 Hz, 1H), 4,42 (quint, J= 7.0 Hz, 1H), 4.07 (q, J= 7.0 Hz, 1H), 3.76 (s, 3H), 1.53 (d, J= 7.0 Hz, 
3H), 1.42 (d, J= 7.0 Hz, 3H), 1.41 (d, J= 7.0 Hz, 3H).  
13C-NMR (125 MHz, CDCl3):  173.21, 171.25, 169.83, 59.12, 52.73, 48.93, 48.37, 18.45, 18.44, 
17.18.  
IR (KBr):  cm-1 3312, 2972, 2116, 2078, 1740, 1641, 1546, 1450, 1376, 1344, 1325, 1218, 1162, 
1106, 1073, 1063, 1008, 984, 956, 855, 663, 572.  
[]D = -104.7 (c= 0.0040 in CHCl3).  
HRMS (ESI) m/z: found 294.1174 (M + Na); calc (C10H17N5NaO4) 294.1173. 
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9.3.22. SYM-PENTA-2-(1,2,3-TRIAZOLE-1-(N-(2-METHYL-ACETYL)-DI-L-ALANINE 
METHYL ESTER)-4-ETHYL)-CORANNULENE (91) 
 
A mixture of sym-penta-(1-butyn-4-yl)-corannulene 67 (9.1 mg, 18 mol), N-(2-azide-
propionyl)-di-L-alanine methyl ester 91 (50.3 mg, 0.19 mmol) and copper nanoparticles (13.4 mg, 
0.21 mmol) in DMF (0.5 mL) in a microwave vessel was heated at 80 °C in a microwave reactor for 
8 hours. The mixture was then filtrated over celite and the solvent was evaporated. The product was 
purified by column chromatography on silica gel eluted with a DCM:MeOH 9:1. The solvent was 
evaporated to yield a yellow solid (19 mg, 57%). 
 
1H-NMR (500 MHz, d6-DMSO):  8.60 (d, J= 7.5 Hz, 5H), 8.39 (d, J= 7.0 Hz, 5H), 8.09 (s, 5H), 
7.82 (s, 5H), 5.43 (q, J= 7.0 Hz, 5H), 4.27 (m, 10H), 3.61 (s, 15H), 3.47 (br, 10H), 3.18 (br, 10H), 
1.60 (d, J= 7.0 Hz, 15H), 1.27 (d, J= 7.5 Hz, 15H), 1.21 (d, J= 7.0 Hz, 15H).  
13C-NMR (125 MHz, d6-DMSO):  172.97, 171.83, 168.36, 145.99, 140.58, 134.05, 129.48, 
123.05, 121.45, 57.68, 51.91, 47.95, 47.53, 32.45, 28.07, 18.15, 18.10, 16.83.  
IR (KBr):  cm-1 3290, 2930, 1741, 1645, 1551, 1455, 1383, 1329, 1222, 1164, 1052, 998, 953, 
684.  
UV (DMSO) λmax, nm: 264, 299.  
[]25D = +3.7 (c= 0.055 in DMSO).  
HRMS (ESI) m/z: found 955.9273 (M + 2Na); calc (C90H115N25Na2O20) 955.9267. 
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9.3.23. SYM-PENTA-2-(1,2,3-TRIAZOLE-1-(N-(2-ETHYL)OCTADEC-9-ENAMIDE)-4-
ETHYL)-CORANNULENE (84) 
 
A mixture of sym-penta-(1-butyn-4-yl)-corannulene 67 (25 mg, 49.0mol), N-(2-
azidoethyl)octadec-9-enamide 95 119 (132 mg, 0.38mmol) and copper nanoparticles (25 mg, 0.39 
mmol) in DMF (2.5 mL) in a microwave vessel was heated at 60 °C in a microwave reactor for 2 
hours. The mixture was then filtrated over celite and the solvent was evaporated. The product was 
purified by column chromatography on silica gel eluted with a DCM:MeOH 93:7. The solvent was 
evaporated to yield a yellow wax (89 mg, 80%). 
 
1H-NMR (500 MHz, CDCl3):  7.47 (s br, 10H), 6.87 (s, 5H), 5.28 (m, 10H), 4.44 (s, 10H), 3.69 (s 
br, 10H), 3.40 (s br, 10H), 3.16 (s br, 10H), 2.11 (t, J= 7.5 Hz, 10H), 1.95 (m, 20H), 1.54 (s br, 
10H), 1.23 (s, 100H), 0.85 (t, J= 7.0 Hz, 15H).  
13C-NMR (125 MHz, CDCl3):  174.13, 139.94, 134.67, 130.07, 129.73, 129.65, 122.82, 49.65, 
31.98, 29.84, 29.81, 29.60, 29.40, 29.26, 27.30, 27.26, 25.78, 22.76, 14.20.  
IR (KBr):  cm-1 3298, 2925, 2854, 1649, 1547, 1456, 1374, 1217, 1145, 1052, 874, 722.  
UV (CHCl3) λmax, nm: 232, 264, 299.  
HRMS (ESI) m/z: found 1164.3731 (M + 2Na); calc (C140H220N20Na2O5) 1154.3696. 
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9.3.24. SYM-PENTA-(2-(1,2,3-TRIAZOLE-4-ETHYL)-ETHYL--D-
GALACTOPYRANOSIDE)-CORANNULENE (100) 
 
A mixture of 96 122,123 (42.0 mg, 0.17 mmol), sym-penta-(1-butyn-4-yl)-corannulene 67 (11.6 
mg, 23 mol) and copper nanoparticles (10.8 mg, 0.17 mmol) in DMF (1 mL) in a microwave 
vessel was heated at 60 °C in a microwave reactor for 2 hours. The mixture was then filtrated over 
celite, the solvent was evaporated and MeOH was added to the crude. The solid was then filtrated 
and washed with cold MeOH to yield a white solid (24 mg, 59%) 
 
1H-NMR (500 MHz, d6-DMSO):  8.19 (s, 5H), 7.81 (s, 5H), 5.01 (d, J= 4.5 Hz, 5H), 4.77 (d, J= 
5.5 Hz, 5H), 4.62-4.51 (m, 15H), 4.17 (d, J= 7.5 Hz, 5H), 4.08 (m, 5H), 3.86 (m, 5H), 3.62 (t, J= 
4.0 Hz, 5H), 3.51 (m, 20H), 3.16 (t br, J= 7.0 Hz, 10H).  
13C-NMR (125 MHz, CDCl3):  146.14, 140.6, 134.02, 129.48, 123.08, 103.45, 75.36, 73.30, 
70.41, 68.16, 67.26, 60.48, 49.50, 32.43, 27.99.  
UV (DMSO) λmax, nm: 264, 300.  
[]D = +349.3 (c=0.15 in H2O).  
HRMS (ESI) m/z: found 878.8647 (M + 2H); calc (C80H107N15O30) 878.8649. 
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9.3.25. SYM-PENTA-2-(1,2,3-TRIAZOLE-1-(2,3,5-TRI-O-ACETYL--
RIBOFURANOSYL)-4-ETHYL)-CORANNULENE (101) 
 
A mixture of sym-penta-(1-butyn-4-yl)-corannulene 67 (10.0 mg, 20 mol), 2,3,5-tri-O-acetyl-β-
D-ribofuranosyl-1-azide 124 (62.0 mg, 21 mmol) and copper nanoparticles (13.2 mg, 0.21 mmol) in 
DMF (1.0 mL) in a microwave vessel was heated at 80 °C in a microwave reactor for 8 hours. The 
mixture was then filtrated over celite and the solvent was evaporated. The product was purified by 
column chromatography on silica gel eluted with a DCM:MeOH 96:4. The solvent was evaporated 
to yield a yellow solid (21.6 mg, 54%). 
 
1H-NMR (500 MHz, CDCl3):  7.62 (s, 5H), 7.55 (s, 5H), 6.11 (d, J= 3.5 Hz, 5H), 5.81 (t, J= 4.0 
Hz, 5H), 5.60 (t, J= 5.0 Hz, 5H), 4.42 (m, 5H), 4.32 (dd, J= 12.5, 3.5 Hz, 5H), 4.19 (dd, J= 12.5, 4.5 
Hz, 5H), 3.50 (m, 10H), 3.29 (m, 10H), 2.10 (s, 15H), 2.08 (s, 15H), 1.97 (s, 15H).  
13C-NMR (125 MHz, CDCl3):  170.47, 169.54, 169.35, 147.69, 140.26, 135.06, 129.74, 123.07, 
120.87, 89.97, 80.88, 74.38, 71.00, 63.14, 33.09, 29.82, 28.29, 20.76, 20.61, 20.52.  
IR (KBr):  cm-1 3422, 2927, 2854, 1750, 1445, 1437, 1373, 1231, 1091, 1062, 1041, 923, 900, 
811, 730, 602.  
UV (DMSO) λmax, nm: 264, 299.  
[]D = - 17.4 (c= 0.008 in DMSO).  
HRMS (ESI) m/z: found 1030.8341 (M + 2Na); calc (C95H105N15Na2O35) 1030.8341. 
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9.3.26. SYM-PENTA-2-(1,2,3-TRIAZOLE-1-(--RIBOFURANOSYL)-4-ETHYL)-
CORANNULENE (103) 
 
A solution of 101 (9.2 mg, 4.6 mol) and MeONa (16.5 mg, 0.31 mmol) in MeOH (1.5 mL) was 
stirred under nitrogen at room temperature for 2 days. Dowex 50 was added until pH 6 was reached. 
The mixture was filtrated and the solvent was evaporated. The product is a yellow solid (6.0 mg, 
94%). 
 
1H-NMR (500 MHz, d6-DMSO):  8.25 (s, 5H), 7.86 (s, 5H), 5.91 (d, J= 4.5 Hz, 5H), 5.63 (d, J= 
5.5 Hz, 5H), 5.30 (d, J= 3.5 Hz, 5H), 4.99 (t, J= 5.0 Hz, 5H), 4.36 (d, J= 4.5 Hz, 5H), 4.11 (d, J= 
3.5 Hz, 5H), 3.95 (q, J= 4.5 Hz, 5H), 3.61 – 3.48 (m, 20H), 3.21 (br, 10H).  
13C-NMR (125 MHz, d6-DMSO):  146.68, 140.60, 134.12, 129.50, 123.02, 120.76, 109.54, 
91.96, 85.72, 75.07, 70.42, 61.46, 32.37, 28.01.  
IR (KBr):  cm-1 3359, 2924, 2853, 1595, 1454, 1383, 1331, 1228, 1101, 1047, 863, 824, 755, 102, 
621.  
UV (DMSO) λmax, nm: 264, 300.  
[]D = +255.0 (c= 0.004 in DMSO).  
HRMS (ESI) m/z: found 1408.5211 (M + Na); calc (C65H75N15NaO20) 1408.5205. 
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9.3.27. SYM-PENTA-2-(1,2,3-TRIAZOLE-1-(1-TRIISOPROPYL-3-(2-(2-(2-YL-1-
ETHOXY)ETHOXY)ETHOXY)-PROP-1-YNE)-4-ETHYL)-CORANNULENE (113) 
 
A mixture of 67 (15.1 mg, 29 mol), 108 (67.3 mg, 0.18 mmol) and copper nanoparticles (12.3 
mg, 0.19 mmol) in DMF (1.5 mL) was loaded in a microwave vessel was heated at 60 °C in a 
microwave reactor for 2 h. The mixture was filtrated over celite and the solvent evaporated. The 
crude was purified by column chromatography on silica gel (DCM:MeOH 95:5) to yield a reddish 
oil (58 mg, 83%).  
 
1H-NMR (500 MHz, CDCl3):  7.64 (s, 5H), 7.52 (s, 5H), 4.49 (t, J=5.5 Hz, 10H), 4.18 (s, 10H), 
3.82 (t, J=5.5 Hz, 10H), 3.66-3.45 (m, 50H), 3.26 (t, J=8.0 Hz, 10H), 1.02 (s, 105H).  
13C-NMR (125 MHz, CDCl3):  147.08, 140.36, 134.89, 129.71, 123.02, 122.39, 103.19, 87.73, 
70.54, 70.50, 70.42, 69.68, 68.68, 59.18, 50.19, 33.39, 28.51, 18.62, 11.16.  
HRMS (ESI) m/z: found 1201.2173 (M+2Na); calc (C130H205N15Na2O15Si5) 1201.2185. 
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9.3.28. COMPOUND (114) 
 
A mixture of 67 (9.4 mg, 18 mol), 111 (83.0 mg, 0.14 mmol) and copper nanoparticles (11.7 
mg, 0.18 mmol) in DMF (1.0 mL) was loaded in a microwave vessel and was heated at 80 °C in a 
microwave reactor for 2 h. The reaction mixture was filtrated over celite and the solvent evaporated. 
The crude mixture was purified by column chromatography on silica gel (from DCM:MeOH 94:6 to 
DCM:MeOH 9:1) to yield a reddish oil (49 mg, 79%).  
 
1H-NMR (500 MHz, CDCl3):  7.69 (s, 5H), 7.64 (s, 5H), 7.53 (s, 5H), 4.62 (s, 10H), 4.48 (q, 
J=5.5 Hz, 20 H), 4.21 (s, 10H), 3.82 (t, J=5.0 Hz, 20H), 3.69 – 3.47 (m, 90H), 3.26 (t, J=8.0 Hz, 
10H), 1.04 (s, 105H).  
13C-NMR (125 MHz, CDCl3):  147.07, 144.81, 140.42, 134.88, 129.74, 123.91, 123.06, 122.47, 
103.21, 87.81, 70.55, 70.54 70.51, 70.47, 69.68, 69.64, 69.52, 68.72, 64.58, 59.28, 50.32, 50.27, 
33.38, 28.49, 18.66, 11.20.  
HRMS (ESI) m/z: found 1163.6590 (M+3Na); calc (C175H280N30Na3O30Si5) 1163.6609. 
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9.3.29. COMPOUND (115) 
 
A mixture of 67 (19.5 mg, 38 mol), 112 (296.0 mg, 0.29 mmol) and copper nanoparticles (23.0 
mg, 0.36 mmol) in DMF (2.0 mL) was loaded in a microwave vessel and was heated at 80 °C in a 
microwave reactor for 2 h. The reaction mixture was filtrated over celite and the solvent evaporated. 
The crude mixture was purified by column chromatography on silica gel (DCM:MeOH 9:1) to yield 
a reddish oil (147 mg, 70%).  
 
1H-NMR (500 MHz, CDCl3):  7.66 – 7.62 (m, 15H), 7.56 (s, 5H), 7.47 (s, 5H), 4.56 – 4.52 (m, 
30H), 4.43 – 4.38 (m, 40H), 4.11 (s, 10H), 3.77 – 3.73 (m, 40H), 3.61 – 3.41 (m, 165H), 3.17 (s br, 
10H), 0.96 (s, 105H).  
13C-NMR (125 MHz, CDCl3):  146.80, 144.51, 140.18, 134.59, 129.48, 123.73, 122.80, 122.24, 
103.00, 87.53, 70.36, 70.34, 70.29, 70.24, 69.38, 69.26, 69.30, 68.53, 64.37, 64.35, 58.93, 50.02, 
50.07, 50.00, 49.96, 49.91, 33.08, 28.22, 18.42, 10.93.  
HRMS (ESI) m/z: found 794.3097 (M+7H); calc (C265H437N60O60Si5) 794.3114. 
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9.3.30. SYM-PENTA-2-(1,2,3-TRIAZOLE-1-( 3-(2-(2-(2-YL-1-
ETHOXY)ETHOXY)ETHOXY)-PROP-1-YNE)-4-ETHYL)-CORANNULENE (116) 
 
A solution of TBAF in THF (1M, 0.77 mL, 0.77 mmol) was added to a solution of 113 (55.4 mg, 
23.5 mol) in THF (0.33 mL) and the reaction mixture was stirred at r.t. for 2 h. The solution was 
then diluted with a saturated aqueous solution of NH4Cl and extracted with ethyl acetate. The 
combined  organic phases were dried over NasSO4 and evaporated to yield the crude product. The 
crude was then heated at 75 °C under high vacuum for 18 h. The product was then purified by 
column chromatography on silica gel (DCM:MeOH 95:5) to yield a reddish oil (15 mg, 40%).  
 
1H-NMR (500 MHz, CDCl3):  7.64 (s, 5H), 7.53 (s, 5H), 4.50 (t, J=5.0 Hz, 10H), 4.13 (d, 
J=2.0Hz, 10H), 3.82 (t, J=5.0 Hz, 10H), 3.62-3.50 (m, 50H), 3.26 (t, J=8.0 Hz, 10H), 2.40 (t, 
J=2.0 Hz, 5H).  
13C-NMR (125 MHz, CDCl3):  147.10, 140.45, 134.90, 129.77, 123.10, 122.54, 79.69, 74.82, 
70.55, 70.43, 69.70, 69.13, 58.48, 50.26, 33.42, 28.53.  
HRMS (ESI) m/z: found 526.2709 (M+3H); calc (C85H108N15O15) 526.2711. 
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9.3.31. COMPOUND (117) 
 
A solution of TBAF in THF (1M, 1.0 mL, 1.0 mmol) was added to a solution of 114 (103 mg, 
30.1 mol) in THF (1.0 mL) and the reaction mixture was stirred at r.t. for 2 h. The solution was 
then diluted with a saturated aqueous solution of NH4Cl and extracted with ethyl acetate. The 
collected organic phases were dried over NasSO4 and evaporated to yield the crude product. The 
crude was then heated at 75 °C under high vacuum for 18 h. The product was then purified by 
column chromatography on silica gel (DCM:MeOH 9:1) to yield a reddish oil (24 mg, 30%).  
 
1H-NMR (500 MHz, CDCl3): 
1H-NMR (500 MHz, CDCl3):  7.70 (s, 5H), 7.64 (s, 5H), 7.53 (s, 
5H), 4.62 (s, 10H), 4.50 – 4.46 (m, 20 H), 4.16 (d, J=2.5 Hz, 10H), 3.82 (t, J=5.0 Hz, 20H), 3.64 – 
3.51 (m, 90H), 3.23 (t, J=8.0 Hz, 10H), 2.44 (d, J=2.5 Hz, 5H).  
13C-NMR (125 MHz, CDCl3):  147.11, 144.83, 140.47, 134.89, 129.76, 123.97, 123.07, 122.47, 
79.70, 74.86, 70.57, 70.55, 70.47, 69.65, 69.52, 69.14, 64.72, 58.48, 50.26, 50.20, 33.39, 28.52.  
HRMS (ESI) m/z: found 529.2767 (M+5H); calc (C130H185N30O30) 529.2769. 
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9.3.32. COMPOUND (118) 
 
A solution of TBAF in THF (1M, 0.9 mL, 0.9 mmol) was added to a solution of 115 (143 mg, 
25.7 mol) in THF (1.0 mL) and the reaction mixture was stirred at r.t. for 2 h. The solution was 
then diluted with a saturated aqueous solution of NH4Cl and extracted with ethyl acetate. The 
collected organic phases were dried over NasSO4 and evaporated to yield the crude product. The 
crude was then heated at 75 °C under high vacuum for 18 h. The product was then purified by 
column chromatography on silica gel (DCM:MeOH 9:1) to yield a reddish oil (81 mg, 66%). 
 
1H-NMR (500 MHz, CDCl3):  7.69 – 7.65 (m, 15H), 7.60 (s, 5H), 7.50 (s, 5H), 4.60 – 4.56 (m, 
30H), 4.48 – 4.41 (m, 40H), 4.13 (d, J=2.0 Hz, 10H), 3.81 – 3.80 (m, 40H), 3.62 – 3.52 (m, 165H), 
3.18 (t br, J=7.5 Hz, 10H), 2.41 (s, 5H).  
13C-NMR (125 MHz, CDCl3):  146.93, 144.71, 140.34, 134.76, 129.65, 123.80, 123.78, 122.92, 
122.31, 79.62, 74.72, 70.47, 70.46, 70.44, 70.42, 70.35, 69.55, 69.41, 69.39, 69.04, 64.47, 58.35, 
50.17, 50.16, 50.12, 50.07, 33.21, 28.35.  
HRMS (ESI) m/z: found 1216.1057 (M+4Na); calc (C220H330N60Na4O60) 1216.1052. 
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9.3.33. 1-AZIDO-6-(-D-(2,3,4,6-TETRAACETATE)-GALACTOPYRANOSIDE)-1-
DEOXYHEXAETHYLENEGLYCOL (120) 
 
A mixture of 2,3,4,6-tetra-O-acetyl-a-D-galactopyranosyl bromide (67, 1.63 g, 4.0 mmol), 2[-2-
(2-{2-[2-(2-hydroxyethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]- ethyl azide (119, 1.73 g, 5.6 mmol) 
and molecular sieves in dry dichloromethane (35 mL) was stirred at r.t. for 50 min; HgBr2 (1.43 g, 
4.0 mmol) was added to the reaction and the mixture was stirred at r. t. for 3 days. The mixture was 
then filtrated and the solid washed with dichloromethane, methanol and THF. The filtrate was 
concentrated in vacuo. The product was purified by column chromatography on silica gel eluted 
with AcOEt:Hexane 1:1. The solvent was evaporated to yield a yellow syrup (1.39 g, 55%).  
 
1H-NMR (500 MHz, CDCl3):  5.36 (d, J=3.0 Hz, 1H), 5.17 (dd, J=10.0 Hz, J=8.0 Hz, 1H), 5.00 
(dd, J=10.5 HZ, J=3.5 Hz, 1H), 4.55 (d, J=8.00 Hz, 1H), 4.16 – 4.10 (m, 2H), 3.97 – 3.89 (m, 2H) 
3.76 – 3.62 (m, 23H), 3.39 (t, J=5.00 Hz, 2H), 2.12 (s, 3H), 2.07 (s, 3H), 2.05 (s, 3H), 1.99 (s, 3H).  
13C-NMR (135 MHz, CDCl3):  170.60, 170.42, 170.33, 101.65, 71.06, 70.89, 70.80, 70.61, 70.45, 
70.06, 69.31, 69.08, 67.27, 61.46, 50.85, 21.04, 20.90, 20.87, 20.79.  
HRMS (ESI) m/z: found 660.2580 (M+Na); calc (C26H43N3NaO15) 660.2586. 
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9.3.34. 1-AZIDO-6-(-D-GALACTOPYRANOSIDE)-1-DEOXYHEXAETHYLENEGLYCOL 
(121) 
 
A solution of sodium methoxide (3 g in 10 mL of methanol) was added to a solution of 120 (1.31 
g, 2.1 mmol) in methanol (10 mL.) until pH 12 was reached. The reaction mixture was stirred at r. t. 
for 2 days. Dowex 50 was added to the reaction until pH 6 was reached; the mixture was then 
filtrated and the solvent evaporated. The crude was purified by chromatography (DCM:MeOH 
85:15). The product is a yellow syrup (560 mg, 58%).  
 
1H-NMR (500 MHz, D2O):  4.44 (d, J=8.0 Hz, 1H), 4.12 – 4.08 (m, 1H), 3.94 (d, J=3.5, 1H), 
3.88 – 3.66 (m, 25H), 3.58 – 3.52 (m, 3H).  
13C-NMR (125 MHz, d4-MeOD):  104.26, 76.36, 74.08, 72.06, 71.01, 70.91, 70.87, 70.83, 70.54, 
69.89, 69.73, 62.14, 51.39. HRMS (ESI) m/z: found 492.2159 (M+Na); calc (C18H35N3NaO11) 
492.2164. 
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9.3.35.SYM-PENTA-(2-(1,2,3-TRIAZOLE-1-(1-YL-6-(-D-GALACTOPYRANOSIDE)-1-
DEOXYHEXAETHYLENEGLYCOL)-4-ETHYL)-CORANNULENE (122) 
 
A mixture of 67 (11.0 mg, 21.5 mol), 121 (89.2 mg, 0.19 mmol) and copper nanoparticles (12.3 
mg, 0.19 mmol) in DMF (1.0 mL) Cwas loaded in a microwave vessel was heated at 80 °C in a 
microwave reactor for 2 h. The mixture was filtrated over celite and the solvent evaporated. The 
crude was purified by size exclusion chromatography (Sephadex® G-25, water) to yield a reddish 
solid (147 mg, 47%).  
 
1H-NMR (600 MHz, d4-MeOD):  7.83 (s, 5H), 7.71 (s, 5H), 4.54 (t br, J=5.0 Hz, 10H), 4.26 (d, 
J=5.0 Hz, 5H), 3.99 – 3.85 (m, 5H), 3.82 – 3.70 (m, 20H), 3.68 – 3.59 (m, 30H), 3.53 – 3.29 (m, 
125H).  
13C-NMR (150 MHz, d4-MeOD):  148.05, 141.66, 135.82, 130.90, 124.67, 124.43, 104.87, 76.70, 
74.88, 72.50, 71.41, 71.31, 71.27, 71.25, 71.24, 71.22, 70.43, 70.28, 69.50, 62.52, 51.33, 34.11, 
29.14.  
HRMS (ESI) m/z: found 737.0824 (M+4Na); calc (C130H205N14Na4O55) 737.0819. 
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9.3.36. COMPOUND (123)  
 
A mixture of 116 (4.5 mg, 2.9 mol), 121 (11.3 mg, 24.1 mol) and copper nanoparticles (1.5 
mg, 23.6 mol) in DMF (300 L) was loaded in a microwave vessel and was heated at 80 °C in a 
microwave reactor for 2 h. The mixture was filtrated over celite and the solid was washed with 
water. The crude was lyophilized and purified by size exclusion chromatography (Sephadex® G-25, 
water) to yield a reddish solid (5.0 mg, 44%).  
 
1H-NMR (500 MHz, D2O/d
4-MeOD):  7.81 (s, 5H), 7.57 (s, 5H), 7.52 (s, 5H), 4.41 – 397 (m, 
40H), 3.85 (m, 5H), 3.71 – 2.99 (m, 220H).  
13C-NMR (125 MHz, D2O/d
4-MeOD):  144.80, 141.30, 137.38, 126.06, 124.82, 124.35, 103.84, 
76.11, 73.67, 71.72, 70.67, 70.47, 70.34, 70.26, 70.22, 70.18, 69.76, 69.73, 69.59, 69.53, 66.85, 
63.97, 61.92, 50.88, 50.75.  
HRMS (ESI) m/z: found 807.3734 (M+5Na); calc (C175H280N30Na5O70) 807.3747. 
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9.3.37. COMPOUND (124) 
 
A mixture of 117 (8.5 mg, 3.2 mol), 121 (11.3 mg, 24.1 mol) and copper nanoparticles (1.5 
mg, 23.6 mol) in DMF (300 L) was loaded in a microwave vessel was heated at 80 °C in a 
microwave reactor for 2 h. The mixture was filtrated over celite and the solid was washed with 
water. The crude was lyophilized and purified by size exclusion chromatography (Sephadex® G-25, 
water) to yield a reddish solid (9.1 mg, 57%).  
 
1H-NMR (500 MHz, D2O/d
4-MeOD):  8.01 (s, 5H), 7.88 (s, 5H), 7.68 (s, 5H), 7.60 (s, 5H), 4.58 – 
4.39 (m, 50H), 4.08 – 4.06 (m, 5H), 3.98 – 3.12 (m, 255H).  
13C-NMR (125 MHz, D2O/d
4-MeOD):  147.90, 144.84, 141.31, 134.78, 130.36, 126.25, 126.05, 
124.76 124.23, 103.86, 76.12, 73.69, 71.73, 70.69, 70.57, 70.52, 70.42, 70.41, 70.35, 70.27, 70.24, 
69.86, 69.79, 69.73, 69.65, 69.61, 69.54, 63.99, 61.93, 50.90, 50.77, 49.52, 33.97, 28.11.  
HRMS (ESI) m/z: found 854.2378 (M+6Na); calc (C220H355N45Na6O85) 854.2366. 
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9.3.38. COMPOUND (125) 
 
A mixture of 118 (16.2 mg, 3.4 mol), 121 (13.6 mg, 29.0 mol) and copper nanoparticles (1.8 
mg, 28.3 mol) in DMF (300 L) was loaded in a microwave vessel was heated at 80 °C in a 
microwave reactor for 2 h. The mixture was filtrated over celite and the solid was washed with 
water. The crude was lyophilized and purified by size exclusion chromatography (Sephadex® G-25, 
water) to yield a reddish solid (10.4 mg, 43%).  
 
1H-NMR (500 MHz, D2O/d
4-MeOD):  8.07 (d, J=5.0 Hz, 5H), 8.02 (d, J=5.0 Hz, 5H), 7.98 (d, 
J=5.0 Hz, 5H), 7.90 (d, J=5.0 Hz, 5H), 7.89 (d, J=5.0 Hz, 5H), 7.63 (s, 5H), 4.69 – 4.39 (m, 90H), 
4.08 (m, 5H), 3.96 – 3.16 (m, 345H).  
13C-NMR (125 MHz, D2O/d
4-MeOD):  147.88, 144.97, 141.36, 134.77, 130.34, 126.15, 126.10, 
126.04, 125.88, 124.59, 124.09, 103.82, 99.49, 76.02, 73.72, 71.72, 70.61, 70.58, 70.46, 70.36, 
70.31, 70.26, 70.24, 69.85, 69.59, 69.57, 69.55, 69.46, 64.00, 61.87, 50.89, 50.87, 50.84, 50.74, 
32.93, 28.06.  
HRMS (ESI) m/z: found 912.8149 (M+8Na); calc (C310H505N75Na8O115) 912.8139. 
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9.3.39. COMPOUND (131) 
 
A mixture of 116 (0.83 mg, 0.53 mol), 130 (5.54 mg, 4.6 mol) and copper nanoparticles (0.33 
mg, 5.2 mol) in water (150 L) was loaded in a microwave vessel was heated at 80 °C in a 
microwave reactor for 2 h. The mixture was filtrated over celite and the solid was washed with 
water. The crude was lyophilized and purified by size exclusion chromatography (Sephadex® G-15, 
water) to yield a colorless solid (1.8 mg, 45%).  
 
1H-NMR (500 MHz, D2O/d
4-MeOD):  7.86 – 7.70 (m, 15H), 4.55 (t, J=10.0 Hz, 25H), 3.81 (d, 
J=10.0 Hz, 10H), 3.76 (t, J=5.0 Hz, 5H), 3.85 – 3.79 (m, 15H), 3.75  3.59 (m, 40H), 3.58 – 3.52 
(m, 20H), 3.47 – 3.41 (m, 20H), 3.64 – 3.33 (m, 25H), 2.69 (d, J=10.0 Hz, 5H), 1.98 (d, J=15.0 Hz, 
15H), 1.93 – 1.84 (m, 5H), 1.55 – 1.54 (m br, 5H), 1.47 – 1.37 (m br, 10H), 1.26 – 1.12 (m br, 
20H), 1.07 – 0.83 (m br, 30H).  
13C-NMR (125 MHz, D2O/d
4-MeOD): the amount of this compound was not enough to measure a 
13C-NMR.  
HRMS (ESI) m/z: found 1507.8678 (M–5H); calc (C325H515N40O160) 1507.6684. 
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9.3.40. COMPOUND (132) 
 
A mixture of 117 (2.88 mg, 1.09 mol), 130 (11.1 mg, 9.3 mol) and copper nanoparticles (0.76 
mg, 12.0 mol) in water (300 L) was loaded in a microwave vessel was heated at 80 °C in a 
microwave reactor for 2 h. The mixture was filtrated over celite and the solid was washed with 
water. The crude was lyophilized and purified by size exclusion chromatography (Sephadex® G-25, 
water) to yield a colorless solid (4.8 mg, 51%).  
 
1H-NMR (500 MHz, D2O/d
4-MeOD):  7.96 – 7.75 (m, 20H), 4.57 – 4.54 (m, 70H), 4.18 – 4.05 
(m, 45H), 3.94 – 3.34 (m, 286H), 2.70 (d, J=10.0 Hz, 5H), 2.06 (d, J=15.0 Hz, 35H), 1.98 – 1.94 (t, 
J=10.0 Hz, 5H), 1.62 – 1.45 (m br, 25H), 1.28 – 1.25 (m br, 20H), 1.11 – 0.90 (m br, 75H).  
13C-NMR (125 MHz, D2O/d
4-MeOD):  175.96, 175.06, 105.70, 103.61, 103.48, 103.18, 102.70, 
75.83, 75.32, 73.47, 71.66, 70.66, 70.64, 70.62, 70.52, 70.50, 70.48, 70.47, 70.45, 69.59, 69.57, 
61,90, 52.61, 52.12, 51.13, 51.11, 29.73, 26.58, 26.23, 23.58, 22.99.  
HRMS (ESI) m/z: found 1721.1778 (M–5H); calc (C370H590N55O175) 1720.7797. 
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9.3.41. COMPOUND (133) 
 
A mixture of 118 (4.77 mg, 1.0 mol), 130 (8.4 mg, 7.0 mol) and copper nanoparticles (0.51 
mg, 8.0 mol) in water (300 L) was loaded in a microwave vessel was heated at 80 °C in a 
microwave reactor for 2 h. The mixture was filtrated over celite and the solid was washed with 
water. The crude was lyophilized and purified by size exclusion chromatography (Sephadex® G-25, 
water) to yield a colorless solid (6.2 mg, 58%).  
 
1H-NMR (500 MHz, D2O/d
4-MeOD):  7.91 – 7.67 (m, 25H), 4.47 – 4.35 (m br, 75H), 4,07 (m 
20H), 3.98 (t, J=5.00 Hz, 10H), 3.88 – 3.15 (m, 280H), 2.60 (d, J=10.0 Hz, 5H), 1.95 (d, J=15.0 
Hz, 25H), 1.85 (s, 40H), 1.55 (s br, 10H), 1.40 (s br, 10H), 1.07 – 0.91 (m br, 60H).  
13C-NMR (125 MHz, D2O/d
4-MeOD):  175.96, 175.61, 175.05, 171.92, 144.86, 126.28, 126.25, 
126.20, 126.17, 126.06, 126.05, 125.47, 105.70, 103.61, 103.47, 103.13, 102.68, 81.39, 79.72, 
78.23, 75.83, 75.67, 75.50, 75.31, 75.04, 75.03, 74.07, 74.06, 73.77, 73.76, 73.74, 73.51, 73.47, 
73.21, 71.66, 71.39, 70.97, 70.64, 70.62, 70.59, 70.49, 70.45, 69.91, 69.87, 69.66, 69.57, 69.00, 
68.88, 64.09, 64.06, 63.80, 62.06, 61.89, 61.54, 52.60, 52.11, 51.13, 50.94, 50.83, 37.86, 30.38, 
30.34, 30.33, 30.31, 29.94, 29.89, 29.86, 29.80, 29.79, 29.74, 29.72, 29.70, 29.68, 29.64, 29.62, 
29.15, 26.60, 26.58, 26.18, 26.16, 24.22, 23.58, 23.00.  
HRMS (ESI) m/z: found 2147.2039 (M–5H); calc (C460H740N85O205) 2147.0024. 
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9.3.42. N-(2-AZIDOETHYL)-HEPTANAMIDE (142) 
 
Oxalyl chloride (1.5 mL, 17.5 mmol) was added dropwise to a solution of heptanoic acid (652 
mg, 5.0 mmol) in dry DCM (2 mL) and DMF (3 drops) and stirred at 0 °C under inert atmosphere. 
After 3.5 h, the solvent and the oxalylchoride were evaporated and the residue was dissolved in dry 
DCM (5 mL); this solution was then slowly added to a mixture of 2-azidoethanamine (550 mg, 6.4 
mmol) in dry TEA (1.5 mL) and dry DCM (15 mL); the reaction mixture was stirred at room 
temperature for 24 h under inert atmosphere. The solvent was evaporated and the product was 
purified by column chromatography on silica gel eluted with a DCM:MeOH 97:3. The solvent was 
evaporated to yield a colorless solid (880 mg, 89%). 
 
1H-NMR (400 MHz, CDCl3):  5.84 (s br, 1H), 3.42 (m, 4H), 2.18 (t, J= 7.2 Hz, 2H), 1.62 (m, 2H), 
1.31 (m, 6H), 0.87 (t, J= 6.8 Hz, 3H).  
13C-NMR (100 MHz, CDCl3): 173.61, 51.12, 39.00, 36.80, 31.64, 29.06, 25.71, 22.61, 14.13.  
HRMS (ESI) m/z: found 221.1370 (M + Na); calc (C9H18N4NaO) 221.1373. 
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9.3.43. N-(2-AZIDOETHYL)-STEARAMIDE (143) 
 
Oxalyl chloride (1.52 g, 12.0 mmol) was added dropwise to a solution of stearic acid (1.06 g, 3.7 
mmol) in dry DCM (20 mL) and DMF (5 drops) and stirred at 0 °C under inert atmosphere. After 
3.5 h, the solvent and the oxalylchoride were evaporated and the residue was dissolved in dry DCM 
(15 mL); this solution was then slowly added to a mixture of 2-azidoethanamine (410 mg, 4.7 
mmol) in dry TEA (1.1 mL) and dry DCM (15 mL); the reaction mixture was stirred at room 
temperature for 18 h under inert atmosphere. The solvent was evaporated and the product was 
recrystallized from MeOH to yield a colorless solid (754 mg, 58%). 
 
1H-NMR (500 MHz, CDCl3):  5.69 (s br, 1H), 3.43 (m, 4H), 2.19 (t, J= 7.5 Hz, 2H), 1.62 (m, 2H), 
1.56 (s, 2H), 1.25 (m, 26H), 0.88 (t, J= 7.0 Hz, 3H).  
13C-NMR (125MHz, CDCl3):  173.54, 51.21, 36.88, 32.88, 29.85, 29.83, 29.81, 29.76, 29.63, 
29.51, 29.49, 29.43, 25.78, 22.85, 14.27.  
HRMS (ESI) m/z: found 375.30906 (M + Na); calc (C20H40N4NaO) 375.30943. 
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9.3.44. SYM-PENTA-2-(1,2,3-TRIAZOLE-1-(N-(2-ETHYL)HEPTANAMIDE)-4-ETHYL)-
CORANNULENE (144) 
 
A mixture of sym-penta-(1-butyn-4-yl)-corannulene (67, 10.6 mg, 20.8mol), N-(2-azidoethyl)-
heptanamide 142 (220 mg, 1.11mmol) and copper nanoparticles (10.1 mg, 0.16mmol) in DMF (1 
mL) in a microwave vessel was heated at 60 °C in a microwave reactor for 2 hours. The mixture 
was then filtrated over celite and the solvent was evaporated. The product was purified by column 
chromatography on silica gel eluted with a DCM:MeOH 90:10. The solvent was evaporated to yield 
a yellow powder (19 mg, 61%). 
 
1H-NMR (500 MHz, CDCl3):  7.48 (s, 5H), 7.43 (s, 5H), 6.71 (t br, J= 5.0 Hz, 5H), 4.43 (t br, J= 
5.0 Hz, 10H), 3,68 (m, 10H), 3.42 (m, 10H), 3.19 (t br, J= 5.0 Hz, 10H), 2.08 (t, J= 5.0 Hz, 10H), 
1.51 (t br, J= 5.0 Hz, 10H), 1.21 (m, 30H), 0.81 (t, J= 10.0 Hz, 15H).  
13C-NMR (125 MHz, CDCl3):  174.19, 140.02, 134.69, 129.71, 122.95, 122.59, 49.64, 39.63, 
36.56, 33.00, 31.62, 29.06, 28.02, 25.74, 22.61, 14.14.  
IR (KBr):  cm-1 3294, 3072, 2927, 2856, 2102, 1657, 1548, 1455, 1368, 1217, 1143, 1052, 723.  
UV (CHCl3) λmax, nm: 257, 264, 299.  
HRMS (ESI) m/z: found 773.4762 (M + 2Na); calc (C85H120N20Na2O5) 773..4767. 
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9.3.45. SYM-PENTA-2-(1,2,3-TRIAZOLE-1-(N-(2-ETHYL)STEARAMIDE)-4-ETHYL)-
CORANNULENE (145) 
 
A mixture of sym-penta-(1-butyn-4-yl)-corannulene (67, 29.8 mg, 58.4mol), N-(2-azidoethyl)-
stearamide 143 (164 mg, 0.47mmol) and copper nanoparticles (33.0 mg, 0.52mmol) in DMF (5 mL) 
in a microwave vessel was heated at 60 °C in a microwave reactor for 2 hours. The mixture was 
then filtrated over celite and the solvent was evaporated. The product was purified by column 
chromatography on silica gel eluted with a DCM:MeOH 93:7. The solvent was evaporated to yield 
a yellow powder (64 mg, 48%). 
 
1H-NMR (500 MHz, CDCl3):  7.51 (s, 5H), 6.71 (s br, 2H), 4.47 (s br, 5H), 3.68 (s br, 10H), 3,44 
(s br, 10H), 3.23 (s br, 10H), 2.10 (m, 10H), 1.53 (s br, 10H), 1.21 (m, 130H), 0.87 (t, J= 10.0 Hz, 
15H).  
13C-NMR (125 MHz, CDCl3):  174.30, 139.84, 134.75, 129.72, 123.11, 39.60, 36.63, 32.07, 
29.85, 29.06, 29.80, 29.69, 29.55, 25.85, 22.83, 14.26.  
IR (KBr):  cm-1 3316, 3133, 3072, 2918, 2850, 1647, 1545, 1468, 1378, 1275, 1258, 1240, 1221, 
1053, 1148, 1053, 865, 720.3, 663, 585 
UV (CHCl3) λmax, nm: 256, 263, 300.  
HRMS (ESI) m/z: found 1159.4065 (M + 2Na); calc (C140H230N20Na2O5) 1159.4086. 
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9.3.46. COMPOUND 147 
 
10 L of a solution of CuBr (92 g, 0.64 mol) and TBTA (0.546 mg, 1.0 mol) in water:THF 
1:1 (100 l) was added to a solution of sym-penta-(1-butyn-4-yl)-corannulene 67 (49 g, 96 nmol) 
and oligonucleotide 146 (1.1 mol) in THF (5 l) and water (15 l) and heated at 60 °C for 2 days 
and at 80 °C for 4 days. The reaction mixture was then desalted with Sephadex G-25. The crude 
product was then purified by 6% D-PAGE (acrylamide:bisacrylamide 19:1, Urea 7 M) at constant 
power of 40 W, using TBE buffer (Tris 11 g, boric acid 5.6 g and EDTA 0.74 g in 1 L of sterile 
water). Following electrophoresis, the plate was wrapped in plastic and placed on a fluorescent TLC 
plate and illuminated with UV lamp (254 nm). The band was quickly excised, and the gel pieces 
were frozen with liquid nitrogen, crushed and incubated overnight in 2 volumes of NaOAc (0.5 M, 
pH 5.2 with HCl) at 37 °C. The samples was then centrifuges and the supernatant collected. The gel 
was the washed with 1/5 volume of NaOAc 0.5 M, centrifuged and the supernatant collected. The 
aqueous solution was then extracted with n-butanol to 1/3 of the original volume. 0.16 volume of a 
solution of LiCl 4 M and MgCl2 0.125 mM and 3 volumes of cold ethanol (100%, -80 °C) were 
added to the aqueous solution and stored overnight at -80 °C. The sample was then centrifuged 
(13200 rpm, 4 °C, 20 min) and the supernatant was removed. The precipitate was washed 3 times 
with cold ethanol (80 %, 0 °C), dissolved in sterile milliQ water and desalted with Float-A-Lyzer 
G2. The amount of 147 was quantified by UV absorption (300 nm assuming =3.28•104) The 
sample was then freeze-dried yielding the desired product as a pale yellow powder (304 g, 12%).  
 
MALDI-TOF MS m/z found 26483.2 (M + 5Na + 18 H); calc. (C875H1195N315O490P80Na2Li) 
26483.7241. 
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9.4. ELISA ASSAYS 
Each well of a 96-well microtiter plate was coated with a 100 μL native GM1 solution (1.3 µM 
in ethanol) after which the solvent was evaporated. Unattached GM1 was removed by washing with 
PBS (3  450 µL), the remaining free binding sites were blocked by incubation with 100 µL of a 
1% (w/v) BSA  solution in PBS for 30 min at 37 °C. Subsequently, the wells were washed with 
PBS (3  450 µL). In separate vials, a logarithmic serial dilution, starting from 2.0 mM, of 150 L 
saccharide-corannulenes in 0.1% BSA, 0.05% Tween-20 in PBS, mixed with 150 L of a 50 ng/mL 
CTB-HRP solution in the same buffer were incubated. This gave an initial inhibitor concentration 
of 1.0 mM. In the case of potent inhibitors, based on the logarithmic experiments, a more accurate, 
serial dilution of a factor two was performed around the expected IC50 values. The inhibitor-toxin 
mixtures were incubated at room temperature for 2 h and then transferred to the coated wells. After 
30 min of incubation at room temperature, unbound CTB-HRP-corannulene complexes were 
removed from the wells by washing with 0.1% BSA, 0.05% Tween-20 in PBS (3 x 500 µL). 100 µL 
of a freshly prepared OPD solution (25 mg OPD·2HCl, 7.5 mL 0.1M citric acid, 7.5 mL 0.1M 
sodium citrate and 6 µL of a 30% H2O2 solution, pH was adjusted to 6.0 with NaOH) was added to 
each well and allowed to react with HRP in absence of light, at room temperature, for 15 min. The 
oxidation reaction was quenched by addition of 50 µL 1M H2SO4. Within 5 min, the adsorbance 
was measured at 490 nm. 
9.5. GELATION TEST 
In a typical gelation experiment a weighed amount of compound and 1 mL of the solvent 
mixture were placed in a vial, which was sealed and then heated until the compound dissolved. The 
solution was allowed to cool to room temperature. Gelation was considered to have occurred when 
a homogeneous substance was obtained, which exhibited no gravitational flow. 
9.6. ASSEMBLING STUDIES OF COMPOUND 147 
9.6.1. KINETICALLY-CONTROLLED PROCEDURE 
A 2 M solution of 22 in TE buffer (Tris 10 mM, EDTA 1 mM pH 7.5 with HCl) with NaCl 100 
mM and MgCl2 5 mM was heated for 5 min at 95 °C in a heating block; the sample was then 
transferred in an ice-bath, kept at 0 °C for 10 min and then loaded on the gel.  
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9.6.2. THERMODYNAMICALLY-CONTROLLED PROCEDURE 
A 1 M solution of 22 in TE buffer (Tris 10 mM, EDTA 1 mM pH 7.5 with HCl) with MgCl2 10 
mM was heated for 5 min at 95 °C in a heating block, then slowly cooled to 55 °C, kept at this 
temperature for 50 hours, then slowly cooled to 4 °C and loaded on the gel. Native PAGE: the 
sample from assembling studies were analyzed by 4% native-PAGE (acrylamide:bisacrylamide 
19:1) at 4 °C and at constant current of 10 mA for 1.5 hours. The gels were stained with ethidium 
bromide. 
9.7. ENZYMATIC DIGESTION 
Digestion of single-stranded DNA with mung bean nuclease was performed for 3 hours at 0 °C in 
sodium acetate buffer (10 mM, Zn(OAc)2 0.1 mM, cysteine 1 mM, Triton X-100 0.001% and 
glycerol 50%) applying 10 units of mung bean nuclease per g of 147. 
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